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ABSTRACT
Relapse to illicit drug-seeking behaviour is a major challenge as no effective 
pharmacotherapy is currently available. Drug dependent individuals experience 
severe negative emotional withdrawal symptoms including anxiety, dysphoria, 
depression and social avoidance during abstinence from the drug, which may 
comprise a motivational trigger to re-administer the drug and relapse. The neuronal 
mechanisms underlying long-term withdrawal and relapse are currently not well 
characterised. There is evidence suggesting that the oxytocin and p-opioid receptor 
(MOPr) system may be involved in the different stages of drug addiction.
This work aimed to elucidate using a mouse model whether an acute administration 
of the oxytocin analogue carbetocin is able to reverse stress- and priming-induced 
reinstatement of opioid-seeking by using the conditioned place preference (CPP) 
paradigm. This thesis has also assessed the regulation of oxytocin receptor and 
MOPr density during acquisition, cocaine priming and cue-elicited reinstatement of 
cocaine-seeking via quantitative receptor autoradiography. Furthermore, the effect 
of chronic methamphetamine (MAP) administration and withdrawal on the 
oxytocin and MOPr systems was examined by means of quantitative receptor 
autoradiography and/or radioimmunoassay.
Carbetocin reversed both the stress- and priming-induced reinstatement of 
morphine-seeking with a concomitant decrease in striatal noradrenaline levels by 
carbetocin following priming- but not stress induced reinstatement of morphine- 
seeking. A 4-day carbetocin treatment did not induce any rewarding or aversive 
effects.
Cocaine self-administration induced a persistent increase in oxytocin receptor 
binding specifically in the central nucleus of amygdala compared with the saline 
controls. A significant reduction of MOPr binding was observed in the nucleus 
accumbens core and caudate putamen following cocaine self-administration and 
cue- but not priming-induced reinstatement of cocaine-seeking compared to saline 
controls. Cue-induced reinstatement of cocaine-seeking decreased MOPr binding in 
the nucleus accumbens and caudate putamen compared to cocaine-primed 
reinstatement.
Chronic MAP administration induced a persistent increase in the OTR binding in 
the hippocampus. An increase in the OTR binding was observed following chronic 
MAP administration in the amygdala which was normalised following withdrawal, 
whilst MAP withdrawal induced a profound increase in the OTR binding in the 
lateral septum. With respect to the MOPr system, chronic MAP administration 
increased MOPr binding in the nucleus accumbens and caudate putamen which 
persisted during withdrawal. These receptor alterations occurred in parallel, with 
the emergence of anxiety-related symptoms during MAP withdrawal.
Collectively, the results described in this thesis highlight the dysregulation of the 
oxytocinergic and MOPr systems in the amygdala and striatum respectively, 
induced by chronic psychostimulant and exposure, withdrawal and reinstatement. 
This brain region-specific dysregulation may at least partly underlie the emotional 
consequences of drug addiction. Additionally, this is the first study to support the 
oxytocinergic system as a novel target for the prevention of relapse and treatment 
of opioid addiction. Lastly, the results of this thesis point toward the existence of a 
possible OT-MOPr interaetion which might underlie some of the effeets observed.
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Chapter 1
General Introduction
1.1 Drug addiction in the United Kingdom
Drug addiction is a chronic relapsing brain disorder that has deleterious 
consequences on an individual’s physical and psychological health. Substance 
dependence has been characterised according to three different criteria: (1) 
compulsivity to obtain the drug despite negative consequences, (2) loss of control 
upon drug administration and (3) emergence of negative physical and emotional 
symptoms following drug cessation (American Psychiatric Association 2013).
Addiction to drugs of abuse has serious societal and economic consequences 
through criminality, decreased productivity and increased healthcare costs (see 
Schumacher et al. 2002). It is predominantly observed in the young adult 
population (15-34 years old) in Europe. It was reported that in 2013, 13.9% of the 
young adults in Europe had used an illicit drug (EMCDDA 2014). Class A 
drugs,for example lysergic acid diethylamide (LSD), cocaine, 3,4-methylenedioxy- 
A-methamphetamine (MDMA), methamphetamine (MAP), and heroin are 
considered to be the most addictive and harmful drugs for the user (Smith and 
Flatley 2011). In particular, 45% of drug users in the European Union that were 
seeking treatment were reported to be opioid abusers (EMCDDA 2014).
A serious consequence of abuse of illicit drugs is criminality (e.g. theft, burglary), 
with an associated annual cost for heroin and cocaine users estimated to reach £15 
billion in the UK (Home Office, 2013). The UK government spends almost £15.4 
billion per year tackling illicit substance use (National Audit Office, 2010). 
Importantly, the cost of healthcare services over the life-span of just one illicit drug 
user is estimated at £35,000, increasing to £480,000 per user when the crime-
related cost is included (National Institute for Health and Clinical Excellence. 
2009).
Drug abuse is also considered a common cause of premature mortality, with illicit 
drug poisoning (i.e., overdose) accounting for approximately 12.5% of total deaths 
among people between 20-40 years old (Office of National Statistics, 2012). In 
fact, the UK has the fifth highest drug-related mortality rate in Europe according to 
the European Monitoring Centre for Drugs and Drug Addiction 2014 report.
1.2 Drug addiction cycle
Addiction can be characterised as a cyele of neuroehemieal and psychological 
changes that bring about a shift from impulsive drug use to compulsive use (Koob 
and Le Moal 2008; also see Figure 1.1). Social drug use, the first stage of this 
cycle, involves the activation of the brain’s reward pathway, which induces 
euphoric effects that positively reinforce the user to repeat drug adminisration 
(Koob and Le Moal 2008). Repeated adminstration of the drug may result in the 
development of tolerance and therefore an escalated dose of the drug is needed to 
achieve the initial euphoric effects. Upon cessation of drug taking, negative 
physical and emotional withdrawal symptoms occur and the positive reinforcement 
associated with the acute drug administration is gradually replaced with the 
negative reinforcement for preventing the emergence of withdrawal-associated 
negative symptoms. Acute withdrawal from drug taking causes unpleasant 
symptoms, including dysphoria and anhedonia (Gawin and Ellinwood 1989). 
Although these negative symptoms are short-lived, they provide strong 
motivational basis for subsequent drug re-administration that will alleviate such
symptoms (Koob and Le Moal 2001). Even following long-term abstinence, 
addicts are still vulnerable to relapse to drug use especially during re-exposure to 
the drug itself, to drug-associated environmental stimuli (cues) and following stress 
(Koob and Le Moal 2001).
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Figure 1.1: The drug addiction cycle.
Acute administration o f drugs o f abuse induces pleasurable effects that positively reinforce the user to repeat 
drug use. Repeated administration leads to the development o f tolerance, meaning that an increased amount o f a 
drug is needed to reach the same pleasurable effects. Acute positive reinforcement is gradually replaced with 
negative reinforcement to prevent the emergence o f negative withdrawal symptoms following drug eessation. 
The acute impulsive use o f the drug becomes eompulsive use. Even after long-term withdrawal individuals are 
still vulnerable to relapse to drug use. Modified fiomLe Moal and Koob (2007)
The shift fi-om impulsivity to compulsivity drives the cyclic nature of drug 
addiction through three different stages: (1) binge/intoxication, (2)
withdrawal/negative affect and (3) preoccupation/anticipation. For a
comprehensive review on this topic the reader is directed to Koob and Le Moal 
(2008).
1.2.1. Binge/intoxication stage
Acute administration of drugs of abuse activates the brain reward system. Olds and 
Milner (1954) demonstrated that rats would perform a task to acquire an electrical 
stimulation within specific brain regions and provided the first evidence for an 
anatomical reward brain circuit. Further evidence to support this finding was 
provided by Phillips and Fibiger (1978), who proposed a link between the 
rewarding effects of electrical brain stimulation and the presence of an intact 
dopaminergic (DAergic) system. Taken together, these findings established the 
basis for the dopamine (DA) theory of addiction.
The brain reward system consists of two DAergic pathways, the mesolimbic and 
mesocortical pathways. Both these systems originate from the ventral tegmental 
area (VTA), but innervate different brain regions. The mesolimbic DAergic 
pathway innervates several limbic structures including the nucleus accumbens 
(Acb), ventral pallidum (VP), hippocampus (Hip), lateral septum (LS) and 
amygdala (Amy) and the mesocortical DAergic pathway innervates the prefrontal 
(PFC), the orbitofrontal and the anterior cingulate cortices (see Feltenstein and See 
2008).
Natural rewards, such as food and sex as well as drugs of abuse increase DA 
release in the Acb, further characterising the mesolimbic pathway as the main 
pathway driving addictive behaviours (see Nestler 2005a). However, drug-induced 
reward is greater compared to the reward produced by natural reinforcers (see Di 
Chiara and Bassareo 2007). All drugs of abuse acutely increase DA release in the 
Acb; however, the mechanism of action of each drug is distinct. For example.
psychostimulants such as cocaine and amphetamines, directly increase the DA 
release into the Acb by blocking the DA re-uptake and/or by inducing vesicular 
release, whereas opioids act indirectly via blocking GABAergic neurotransmission 
in the VTA to disinhibit DA release (see Calipari and Ferris 2013; Daberkow et al. 
2013; Pierce and Kumaresan 2006). However, apart from the DAergic system, 
other neurotransmitter systems have also been implicated in the positive 
reinforcement effects of drugs of abuse, including the endogenous opioid system 
(see Koob and Voikow 2010). For extensive discussion of the role of the 
endogenous opioid system in drug addiction, see Section 1.8.
1.2.2. Withdrawal/negative affect stage
The neurobiological mechanisms driving the negative motivational effects of drug 
withdrawal may involve the disruption of the same neurochemical systems and 
neurocircuits implicated in the positive reinforcing effects of drug of abuse. In 
particular, following acute drug withdrawal, increases in brain reward thresholds 
(decreased reward) have been demonstrated as determined by direct ‘brain 
stimulation reward’ (Epping-Jordan et al. 1998; Gardner and Vorel 1998; Markou 
and Koob 1991; Paterson et al. 2000; Schulteis et al. 1995; Schulteis et al. 1994). 
Indeed, acute drug withdrawal induces a decrease in the release of several 
neurotransmitters that are implicated in the positive reinforcing effects of drugs of 
abuse, such as the mesocorticolimbic DA system as well as P-endorphins, y- 
aminobutyric acid (GABA) and glutamate in the Acb and the Amy (see Koob and 
Volkow 2010).
Moreover the disruption observed in basal DAergic transmission during acute 
withdrawal has been proposed as a possible mechanism underlying drug craving
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(Shen 2003; Weiss et al. 1996). Specifically, the decreased DA release observed in 
the limbic forebrain regions (i.e., PFC, Acb, Hip and Amy) has been shown to be 
associated with several opioid withdrawal symptoms in rats (Druhan et al. 2000). 
Hence, the mesocorticolimbic DAergic system might be also implicated in the 
negative reinforcing effects of drugs of abuse (i.e. dysphoria, anxiety and stress). 
Nevertheless, DAergic neuronal firing has been shown to be activated, to not 
respond or even to be inhibited in response to several aversive stimuli (Matsumoto 
and Hikosaka 2009). Thus, the precise role of the mesocorticolimbic DAergic 
system on the withdrawal-associated negative effects still remains unclear.
Several functional observations have provided evidence for the existence of a 
common neuroanatomical entity, termed the extended Amy, within the basal 
forebrain underlying the negative emotional states that drive compulsive drug 
administration as well as the aversive effects associated with drug withdrawal (see 
Koob 2009a). This neurocircuit is composed of the central nucleus of the Amy 
(CeA), the bed nueleus of the stria terminalis (BNST) and the shell 
subcompartment of Acb (AcbSh) and composes one of the body’s stress systems 
(Heimer and Alheid 1991).
During the withdrawal/negative affect stage of drug addiction, stress systems are 
activated in an attempt to restore normal function. These stress systems include the 
hypothalamic-pituitary-adrenal (HP A) axis, the extended Amy and the 
dynorphin/K-opioid receptor system. During acute withdrawal from all drugs of 
abuse an increase in adrenocorticotropic hormone (ACTH), corticosterone and 
amygdalar corticotropin-releasing factor (CRF) levels occurs, further supporting
the existence of common withdrawal-associated neurochemical changes underlying 
the withdrawal/negative affect stage (Delfs et al. 2000; Koob et al. 1994; Merlo 
Pich et al. 1995; Olive et al. 2002; Rasmussen et al. 2000; Rivier et al. 1984). 
Additionally, dynorphin levels are increased in the Acb and Amy during opioid and 
cocaine withdrawal; this overactivity of the dynorphin system reduces DAergie 
function, which has been shown to induce aversive effects (see Wee and Koob 
2010).
Therefore, acute withdrawal is not only associated with alterations in the function 
of neurotransmitter systems linked with the acute reinforcing effects of drugs, such 
as the DAergic and opioid systems, but it is also associated with the recruitment of 
stress systems (see Koob and Le Moal 2001).
1.2.3 Preoccupation/anticipation stage
The preoccupation/anticipation stage of the addiction cycle has long been 
hypothesised to be a key element of relapse to drug-seeking and defines addiction 
as a chronic relapsing disorder. While it is often associated with the construct of 
craving, drug craving per se has been difficult to measure in clinical studies 
(Tiffany et al. 2000) and does not always correlate with relapse potential. 
Reinstatement to drug-seeking behaviour can be induced by re-exposure to the drug 
itself (drug-induced reinstatement), exposure to drug-associated environmental 
stimuli (cue-induced reinstatement) or exposure to stressful conditions (stress- 
induced reinstatement).
Drug-induced reinstatement has been shown to be localised to the medial PFC 
/Acb/VP circuit mediated by glutamate (McFarland and Kalivas 2001). 
Specifically, the glutamatergic projection from the medial PFC to the Acb, which is 
modulated by DAergic afférents from the VTA innervating the PFC, has been 
shown to be implicated in drug-induced reinstatement (Krimer et al. 1997). In fact, 
priming-induced reinstatement of cocaine- (McFarland and Kalivas 2001) and 
MAP-seeking (Rocha and Kalivas 2010) was prevented by inactivation of PFC in 
rodents (microinjection of GABA agonists into the PFC), further supporting the 
important role of PFC in regulating priming-induced reinstatement to 
psychostimulant-seeking.
In addition, the basolateral amygdala (BLA) appears to be a critieal substrate in 
cue-induced reinstatement of both cocaine- (Ciccocioppo et al. 2001; Kantak et al. 
2002; McLaughlin and See 2003) and opioid-seeking (Fuchs and See 2002). 
Specifically, both the DAergic neurotransmission in the BLA (Berglind et al.
2006), as well as the glutamatergic projections originating from the BLA and 
ventral subiculum that innervate the Acb, are hypothesised to be involved in cue- 
induced reinstatement (see Everitt and Wolf 2002; Kalivas and O'Brien 2008; 
Shalev et al. 2002; Vorel et al. 2001).
Stress-induced reinstatement of drug-related responding in animal models appears 
to depend on the activation of both CRF and noradrenaline (NA) in the extended 
Amy (Shaham et al. 2003; Shalev et al. 2002). For instance, intra-BNST injections 
of a CRF antagonist prevented stress-elicited reinstatement of cocaine-seeking 
induced by footshock stress, while cocaine-seeking behaviour was reinstated by
injections of CRF into the BNST (Erb et al. 2001; Erb and Stewart 1999). 
Similarly, footshock-induced reinstatement of opioid-seeking was blocked by intra- 
BNST injection of a CRF receptor 1 (CRFi) antagonist in rats (Wang et al. 2006). 
Further, peripherally administered ui-adrenoceptor agonists in doses sufficient to 
inhibit NA release, prevented stress-induced reinstatement of cocaine-seeking in 
rats (Erb et al. 2000), whereas a peripherally administered Ui-adrenoceptor 
antagonist reinstated MAP-seeking behaviour (Shepard et al. 2004).
1.3 Animal Models of Drug Addiction
Different drugs of abuse exert different patterns of neuroadaptation after repeated 
administration. Understanding of these neurobiological alterations during different 
phases of the addiction cycle has been derived mostly from the development of 
animal models (see Koob et al. 2009; Table 1.1).
The elucidation of the neurobiological substrates involved in the reinforcing effects 
of drugs of abuse can be traced to early work on the identification of a reward 
system in the brain with the discovery of the electrical ‘brain stimulation reward’ 
(Olds and Milner 1954). The most sensitive rewarding sites in the brain were found 
to be the medial forebrain bundle that connects the VTA to the basal forebrain 
(Olds and Milner 1954). All the drugs of abuse, when administered acutely, 
decrease brain stimulation reward thresholds (meaning that they increased reward; 
Kometsky and Esposito 1979). However, upon chronic administration of the drug, 
reward thresholds are increased due to several neuroadaptations in the brain and 
this is where escalation of the dose is needed in order to achieve the same 
pleasurable effects of initial drug-taking.
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Another paradigm that is used to study drug addiction processes is conditioned 
place preference (CPP). Conditioned place preference is a classical conditioning 
procedure in which administration of a drug is paired with one distinct environment 
and administration of placebo with another (Sanchis-Segura and Spanagel 2006). 
Repeated conditioning produces contextual associative learning between the 
euphoric effects of the drug and the environment in which it was received. After 
several environmental pairings, animals are allowed to aceess both environments 
without being treated with the drug (Sanchis-Segura and Spanagel 2006). The 
animal’s choice to spend more time in either environment provides a direct 
measure of the conditioned reinforcing effects of a drug. Animals exhibit a 
conditioned preference if they spend more time in the environment previously 
associated with the administered drug that functions as a positive reinforcer. 
Avoidance of the previous drug-paired environment is considered as an indication 
of the drug’s aversive effect and the animal exhibits the so-called condition place 
aversion -  indicative of the negative reinforcement effects of drugs of abuse during 
withdrawal (Tzschentke 1998). Place conditioning can be also modified to serve as 
a model of relapse, by assessing the time a drug-extinct animal will spend in the 
previously drug-paired environment following exposure to stimulus that trigger 
relapse such as exposure to a stressor including foot-shock stress, forced swim 
stress, restraint stress or food deprivation, by a challenge with the drug itself or by 
a presentation of a cue previously associated with drug administration (Mueller and 
Stewart 2000; Stinus et al. 2000).
The effect of drug reinforcement has been also modelled in the self-administration 
animal paradigm, which is considered the most reliable predictor of drug taking
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liability in animals as it mimics the human pattern of drug-taking (Collins et al. 
1984). In fact, more than twenty psychoactive drugs that are abused by humans are 
also self-administered by rodents (Howell and Fantegrossi 2009). In this paradigm, 
animals learn to perform a task (for example lever pressing, nose poking or wheel 
turning) in order to acquire a drug infusion (Collins et al. 1984). This allows the 
determination of a “break point”, which sets the level at which the animal stops 
responding to get the drug, as the task to obtain this drug exceeds its rewarding 
effects (Bedford et al. 1978). The animal associates the positive reinforcement of 
the drug with the drug self-administration; therefore this method can be also used 
to study the relapse potential of a drug after a period of abstinence. Following a 
stable self-administration period animals are extinguished from the drug; the 
operant task previously associated with drug administration (lever pressing, nose 
poking or wheel turning) is disabled leading to a forced abstinence. After extinction 
is achieved, operant responding can be reinstated by the presentation of one 
stimulus including stress, drug-paired cues or re-exposure to the drug itself.
Another animal model assessing the positive and negative reinforcement effects of 
the drugs of abuse is the so-called “drug discrimination” paradigm. In this model, 
animals are trained to respond differentially depending on the nature of the drug 
with which they have been treated (Falk and Lau 1995; See et al. 1999). The goal 
of this behavioural assay is to train the animal to use the drug effect as a cue 
(technically termed a discriminative stimulus), for which the animal will respond 
showing preference for the drug -  positive reinforcement, or, in some cases, to 
avoid an aversive stimulus -  negative reinforcement. The drug discrimination 
procedure provides information analogous to a human testing situation, in which
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people who are experienced in illicit use of psychoactive drugs categorise test 
drugs as similar or dissimilar to other drugs with which they are familiar.
Finally, pre-clinical studies are necessary for the development of novel 
pharmacological treatments of addiction to prevent anxiety- and depressive-related 
behaviours following withdrawal from drug taking since there is high comorbidity 
between addiction and mental disorders in humans. The most widely used animal 
model of anxiety is the elevated plus-maze (EPM), for example see Fellow et al. 
(1985). The apparatus consists of two open arms and two enclosed arms that form a 
plus shape, and it is elevated from the floor (see methods Section 4.2.3). The plus- 
maze theory is based on the conflict between the natural tendency of rodents to 
explore novel environments and their fear of exposed areas (Treit et al. 1993). The 
EPM has been widely validated by using anxiolytic as well as anxiogenic drugs 
(Anseloni et al. 1995). For the depressive-related behaviours in rodents, the most 
well-known and widely used test is the “Porsolt” forced swim test (FST; see 
Porsolt 1979). Rodents are placed in cylinders filled with water where they have 
the tendency to swim in the water to find an escape route. After some time the 
rodents will stop fighting to escape and will stay immobile in the water. Enhanced 
immobility indicates depressive-like behaviour of the animal (see methods Section 
4.2.3). This test has been validated and it is sensitive with both the acute and 
chronic administration of several antidepressant drugs (Lucki et al. 2001), also see 
(Willner 1984).
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Table 1.1: Animal models used to study addictive-related behaviours iu animal 
models.
Stage of the addiction cycle Behavioural paradigms References
Binge / Intoxication
(Acute effects of drugs of 
abuse; mainly assoeiated with 
positive reinforcement)
Brain stimulation reward
(Bain and 
Kometsky 1989; 
Olds and Milner 
1954)
Conditioned-place preferenee
(Sanchis-Segura 
and Spanagel 
2006)
Self-administration 
(intravenous or oral)
(Collins et al. 
1984; Hyytia et 
al. 1996)
Drug diserimination
(Falk and Lau 
1995; See et al. 
1999)
Withdrawal / Negative 
Affect
(Effects of prolonged drug 
administration abuse and 
withdrawal; mainly associated 
with negative reinforcement)
Brain stimulation reward (Epping-Jordan et al. 1998)
Conditioned-plaee aversion
(Funada and 
Shippenberg 
1996; Hand et al. 
1988)
Self-administration (Roberts et al. 1996)
Drug diserimination
(Brandt and 
Franee 1998; 
Emmett-Oglesby 
et al. 1990)
Anxiety- and depressive- 
related responses
(Che et al. 2013; 
Schulteis et al. 
1998)
Preoccupation / 
Anticipation
(Reinstatement to drug- 
seeking)
Self-administration (Stewart and Wise 1992)
Conditioned-place preference
(Mueller and 
Stewart 2000)
Addiction is often characterised by three different stages; the binge/intoxication, 
withdrawal/negative affect and preoccupation/ anticipation stages. To examine the neurobiological 
and behavioural effects o f each o f these stages, several animal models have been developed. 
Modified from (Koob et al. 2009)
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1.4 Current pharmacotherapies for drug addiction
The biggest problem in drug addiction is the failure of former drug addicts to 
maintain a drug-free state and prevent relapse to drug use. Therefore, prevention of 
relapse following abstinence is the ultimate aim for the treatment of drug addietion. 
As this thesis concentrates on opioids and psychostimulant drugs of abuse, current 
pharmacotherapies for nicotine and aleohol addictions will not be discussed. For a 
review on current pharmaeotherapies for all the drugs of abuse, the reader is 
direeted to a review article by Holmes (2012).
Current treatment strategies for opioid addiction include substitution therapies, 
such as methadone (full p-opioid receptor (MOPr) agonist), buprenorphine (partial 
MOPr and nociceptin reeeptor agonist and KOPr antagonist) and naltrexone (global 
opioid reeeptor antagonist; see Stein et al. 2012). Methadone is the most commonly 
used drug for the treatment of opioid dependence because of its high bioavailability 
when taken orally. However, methadone has a substantial addiction liability 
making its availability highly controlled, thus redueing compliance (see Connock et 
al. 2007). Buprenorphine, on the other hand, induees less euphorie effects than 
methadone (see Lintzeris et al. 2009), but the safety of this drug when administered 
along with other sedative substances such as alcohol is still unclear, and may also 
lead to death (see Lintzeris et al. 2009). Naltrexone is another option for the 
treatment of opioid dependence, whieh has been shown to reduee opioid use 
(Giordano et al. 1990) and does not display any abuse potential (see Mannelli et al.
2011). Nonetheless, this treatment has been assoeiated with poor treatment 
retention and low patient compliance, mainly due to the development of side- 
effects including depression and dysphoria (Crowley et al. 1985; Hollister et al.
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1981). Lastly, a buprenorphine-naloxone combination, called Suboxone, has been 
used as another strategy for the management of opioid addiction yielding some 
positive results in reducing heroin use (MeKeganey et al. 2013; Rothman et al. 
2000). While naloxone has been shown to reduee the abuse potential of 
buprenorphine (Alho et al. 2007), it has been reported that drug addicts still abuse 
this combination therapy (Robinson et al. 1993). Therefore, it is eritical to further 
understand how MOPrs are regulated by drugs of abuse in order to be able to 
develop new pharmaeotherapies possessing the beneficial effects but not the 
rewarding potential of MOPr ligands.
With respect to psychostimulant addiction, there is currently no approved effective 
pharmaeotherapy, despite many years of extensive research (see Kampman et al. 
2005). Drugs targeting DAergie transmission have been considered as possible 
therapeutie interventions for the treatment of psyehostimulant addietion and they 
were widely tested both in pre-elinical and elinical trials (Jupp and Lawrence 
2010). However, they were not effective in redueing the reinforeing effects of the 
drugs in humans (Haney et al. 2001) and/or had severe side-effects (Saadan et al. 
2013).
The use of vaeeines for opioid and psychostimulant addiction has been shown to 
have promising therapeutic efficacy in decreasing drug eraving (see Shen et al.
2012). Nevertheless, possible side effects and ethical implications may prevent 
these vaeeines fi*om being manufactured. Therefore, it is clear that novel, safer and 
more effective pharmaeotherapies are needed for the prevention of relapse, which 
is the hallmark for the treatment of drug addietion.
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A possible target for the prevention of relapse is the alleviation of comorbid mood 
disorders whieh is developed during abstinence (Quello et al. 2005). Several lines 
of evidenee show a strong interaetion between neuronal markers of soeial 
behaviour and mood regulation (Dabrowska et al. 2011; Debiee 2005; Di Simplicio 
et al. 2009; Heinrichs and Gaab 2007; Windle et al. 2004) and of drug 
reward/withdrawal (Liu et al. 2011; Young et al. 2011), suggesting that the ‘soeial’ 
neuropeptide oxytocin (OT) and its central reeeptor system may be implicated in 
the modulation of negative emotional aspeets of drug addietion and relapse. 
Considering the therapeutic success of social support programs (e.g. Alcoholics 
Anonymous; (see Loder 2009) and the benefits of soeial rehabilitation and social 
reintegration (McGregor and Bowen 2012) in keeping addicts abstinent, the use of 
OT agents may prove an important tool to assist in relapse prevention by promoting 
pro-social behaviour.
1.5 Oxytocin and the oxytocin receptor system
Oxytocin was the first peptide hormone to be chemically synthesised in 
biologieally active form (Du Vigneaud et al. 1953). It is a nine amino-acid 
neuropeptide and it is synthesised both in the brain and in the periphery (Gimpl and 
Fahrenholz 2001). In the brain, OT is primarily synthesised in the magnoeellular 
neurosecretory cells of the supraoptic (SON) and paraventricular (PVN) nuclei of 
the hypothalamus (Hyp). Following its synthesis, the majority of the neuropeptide 
is transported and stored in vesicles in the posterior pituitary gland from where it is 
released into the bloodstream to exert its peripheral actions, which include its role 
in reproduction and parturition. However, OT is also transported and released from
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the dendrites and cell bodies of the PVN and SON, where it influences a broad 
network of extra-hypothalamic brain regions by volume transmission (see Landgraf 
and Neumann 2004). Moreover, OT is also generated, although to a lesser extent, 
by the parvoeellular neurons of the PVN, which innervate several brain regions 
including the olfactory nuclei, frontal and cingulate cortices, Aeb, LS, vertical limb 
of the diagonal band of Broca (VDB), Amy, BNST and also the brainstem and 
spinal cord (Badoer 2001; Mack et al. 2002; Petersson 2002; Sofroniew and 
Weindl 1978; Tang et al. 1998).
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Figure 1.2: Prominent oxytocinergic projections in the brain of rodents.
Oxytocin is primarily synthesised in the magnoeellular neuroseeretory cells in the supraoptic (SON) 
and paraventricular (PVN) nuclei; it is then transported to the posterior pituitary gland where it is 
stored in vesicles and is released into the bloodstream to exert its peripheral effects. Moreover, OT 
is also synthesised in the parvoeellular neurons o f the PVN, which innervate several 
extrahypothalamic regions in the CNS, including the olfactory nuclei, the nucleus accumbens, the 
lateral septum, the amygdala, bed nucleus o f the stria termnalis, and also to the brainstem and spinal 
eord, to exert its local effects. ( O magnoeellular neurons; O——  parvoeellular neurons)
(Zanos et al. 2014b)
There is also evidenee supporting the local synthesis and release of OT in several 
brain regions including the BNST, medial preoptic area (MPCA), and lateral part 
of the Amy (Young and Gainer 2003). However, there is continued disagreement as
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to whether OT that is released in these extra-hypothalamie brain areas eomes from 
the dendrites of unidentified OT eell bodies or from axonal projections (volume 
transmission) of OT-containing neurons projecting from the PVN (see Neumann
2007). Moreover, there is some evidence showing that scattered OT fibres 
projecting from magnoeellular hypothalamic neurons lie in diverse brain regions 
including the Hip, cortex, Amy, substantia nigra (SN), VTA, dorsal raphe nucleus 
(DR), locus coeruleus, and densely throughout the brain stem and spinal cord 
(Sofroniew 1980; Sofroniew 1983).
Oxytocin exerts its functions by acting on the oxytocin receptor (OTR). OT has 
high affinity for the OTR since it has been shown that the dissociation constant 
{Kd) of OT on the OTR is 0.76±0.04nM and the maximal OTR density {Bmax) is 
153±4 fmol/mg protein as measured on human uterine smooth muscle cells (Tahara 
et al. 2000). The OTR is a G protein-coupled reeeptor (GPCR) which is primarily 
coupled to G q /lla  class guanosine-5'-triphosphate (GTP) binding proteins 
enhancing the activity of phospholipase C (PLC) (Kimura et al. 1992). 
Subsequently, inositol trisphosphate (IP3) and 1,2-diaeylglycerol (DAG) are 
generated. Diffused cytosolic IP3 binds to calcium channels on the endoplasmic 
reticulum (ER) and stimulates the secretion of calcium. Elevated levels of calcium 
in neuroseretory cells control neuronal excitability, modulate their firing patterns 
and result in neurotransmitter release (see Berridge 1998). Protein kinase C (PKC) 
is directly activated by DAG in the presence of calcium and then phosphorylates 
other proteins.
The OTR is widely distributed throughout the brain. In humans, OTR are highly 
expressed in the basal nueleus of Meynert, LS, VP, VDB, posterior hypothalamic 
area, SN, Sol and substantia gelatinosa of trigeminal nucleus (Loup et al. 1991; 
Loup et al. 1989). In mice, high expression of OTR is found in the olfactory 
nucleus, LS, piriform cortex, hippocampal formation (especially CA3 region) and 
PVN (e.g. Curley et al. 2009; Insel et al. 1991; Insel et al. 1993); also see Table 1.2.
Table 1.2: Distribution of oxytocin receptors in the brain of different species.
Brain Regions Human Rat Mouse
Olfactory system
Anterior olfactory nucleus N/R + + + +
Olfactory tubercle N/R + + N/R
Islands of Calleja + + + + -
Piriform cortex N/R N/R + + +
Entorhinal/pcrirhinal area - + N/R
Cortical areas
Peduncular cortex +/- + + + N/R
Insular cortex N/R + N/R
Cingulate cortex N/R - -
Frontal cortex - +/- N/R
Temporal cortex - + N/R
Taenia tecta N/R +/- -
Ventral limb of the Diagonal band 
of Broca
+ N/R N/R
Basal nucleus of Meynert + + + - N/R
Basal ganslia
Caudate putamen - + + N/R
Ventral pallidum + + + + + N/R
Glopus pallidus + + - N/R
Nucleus Accumbens - + N/R
Limbic system
Lateral septum + + + + + + +
Bed nucleus of stria terminalis - + + + -
Amygdaloid-hippocampal area - + N/R
CAl region of Hip N/R N/R -
CA3 region of Hip N/R - + + +
Central amygdaloid nucleus - + + + -
Medial amygdaloid nucleus - + +
Basolateral amygdaloid nucleus - + + +
Parasubiculum and presubiculum - + + -
Dorsal subiculum - +/- -
Ventral subiculum - + + + -
Thalamus and Hyp
Anteroventral thalamic nucleus - - N/R
Paraventricular thalamic nucleus + + + + +
Ventromedial hypothalamic - + + +
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nucleus
Anterior medial preoptic area -H- - N/R
Supraoptic nucleus - 4-/- N/R
Paraventricular nucleus - 4-/- N/R
Medial tuberal nucleus + 4-4- N/R
Posterior hypothalamic area 4-4- - N/R
Supramammillary nucleus - 4- N/R
Lateral mammillary nucleus 4-4- 4- N/R
Medial mammillary nucleus 4- - N/R
Brain stem
Substantia nigra 4-4-4- - N/R
Ventral and dorsal tegmental area - - N/R
Central gray 4- - N/R
Dorsal raphe nucleus 4- - N/R
Reticular nuclei - - N/R
Medial vestibular nucleus - - N/R
Hypoglossus nucleus 4-4- - N/R
Nucleus of the solitary tract ■4- -f- -+- 4-/- N/R
Dorsal motor nucleus of the vagus 
nerve
4- 4- N/R
Inferior olive nucleus 4-/- 4- N/R
Substantia gelatinosa of trigeminal 
nucleus
4-4-4- 4- N/R
OT receptor binding levels in the brain o f humans, rats and mice. There is a high diversity o f OT 
receptor distribution between different species. The data have been derived from (Adan et al. 1995; 
Curley et al. 2009; Elands et al. 1988; Freund-Mercier et al. 1994; Freund-Mercier et al. 1987; 
Gimpl and Fahrenholz 2001; Insel et al. 1993; Jarrett et al. 2006; Klein et al. 1995; Kremarik et al. 
1993; Loup et al. 1991; Loup et al. 1989; Shapiro and Insel 1989; Tribollet et al. 1990; Tribollet et 
al. 1997; Tribollet et al. 1992a; Tribollet et al. 1988; Tribollet et al. 1992b; Yoshimura et al. 1996; 
Yoshimura et al. 1993). Abbreviations: +, low binding; ++, moderate binding; +++, high binding; 
+/- at the detection limit; -, not detectable; N/R, not reported.
Along with its peripheral actions OT has numerous central effects by binding to 
OTR in the central nervous system (Baskerville and Douglas 2010; Fuxe et al. 
2012; Meyer-Lindenberg et al. 2011; Rutherford et al. 2011). Indeed, activation of 
oxytocinergic (OTergic) system in the brain has been demonstrated to play an 
important role in modulating different behaviours such as social/sexual (Argiolas 
1999; Argiolas and Melis 2004; Insel et al. 1997; Kendrick 2000; Kendrick 2004), 
anxiety-, depressive- and psychotie-like behaviours (Baumgartner et al. 2008; 
Dabrowska et al. 2011; Di Simplicio et al. 2009; Kirsch et al. 2005; Rosenfeld et al. 
2011; Windle et al. 2004) and autonomie functions (Badoer 2001; Mack et al. 
2002; Petersson 2002; Tang et al. 1998).
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The role of OT in these behaviours is further supported from the behavioural 
phenotype of OTR knockout mice. Although OTR knockout mice are 
phenotypically healthy mice and both male and female mice are fertile (see 
(Winslow et al. 2000), they appear to have deficits in social recognition, reduced 
aggression but normal social interaction behaviours (Crawley et al. 2007; Ferguson 
et al. 2000; Winslow et al. 2000). In addition, male OTR knockout mice pups 
produce less ultrasonic vocalisations than wild type littermates in response to social 
isolation (i.e., decreased distress following social isolation) and adult mice 
displayed social amnesia and increased aggressiveness as measured by the soeial 
discrimination and resident-intruder aggression tests respectively further supporting 
the important role of the OTergic system in regulating stress-related and soeial 
behaviours (Takayanagi et al. 2005). Moreover, Macbeth et al. (2009) showed that 
OTR knockout male mice were unable to discriminate individuals of the same 
strain but were capable to discriminate between females from different suggesting 
that OTR is involved in 'fine' intrastrain recognition, but is less important in 'broad' 
interstrain recognition.
1.6 Role of oxytocin in drug addiction
Early evidence suggests that OT might play a role in drug addiction processes 
(Kovacs 1986; Kovacs and Telegdy 1987). Increasing interest in the involvement 
of the OTergic system in drug addiction came from the initial findings that the 
brain systems involved in drug reward interact with systems involved in natural 
rewards such as sexual behaviour and soeial bonding. In support of this, recent 
findings showed that the pro-social properties of some drugs of abuse, such as
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MDMA and MAP, induce stimulation of the OTergic system in both humans 
(Dumont et al. 2009; Wolff et al. 2006) and animals (Broadbear et al. 2011; 
Thompson et al. 2007). In addition to the early findings about the involvement of 
OT in opioid and cocaine addietion, more recent findings suggest a role of this 
system in other types of psychostimulant addiction as well as addiction to 
marijuana and alcohol (Bowen et al. 2011; Butovsky et al. 2006; McGregor and 
Bowen 2012). These preclinical data were followed by clinical trials, where 
intranasal administration of oxytocin decreased stress-induced reactivity and 
craving in marijuana-dependent individuals (McRae-Clark et al. 2013) and blocked 
alcohol withdrawal symptoms in human subjects (Pedersen et al. 2013). Therefore, 
the current evidence suggests a role of OT in several behaviours related to 
addiction including reward, tolerance, withdrawal and reinstatement (see Tables 
1.3-4).
Moreover, it has been postulated that early life events, such as stress and social 
adversity can affect the development of the endogenous OT system resulting in a 
less fine-tuned system. A well-developed OT system is able to directly and 
indirectly increase resilience, for example by reducing drug reward, increasing 
social reward, redueing anxiety and stress response leading to a decrease in the 
possible escalation in the dose of the drug administered and to a decrease relapse 
potential (see Buisman-Pijlman et al. 2014). As the focus of this thesis involves 
cocaine, opioid and MAP addiction, the role of OT in ethanol and nicotine 
addictions will not be discussed.
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1.6.1 Opioid addiction
Acutely, morphine administration decreases OT release from the Hyp (Clarke et al. 
1979) and reduces OT release during suckling (Haidar and Sawyer 1978). 
Conversely, increased OT immunoreactivity in extra-hypothalamic regions 
including Hip, Amy and basal forebrain was observed following acute morphine 
administration, suggesting differential regulation of the OTergic system in different 
regions of the brain (Kovacs et al. 1987a).
A decrease in OT immunoreactivity in the Hip, and a reduction in OT messenger 
ribonucleic acid (mRNA) levels within the SON, median eminence (ME) and 
arcuate nucleus of the Hyp (ARC) were observed following chronic morphine 
administration (Kovacs et al. 1987a; Laorden et al. 1998). The down-regulation 
observed in the OTergic system following chronic administration of opioids, 
compared with the stimulatory effect of acute opioid administration, might be a 
result of several neuroadaptive alterations in the OTergic system caused by chronic 
exposure to opioids.
Peripheral as well as central OT administration dose-dependently attenuated the 
development of tolerance to morphine’s analgesic effects in rodents (Kovacs et al. 
1985; Kovacs et al. 1998; Kovacs and Telegdy 1987). In agreement, central 
administration of OT was also able to attenuate the development of tolerance to the 
antinociceptive effect of y^-endorphin, an endogenous opioid peptide, in a dose- 
dependent manner (Kovacs and Telegdy 1987). Oxytocin treatment has been shown 
to inhibit the development of tolerance to locomotor hyperactivity following the 
administration of morphine in mice (Kovacs and Telegdy 1987). Moreover, OT
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administration induced a decrease in heroin self-administration in heroin-tolerant 
rats, but not in non-tolerant rats (Kovacs et al. 1998). Local microinjections of the 
OTR antagonist, V-a-aeetyl-[2-0-methyltyrosine]-OT into limbic brain areas (i.e.. 
Hip, thalamus. Hyp, Amy, olfactory bulb, Acb) effectively antagonised OT’s 
inhibitory effects on the development of morphine tolerance (Samyai et al. 1988) 
and heroin self-administration in rats (Ibragimov et al. 1987), suggesting a 
regulatory role of the OT system in limbic regions in order to counterbalance 
opioid-indueed effects. Taken together, these findings suggest that OT is able to 
modulate several adaptive mechanisms underlying opioid tolerance by acting on 
OTRs in the limbic regions of the brain.
Oxytocin has also been shown to play a role during opioid withdrawal. In particular, 
peripheral administration of OT decreased hypothermia and loss of body weight and 
increased the latency of the beginning of stereotyped jumping induced by naloxone- 
precipitated morphine withdrawal in mice (Kovacs et al. 1985). An increase in both 
plasma OT levels and firing rate of SON OT neurons was observed following acute 
naloxone-precipitated morphine withdrawal in chronically morphine-treated 
lactating rats, suggesting a possible regulation of the OTergic system by the 
endogenous opioid system (Bicknell et al. 1988). Naloxone administration 
significantly increased OT levels in the cerebrospinal fluid (CSF) of opioid- 
dependent rats (Coombes et al. 1991) and Fos protein expression within the SON in 
rats (Johnstone et al. 2000; Murphy et al. 1997). OT mRNA levels within the ME 
and PVN has been shown to be increased following naloxone administration in rats 
(Laorden et al. 1998), which might suggest that an increase in OT biosynthesis in 
the PVN and an increase in the transport and release of OT into the plasma from the
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posterior pituitary gland. Moreover, a 7-day withdrawal period from a chronic 
escalating morphine paradigm has been shown to induce a decrease in the 
hypothalamic OT levels, concomitant with an increase in OTR binding in the LS 
and Amy, which were associated with the development of emotional impairment 
(Zanos et al. 2014a). The peripheral administration of an OT analogue reversed the 
withdrawal-induced emotional impairment (Zanos et al. 2014a), supporting a key 
role of the OTergic system in regulating opioid withdrawal-associated mood 
disorders.
1.6.2 Cocaine addiction
The effects of OT on cocaine-induced behavioural and neurochemical alterations 
have been extensively studied in rodent models. Systemic OT administration 
inhibits the cocaine-indueed DA utilisation in the Acb, but not the caudate putamen 
(CPu), and decreases cocaine-induced hyperactivity in mice (Kovacs et al. 1990). In 
addition, Samyai et al. (1991) demonstrated that systemic or central administration 
of OT into the Acb and Tu, but not the CPu or the CeA were able to block cocaine- 
induced stereotypic sniffing. The inhibition of cocaine-induced sniffing behaviour 
by peripherally administered OT was able to be reversed by the central 
administration of an OTR antagonist (Kovacs et al. 1998), suggesting that the OT 
system is involved in the regulation of the cocaine-induced stereotypic effects. A 
possible mechanism for the inhibitory effects of OT on the cocaine-induced 
behavioural alterations might its actions on the DAergic system. Indeed, it has been 
shown that OT administration blocks DA utilisation across a network of limbic and 
basal forebrain areas of the brain (Kovacs et al. 1998) and OTR are co-localised and 
functionally interact with DA D] receptors in the Acb (Romero-Femandez et al.
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2013). Therefore, OT might activate DA D2 receptors in the Acb, which in turn will 
inhibit DA release.
Further, acute administration of cocaine decreased the OT immunoreactivity levels 
in the basal forebrain and increased OT peptide levels in the Hyp and Hip (Samyai 
et al. 1992c). In contrast, acute cocaine did not induce any alterations in either 
plasma OT levels or OT immunoreactivity levels in the Amy, suggesting a region- 
specific effect of cocaine on the OTergic system (Samyai et al. 1992c).
Chronic cocaine administration can result in either tolerance or sensitisation, 
depending on the dose and route of administration, treatment schedule or 
environmental effects in both rodents and humans (Hammer et al. 1997; Johanson 
and Fischman 1989). The development of behavioural tolerance to the sniffing- 
inducing effects of cocaine was inhibited by pre-treatment with oxytocin 
administered prior to each daily injection of the 5-day cocaine regimen (Samyai et 
al. 1992a). However, behavioural locomotor sensitisation induced by the sub- 
ehronic administration of cocaine was enhanced by the peripheral daily (5 days) 
injections of OT prior to cocaine administration, suggesting a differential role of OT 
in the modulation of both tolerance and sensitisation to cocaine (Samyai et al. 
1992b).
With respect to withdrawal, it has been demonstrated that mandarin voles, which are 
socially monogamous species and display high levels of patemal care, displayed 
attenuated licking/grooming and contact behaviour and shortened the latency to 
crouching, contact and pup retrieval 24 hours after a 4-day cocaine administration
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paradigm which was accompanied with decreased OT immunoreactive neurons in 
the in cocaine-treated fathers, suggesting that cocaine withdrawal disturbs the 
expression of partial patemal behaviour by altering at least partly the central levels 
OT (Wang et al. 2014). A possible involvement of the OT system in cocaine 
reinstatement has been also proposed since centrally administered OT prior the 
reinstatement testing attenuated cue-induced reinstatement of cocaine-seeking 
behaviour and decreased the anxiety triggered by cue-induced reinstatement 
suggesting a regulatory role of the OT system in cue-induced reinstatement of 
cocaine-seeking as well as the reinstatement-induced anxiety (Morales-Rivera et al.
2014).
Evidenee shows that chronic administration of cocaine induces a hypo-activity in 
the OTergic system. For instance, it was shown that long-term administration of 
cocaine decreased plasma OT levels and OT immunoreactivity within the Hyp and 
Hip in rats (Samyai et al. 1992a). In agreement, chronic gestational and post- 
gestational cocaine treatment decreased OT levels in the MPOA, VTA, and Hip, and 
OTR binding in the ventromedial Hyp (VMH) and BNST of rat dams (Jarrett et al. 
2006; Johns et al. 2004; Johns et al. 1997; Johns et al. 1998). The negative outcome 
of gestational cocaine treatment appeared to be long-lasting, since young adult 
female offspring of cocaine-treated dams exhibited higher levels of aggression 
associated with lower levels of OT in the Amy (McMurray et al. 2008). In addition 
to the pre-clinical evidence of a role of OT in cocaine addiction. Light et al.(2004) 
demonstrated that mothers using cocaine during pregnancy have lower plasma OT 
levels, greater hostility and depressed mood, and less social support and adaptive 
coping strategies for stressful life events compared to coeaine-naive mothers.
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1.6.3 Methamphetamine addiction
Several studies have investigated the involvement of the OTergic system in 
methamphetamine addietion. Specifically, Qi et al (2008) demonstrated that central 
OT administration dose-dependently decreased MAP-induced hyperlocomotion (Qi 
et al. 2008), which was accompanied by reduced ratios of the DA metabolites 3,4- 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) to DA in the 
striatum, indicating decreased DA metabolism. These effects were attenuated by 
the central administration of atosiban, an OTR antagonist, suggesting that OT 
exerted its inhibitory effects on MAP-related behaviours via acting on the OTRs in 
the brain. Since it is known that reduction in extracellular DA levels is associated 
with decreased motor activity in rodents (Alexander and Crutcher 1990), OT might 
have caused the reduction in MAP-induced hyperactivity, at least partly, by 
triggering a hypo-DAergic state in the brain.
Central OT administration significantly inhibited the acquisition of MAP-induced 
CPP, while no effect was observed on the expression of an already acquired MAP 
CPP (Qi et al. 2009). Further, OT treatment was able to facilitate the extinction of 
MAP-induced CPP and to prevent stress-, but not priming-induced, reinstatement 
of MAP CPP (Qi et al. 2009). The effect of OT in blocking stress-induced 
reinstatement to MAP-seeking has been attributed to the ability of OT to prevent 
increased glutamate levels in the mPFC following restraint stress- but not MAP- 
induced reinstatement of CPP. In agreement, Han et al. (2014) demonstrated that 
microinjeetion of OT in the mPFC and dorsal Hip prevented stress-induced 
reinstatement of MAP-seeking via a glutamate-dependent manner. Evidence 
suggests that psychostimulants trigger drug-induced reinstatement by directly
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activating the mesolimbic DAergic system, which in turn enhances glutamate 
release in the PFC. In contrast, stress can activate VTA DAergic neurons via the 
activation of an excitatory glutamatergic projection from the PFC innervating the 
VTA (Moghaddam 1993). Stress-induced increase in glutamate levels is thought to 
be a mechanism underlying reinstatement following exposure to stress in rodents. 
Therefore, OT might differentially regulate glutamate release in the mPFC, thus 
having a prominent role in stress-induced, but not MAP-primed reinstatement. 
However, recently it has been shown that systemic administration of OT dose- 
dependently decreased MAP self-administration and reinstatement induced by 
priming injections of MAP suggesting a possible role of the OTergic system in the 
regulation of priming-induced reinstatement of drug-seeking (Carson et al. 2010a; 
Cox et al. 2013). These discrepancies may be due to the different protocols of drug 
administration used in these studies (i.e. contingent vs non-contingent). Indeed, it 
has been shown that contingent and non-contingent drug administration protocols, 
including that of nicotine (Metaxas et al. 2010) and cocaine (Markou et al. 1999), 
exerted differential neurochemical as well as behavioural responses.
MAP administration induced a marked increase in OTR binding in the Hyp and 
Amy which are brain regions associated with stress, emotionality and social 
bonding (Zanos et al. 2014b). However, MAP self-administration in rats did not 
induce any alterations in the firing of OT neurons in the Hyp (Carson et al. 2010b). 
In addition to the investigation of the effects of MAP on the hypothalamic OT 
system which is the main site of OT synthesis, several other regions where also 
investigated. It has been shown that peripherally administered OT significantly 
decreased c-Fos expression induced by MAP in the subthalamic nucleus (STh) and
30
Acb core (AcbC), two regions involved in impulsivity and drug addiction (Eagle 
and Baunez 2010). Additionally, both peripherally administered or microinjections 
of OT into the STh and AcbC attenuated the acquisition of MAP CP? (Baracz et al.
2012). These findings provide evidence for an important role of the STh and AcbC 
in the inhibitory effects of OT on the rewarding properties of MAP. In support of 
this, Baracz and Cornish (2013) demonstrated that a single-dose of DA directly 
injected in the STh of rats resulted in the acquisition of CPP, while the 
administration of fiuphenazine, a DA receptor antagonist, or OT into the STh 
blocked this effect (Baracz and Cornish 2013). Altogether, these data support the 
existence of local OTRs in the STh that exert an inhibitory action on DAergic 
reward processes associated with the effects of MAP.
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1.7 The endogenous opioid system
The endogenous opioid system consists of three classical opioid receptors (p, 8 and 
k) and three families of endogenous peptides (endorphins, enkephalins and 
dynorphins). The first radioligand binding evidence for the existence of membrane 
receptors for opioids in the brain came in 1973 by three independent groups (Pert 
and Snyder 1973; Simon et al. 1973; Terenius 1973) and few years later, different 
opioid binding sites were identified, confirming that opioid receptors did not 
constitute a homogenous population (Lord et al. 1977; Martin et al. 1976b).
The three opioid peptides are derived from precursors molecules; 
proopiomelanocortin (POMC), proenkephalin (PENK) or prodynorphin (PDYN), 
which are enzymatically cleaved to form the final active peptides, y^-endorphin, 
met- and leu-enkephalin and dynorphins, respectively (Kieffer and Gaveriaux-Ruff 
2002). The endogenous opioid ligands exhibit different affinities for each opioid 
receptor, yg-endorphin binds with higher affinity to MOPr, met- and leu-enkephalin 
binds with higher affinity to 5-opioid receptor (DOPr) and dynorphin binds with 
higher affinity to K-opioid receptor. As this thesis is mainly focuses on the MOPr 
system, the KOPr and DOPr systems will not be discussed.
MOPr belong to the superfamily of G protein-coupled receptors and exert their 
cellular effects via coupling with pertussis toxin sensitive GTP-binding proteins 
Gi/Go and upon activation cause inhibition of cyclic adenosine monophosphate 
(cAMP) formation and activation of mitogen-activated protein kinase (MAPK) 
pathways. Moreover, when the receptor is activated the inwardly rectifying 
channels stimulates and cause a reduction in Ca^  ^currents that are sensitive to
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P/Q-type, N-type, and L-type channel blockers. This process causes cellular 
hyperpolarisation and inhibits tonic neural activity (see Al-Hasani and Bruchas 
2011). Following these stages, the opioid receptors are phosphorylated, which leads 
to the activation of more MAPK pathways and the recruitment of arrestins resulting 
in the desensitisation of the receptors (see Al-Hasani and Bruchas 2011). MOPr 
and its endogenous peptide ligands (yg-endorphins and enkephalins) are widely 
distributed throughout the central nervous system as well as in peripheral tissues 
and modulate several physiological processes including nociception, mood 
regulation, learning and memory and reward (see Bodnar 2008) also see Table 1.5.
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Table 1.5: Distribution of MOPr receptors in the brain of different species.
Brain Regions Human Rat Mouse
Olfactory system
Anterior olfactory nucleus N/R + + + +
Entorhinal area N/R + + + +
Piriform cortex N/R + +
Cortical areas N/R
Parietal cortex N/R + + + +
Insular cortex -H- N/R N/R
Occipital cortex N/R + +
Frontal cortex N/R + + + +
Temporal cortex N/R + + + +
Endopiriform cortex N/R + + + + + +
PFC ++ + +
Presubuculum + + + + + + +
Basal ganglia
Caudate putamen + + -1- + + + +
Ventral pallidum + + + + + +
Glopus pallidus N/R + + + +
Nucleus accumbens + + + + + + +
Islands of Calleja + + + N/R N/R
Limbic system + + + +
Septum + + + + + + +
Bed nucleus of stria terminalis N/R + + + +
Cortical nucleus, Amy + + + + + + + + +
Medial nucleus, Amy + + + + + + + + +
Basolateral amygdaloid nucleus + + + + + + + + +
Hip + + + + + + +
Thalamus and Hyp
Thalamus + + + + + + + + +
Reuniens thalamus N/R + + + + + +
Ventrolateral thalamus N/R + + + + + +
Centrolateral thalamus N/R + + + + + +
Ventromedial thalamus N/R + + + + + +
Zona incerta N/R + + + +
Centromedial thalamus N/R + + + + + +
Dorsomedial Hyp N/R + +
Mediodorsal thalamus N/R + + + + + +
Paraventricular thalamus N/R + + + + + +
Nucleus gelatinosus, thalamus N/R + + + + + +
Lateral Hyp N/R + +
Laterodorsal thalamus N/R + + + + + +
Posterior thalamus N/R + + + + + +
Medial geniculate N/R + + + + + +
Medial habenula + + + + + + + + +
Medial mammillary nucleus N/R + + + + + +
Preoptic area N/R + +
Ventroposterolateral thalamus N/R + + + +
Raphe magnus + + + + + + +
Brain stem
Substantia nigra N/R + + + + + +
Nucleus reticularis gigantocellularis N/R + +
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Pedunculopontine nucleus N/R + +
Nucleus ambiguus N/R + + + + + +
VTA N/R + + + +
Locus coeruleus + + + + + + + + +
Interpeduncular nucleus N/R + + + + + +
Dorsal and medial raphe N/R + + + +
Dorsal tegmental nucleus N/R + + + +
Periaqueductal gray + + + + +
Nucleus tractus solitarius + + + + + + +
Red nucleus N/R + + + + + +
Sensory trigeminal nucleus +++ + +
Spinal trigeminal nucleus N/R + + + + + +
Pontine reticular N/R + +
Lateral reticular nucleus N/R + +
Accessory optic tract + N/R N/R
Inter- peduncular nuclei + + + N/R N/R
Fasciculus retroflexus + N/R N/R
Parabrachial nuclei + + + N/R N/R
MOPr receptor binding levels in the brain o f humans, rats and 
from (Arvidsson et al. 1995; Kitchen et al. 1997; Le Merrer 
Mansour et al. 1995; Mansour et al. 1987; Zubieta et al. 2005; 
2001). +, low binding; ++, moderate binding; +++, high binding;
mice. The data have been derived 
et al. 2009; Lesscher et al. 2003; 
Zubieta et al. 1999; Zubieta et al. 
N/R, not reported
1.8 Role of fi-opioid receptor system in drug addiction
In addition to the endogenous opioids, MOPrs can be activated by the exogenous 
administration of opioid ligands, including morphine, codeine and heroin (see Le 
Merrer et al. 2009; Trigo et al. 2010). Morphine as well as other opioid-based 
compounds are widely used clinically due to their effectiveness in pain 
management (see Kapur et al. 2014). However, the most important drawback of 
these compounds is their abuse potential during chronic use (see Kapur et al. 2014). 
The key finding by Matthes et al. (1996) that morphine-induced analgesia and the 
addictive properties of morphine were abolished in MOPr knockout mice indicated 
that MOPr mediates both the therapeutic and the adverse effects opioids. 
Importantly, these effects observed in the mice lacking the MOPr were not limited 
to opioids as the reinforcing properties of alcohol, cannabinoids, and nicotine, are 
also reduced in these mutant mice suggesting a key role of the MOPr system in the 
regulation of the rewarding properties of several drugs of abuse (Charbogne et al.
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2014; Kieffer and Gaveriaux-Ruff 2002). Beyond the rewarding aspect of drug 
consumption, pharmacological studies have also suggested a role for this receptor 
in the maintenance of drug use, as well as craving and relapse (Gerrits et al. 2003). 
Indeed, MOPr are highly expressed in brain areas involved in reward and 
motivation, including the VTA, Acb, PFC, Hyp and extended Amy (Table 1.4; 
Delfs et al. 1994; Mansour et al. 1995; Mansour et al. 1994a; Mansour et al. 
1994b).
1.8.1 Opioid addiction
Ligands acting directly or indirectly on the MOPr, such as morphine and heroin 
respectively, possess high abuse liability and therefore, are self-administered by 
humans and experimental animals (Devine and Wise 1994). It has been 
demonstrated that MOPr are essential for the mediation of rewarding effects of 
opioids since MOPr knockout mice do not respond to morphine (Matthes et al.
1996). It has been shown that intra-VTA microinfusions of morphine as well as the 
selective MOPr agonist [D-Ala2,N-Me-Phe4-Gly5-ol]-enkephalin (DAMGO) were 
able to establish self-administration behaviour and induce reinstatement following 
extinction demonstrating a key role of the VTA MOPr in the regulation of 
reinforcing effects of opioids as well as in reinstatement to opioid-seeking (Devine 
and Wise 1994). Mice lacking the MOPr gene have blunted response to the intra- 
VTA induced morphine reward which was associated with the decreased number of 
Fos-positive neurons in the Amy, Hip and mammillary nucleus and ventral 
posteromedial thalamus further supporting the important role of MOPr in the 
regulation of the reinforcing effects of opioids (David et al. 2008). Additionally, 
intra-VTA or intra-Acb administration of endorphin, a MOPr agonist, induces a
48
CPP whereas prior administration of the MOPr antagonist D-Phe-Cys-Tyr-D-Trp- 
Om-Thr-Pen-Thr-NHi (CTOP) or the opioid receptor antagonist 3- 
methoxynaltrexone in the VTA or Acb, respectively prevented CPP behaviour 
(Terashvili et al. 2004).
In agreement, intra-Acb infusions of DAMGO decreased the brain reward 
thresholds, which revealed an activation of the reward circuit (Duvauchelle et al.
1997) suggesting that accumbal MOPr might mediate the reinforcing effects of 
opioids. The essential role of the accumbal MOPr in driving the rewarding effects 
of morphine was confirmed by Cui et al. (2014) who showed that rescue of MOPr 
in the Acb in mice lacking the MOPr gene restores opioid reward and opioid- 
induced striatal DA release and partially restores motivation to self-administer 
opioids. Pre-treatment with (+)-morphine (inactive isomer) into the posterior shell 
of the Acb decreased the (-)-morphine (active isomer)-indueed CPP as well as the 
MOPr-mediated increase of extracellular DA in the posterior AcbSh of the rat, 
proposing a specific role of the AcbSh MOPr in the observed morphine effects 
(Terashvili et al. 2008). Intra-Acb administration of DAMGO prior to the systemic 
morphine treatment blocked the induction of CPP suggesting that stimulation of 
accumbal MOPr competes with systemic opioid-seeking by producing direct 
reinforcing effects (Liang et al. 2006). A discrimination between the striatal MOPr 
localisation that regulate reinforcing effects of opioids was also suggested by David 
and Gazala (2000) who showed that mice self-administer morphine into the Acb, 
but not into the CPu, an effect that is reduced by systemic naloxone administration.
49
In contrast, systemic administration of the MOPr preferring antagonists, naloxone 
and naltrexone produces dysphoria in humans and conditioned place aversion 
(CPA) in animals (see Shippenberg et al. 2008) and intra-accumbal injections of 
opioid receptor antagonists attenuate the systemic opioid-induced rewarding effects 
(McBride et al. 1999; Shippenberg and Elmer 1998; van Ree et al. 1999) further 
supporting the essential role of MOPr in the Acb in the development of opioid 
dependence. Administration of the MOPr antagonist, p-flinaltrexamine, into the 
caudal, but not the rostral part, of the Acb reduced the heroin self-administration 
(Martin et al. 2002) providing evidence for a critical role of the caudal part of the 
Acb in regulating the rewarding effects of opioids. Intra-Acb injection of the MOPr 
antagonist CTOP, the Di DA receptor antagonist (5R)-8-Chloro-3-methyl-5- 
phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol hydrochloride (SCH23390), the 
D2 DA receptor antagonist raclopride or the combination of SCH23390 and CTOP, 
dose-dependently decreased breakpoints to self-administer intravenous speedball (a 
combination of cocaine and heroin) suggesting that accumbal DA receptors and 
MOPr are involved in the reinforcing effects of speedball and that combination 
treatment with DA Di and MOPr antagonists may be more effective at reducing the 
reinforcing effects of speedball self-administration than either drug alone (Cornish 
et al. 2005).
In addition to the involvement of VTA and Acb in the rewarding effects of opioids, 
a possible role of the VP and Amy has also been suggested. It has been shown that 
intra-VP administration of morphine was able to produce CPP (Olmstead and 
Franklin 1997). Interestingly, naloxone injected into the VP produced CPA, an 
effect that was reproduced using the MOPr antagonist CTOP, suggesting that
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MOPr in the VP, activated by endogenous opioid peptides, modulate basal 
affective states (Skoubis and Maidment 2003). Repeated intra-VP morphine 
injections facilitated a CPP induced by a low dose of systemic morphine and 
peripheral pre-treatment with naloxone or DArgic antagonists suppressed the CPP, 
indicating that the facilitatory effects of intra-VP morphine involve activation of 
MOPr and DArgic receptors (Zarrindast et al. 2007). With respect to the Amy, it 
has been shown that mice self-administer morphine into the Amy (David and 
Cazala 1994), while administration of morphine in the lateral nucleus of Amy did 
not produce CPP in rats (Olmstead and Franklin 1997) suggesting that MOPr in the 
different amygdalar sub-regions might respond differentially to the rewarding 
effects of opioids.
Repeated exposure to opioids induces adaptive alterations in the MOPr system, 
such as decrease in the number of functional receptors or uncoupling of the 
signalling pathway, which results in the development of tolerance and physical 
dependence (see Williams et al. 2013). While it has been suggested that 
desensitisation of MOPr and recruitment of several downstream mechanisms are 
the major factors involved in the development of tolerance, evidence for receptor 
down-regulation is not consistent (see Christie 2008). Indeed, following chronic 
treatment with MOPr agonists, MOPr binding has been shown to increase (Holaday 
et al. 1982; Zadina et al. 1989), decrease (Dingledine et al. 1983; Tao et al. 1987) 
or remain unaltered (Hollt et al. 1975; Klee and Streaty 1974) in the brain of 
rodents, depending on the opioid ligands used and the brain region tested. 
Following heroin self-administration, a decrease in MOPr stimulated [^^S] 
guanosine 5'-0-[gamma-thio]triphosphate (GTPyS) binding was observed in
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several brain regions, including periaqueductal grey, locus coeruleus, thalamus and 
Amy, with a concomitant increase in MOPr binding in numerous brain regions, 
including PFC, Acb, locus coeruleus and Hip (Sim-Selley et al. 2000) and 
decreased MOPr G-protein efficiency in these regions (ratio between agonist- 
activated G-proteins and MOPr binding) (Sim-Selley et al. 2000). These results 
provide evidence for a possible desensitisation of the MOPr despite the increase in 
surface MOPr which might underlie the development of opioid tolerance and 
dependence (Sim-Selley et al. 2000). In agreement, chronic morphine treatment 
decreased MOPr stimulated [^^SJGTPyS binding compared with control rats in 
brainstem nuclei, which are involved in physiological homeostasis and autonomic 
function, suggesting a possible implication of these alterations in the development 
of opiate tolerance and physical dependence (Sim et al. 1996). In contrast, in 
morphine-sensitised animals an increase was observed both in MOPr-stimulated 
[^^SJGTPyS binding in the CPu and Hyp and MOPr binding in the CPu, AcbSh, 
PFC, frontal cortex, medial thalamus and Hyp (Vigano et al. 2003). An increase in 
the basal striatal cAMP levels in sensitised rats was also observed suggesting that 
these cellular events induced by morphine pre-exposure might underlie the 
neuroadaptations involved in morphine sensitisation (Vigano et al. 2003). These 
discrepancies in the activation of G proteins might be due to region-specific 
morphine-induced neuroadaptations or due to different administration paradigms 
used.
Moreover, ligand-specific differences exist in the ability of opioid agonists to 
induce MOPr down-regulation; however this does not correlate with differences in 
their ability to develop tolerance (Patel et al. 2002). The principal mechanism for
52
MOPr desensitisation and internalisation includes the phosphorylation of activated 
receptors by G-protein-coupled receptor kinases (GRKs) and the consequent 
conformational change, which increases the affinity of the receptor for the cytosolic 
P-arrestin proteins. The interaction between P-arrestins and MOPr results in the 
uncoupling of G-protein signalling, leading to the recruitment of the endocytotic 
machinery and to receptor internalisation (see Koch and Hollt 2008). In support of 
this, it has been shown that MOPr desensitisation as well as development of 
antinociceptive tolerance was not observed in P-arrestin-2 knockout mice 
chronically treated with morphine suggesting a possible differential regulation of 
MOPr by opioids in the induction of tolerance and dependence (Bohn et al. 2000). 
However, p-arrestin-2 knockout mice still become physically dependent on the 
drug and chronic morphine treatment induces an increase in adenylyl cyclase 
activity which is a cellular marker of dependence (Bohn et al. 2000) Moreover, a 
decrease in the recovery from acute [Met]5-enkephalin-induced desensitisation and 
receptor recycling was observed in morphine-treated animals, which was absent in 
animals lacking p-arrestin-2 (Quillinan et al. 2011). Although pharmacological 
inhibition of GRK2 did not affected the ability of [Met] 5-enkephalin to induce 
desensitisation, the delay in recovery from desensitisation produced by chronic 
morphine treatment was reversed suggesting that the GRK/arrestin system might 
also control the recovery from desensitisation by regulating receptor reinsertion to 
the plasma membrane after chronic treatment with morphine (Quillinan et al. 
2011).
It has been suggested that morphine is a poor desensitising agent since no 
desensitisation was observed in MOPr in mature rat locus coeruleus neurons in
53
response to morphine, whereas DAMGO and methadone a produced profound 
rapid desensitisation (Bailey et al. 2003). However, Dang and Williams (2005) 
demonstrated that morphine induces a slower and smaller desensitisation compared 
to the desensitisation induced by [MET] 5-enkephalin, and although the peak 
current induced by morphine in tissue taken from morphine-treated animals was the 
same as in untreated animals, the morphine-induced desensitisation was facilitated 
suggesting that morphine ean initiate MOPr desensitisation but not in the same way 
as other MOPr agonists. It has been also demonstrated that ehronic morphine 
administration induces extensive homologous desensitisation of MOPr in mature 
neurons, which is, at least partly PKC-dependent and suggests that this 
desensitisation might underlie the maintenance of morphine tolerance (Bailey et al. 
2009).
It is also suggested that receptor internalisation might be a mechanism to ensure 
that inactivated receptors are not degraded, but dephosphorylated and recycled to 
the cell surface in a reactivated state (Bailey and Connor 2005; Koch and Hollt 
2008). Therefore, non-intemalising opioid compounds, such as morphine might 
induce a greater degree of tolerance compared to opioid drugs with high 
endocytotic efficacy (Borgland et al. 2003). In fact, Duttaroy and Yobum (1995) 
demonstrated that tolerance to the antinociceptive effects of morphine was greater 
compared to opioid agonists with higher efficacy, like etorphine and fentanyl, 
which might be associated with low morphine-induced MOPr internalisation 
(Borgland et al. 2003). Moreover, it is widely accepted that morphine stimulates 
the long-lasting transfer of MOPr-activated Ga subunits to proteins of the regulator 
of G-protein signalling (RGS) R7 and RGS-Rz subfamilies (Garzon et al. 2005;
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Rodriguez-Munoz et al. 2007a). While acute central administration of morphine did 
not cause any significant internalisation of MOPr, a fraction of the Ga subunits was 
stably transferred to RGS proteins in a time-dependent manner, resulting in the 
production of a weaker antinociceptive response on the second dose of morphine 
administered six hours after the first one (Rodriguez-Munoz et al. 2007b). 
However, the second morphine injection stimulated the internalisation and 
recycling of MOPr and hence further exposure to morphine promoted little 
tolerance to this moderate antinociception. In contrast, the acute administration of 
DAMGO stimulated a greater degree of internalisation of the MOPr associated 
with a transient transfer of Ga subunits to the RGS proteins, recovering MOPr 
control shortly after the effects of the opioid had ceased (Rodriguez-Munoz et al. 
2007b). Accordingly, the recycled MOPr re-established their association with G 
proteins and neurons were rapidly re-sensitised to DAMGO (Rodriguez-Munoz et 
al. 2007b). Therefore, these results highlight the different mechanisms involved in 
the development of tolerance to different MOPr agonists, like morphine and 
DAMGO.
Genetic studies confirmed that exogenous opioids, such as morphine, exert their 
therapeutic as well as side effects by activating the MOPr in the brain (see Contet 
et al. 2004; Table 1.6 ). It has been shown that mice lacking the MOPr failed to 
acquire both morphine (Matthes et al. 1996; Nguyen et al. 2012b; Sora et al. 2001) 
and heroin (Contarino et al. 2002) GPP. Similarly, intravenous as well as intra- 
VTA morphine self-administration was completely abolished in MOPr knockout 
mice compared to wild type mice (David et al. 2008; Sora et al. 2001). Further, 
morphine- (Becker et al. 2000; Chefer et al. 2003; Yoo et al. 2006) and heroin- 
induced (Contarino et al. 2002) hyperlocomotion were decreased in MOPr
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knockout mice. However, the ^-endorphin knockout mice do not share the same 
behavioural responses with MOPr knockout mice since they exert a robust 
morphine-induced CPP (Niikura et al. 2008; Skoubis et al. 2005) suggesting that p~ 
endorphin is not involved in the induction of the rewarding effects of morphine but 
these effects of morphine are mediated by its action on the MOPr and possibly the 
recruitment of the MOPr’s downstream pathways. Knock-in mice expressing a 
mutant recycling MOPr that it desensitises and is internalised in response to 
morphine, are more sensitive to the rewarding effects of morphine but were less 
motivated to obtain the drug over time compared to wild type mice and therefore 
showing a decrease in the development of compulsive use of the drug. These 
findings suggest that facilitating MOPr trafficking enhances the desirable, 
therapeutic potency of opioids, while reducing their negative side effects (Berger 
and Whistler 2011).
The MOPr gene (OPRMl) polymorphism, A118G, has been linked with heroin 
abuse since around 90% of European Caucasian heroin addicts tested positive for 
the 118G allele (Drakenberg et al. 2006). A greater down-regulation of 
preproenkephalin gene was demonstrated in 118G subjects in the AcbSh 
concomitant with an increase in enkephalin peptide levels only in 118G heroin 
addicts, suggesting that the peptide processing is associated with the 
polymorphisms in OPRMl gene and changes in opioid neuropeptide systems might 
underlie the enhanced opioid abuse vulnerability in 118G subjects (Drakenberg et 
al. 2006). In support of this, polymorphisms in the OPRMl gene have been linked 
with self-reported positive responses on first use of heroin, which is possibly 
associated with increased heroin consumption (Zhang et al. 2007). While a meta­
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analysis study reported no association between the A118G allele and genotype 
frequencies in opioid dependence, the significant heterogeneity between studies 
precluded highly definitive conclusions. Although there is no evidence for direct 
association with risk of dependence, A118G may still influence the 
pharmacological response to opioids impacting on an individual’s dosage 
requirements (Coller et al. 2009).
1.8.2 Cocaine addiction
Acute and chronic administration of psychostimulants induces alterations in the 
opioid peptide content, gene expression and receptor densities in brain regions 
associated with reward (see Yoo et al. 2012). Specifically, an increase in p~ 
endorphin levels in the Acb was observed following cocaine self-administration as 
well as acute non-contingent administration of cocaine (Olive et al. 2001; Roth- 
Deri et al. 2003). Cocaine administered acutely was shown to increase MOPr 
mRNA levels in the frontal cortex, Acb, and Amy, but no change was observed in 
the CPu, thalamus. Hip, and Hyp in rats (Yuferov et al. 1999), suggesting a 
differential regulation of the MOPr by cocaine depending on the brain region. 
Acute ‘binge’ cocaine increased frontal cortex MOPr mRNA levels in both DA Di 
and Ds receptor knockout mice to levels comparable with the respective wild type 
controls (Zhou et al. 2007) suggesting that both Di and Dg receptors are involved in 
frontal cortex MOPr gene regulation by cocaine. MOPr mRNA levels in the AcbC 
have been shown to be decreased in Di knockout mice and increased in Dg 
knockout mice following an acute ‘binge’ cocaine administration, whereas in the 
CPu MOPr mRNA levels were increased in Di knockout mice and decreased in Dg 
knockout mice following the same administration paradigm (Zhou et al. 2007),
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showing that Di and Dg receptors play opposite roles in the effects of cocaine on 
MOPr gene regulation differentially in the AcbC or CPu. In addition, Soderman 
and Unterwald (2009) showed that acute ‘binge’ cocaine administration induces a 
time- and dose-dependent decrease in MOPr binding within the AcbC and AcbSh. 
This reduction in MOPr binding was attenuated by pre-treatment with the DA D2 
receptor antagonist eticlopride, suggesting that by acting on the DA D2 receptors 
cocaine may cause the release of an endogenous opioid peptide that binds to and 
desensitises accumbal MOPr (Soderman and Unterwald 2009).
Sub-chronic cocaine treatment has been shown to increase the expression of MOPr 
mRNA and MOPr binding in the Acb (Azaryan et al. 1998). Similarly, chronic 
treatment with cocaine induced an up-regulation of MOPr binding in cingulate 
cortex, Acb, CPu and BLA (Unterwald et al. 1992; Unterwald et al. 1994) and an 
up-regulation in MOPr stimulated [^^SJGTPyS binding (Bailey et al. 2007). In 
contrast, a decrease in the levels of MOPr binding was observed in the CPu in 
human post-mortem brain samples from cocaine addicts compared to control 
subjects (Hurd and Herkenham 1993). These discrepancies might be due to either 
the differences between human and rodent brains or due to the possibility of 
multidrug use which would lead to different neuroadaptations in the brain. 
However, an up-regulation of MOPr binding was shown in several brain regions 
following short-term abstinence in cocaine addicts which was persistent following 
4 and/or 12 weeks of monitored cocaine abstinence and was positively correlated 
with the severity of cocaine craving, suggesting that the dysregulation of the MOPr 
is associated with cocaine dependence and cocaine craving in cocaine addicts 
(Gorelick et al. 2005; Zubieta et al. 1996). Ghitza et al. (2010) demonstrated that
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the increased MOPr binding in brain regions associated with reward sensitivity 
might be a significant independent predictor of treatment outcome in cocaine- 
abusing outpatients, suggesting a key role for the brain MOPr system in cocaine 
addiction.
In addition to the biochemical evidence for the role of MOPr system in cocaine 
addiction, there are numerous pharmacological findings confirming the 
involvement of MOPr in the rewarding effects of cocaine. Specifically, 
peripheral administration of the MOPr-preferring opioid antagonists naloxone 
and naltrexone (Bilsky et al. 1992; Gerrits et al. 1995; Houdi et al. 1989; Kim 
et al. 1997; Kuzmin et al. 1997; Suzuki et al. 1992), or peripheral 
administration of the specific MOPr antagonist, naloxonazine (Rademacher and 
Steinpreis 2002) as well as central administration of the MOPr antagonist D- 
Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH] (CTAP; Schroeder et al. 2007), 
attenuated the cocaine-induced CPP in rodents, providing evidence for the 
involvement of MOPr in the rewarding effects of cocaine. It was demonstrated 
that systemic administration of naloxone and naltrexone reduce cocaine self­
administration in rats (Corrigall and Coen 1991) and cocaine-induced CPP was 
decreased in mice receiving an antisense oligonucleotide directed against the 
MOPr (Hummel et al. 2006), further supporting the regulatory role of MOPr in 
the reinforcing effects of cocaine. Peripheral administration of the MOPr 
specific antagonist, N-{[3,5-difluoro-31007573-18-3,N-((3,5-Difluoro-3’-(lH- 
1,2,4-triazol-3 -yl)-4biphenylyl)methyl(-2,3 -dihydro-1 H-inden-2-amine 
(GSK1521498), was able to dose-dependently decrease the responding on the 
active lever in rats trained under a second-order schedule of reinforcement,
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suggesting that inhibition of MOPr might have therapeutic potential to reduce 
propensity to cocaine-seeking (Giuliano et al. 2013). Moreover, morphine 
administration increased the cocaine-induced rotational behaviour suggesting 
that activation of the MOPr potentiates the effects of cocaine probably by 
increasing DA levels in the Acb (Kimmel and Holtzman 1997).
Several lines of evidence suggest that the effects observed following the 
systemic manipulation of the MOPr system might be mediated by MOPr 
localised in specific brain regions. Intra-VTA infusions of naltrexone 
attenuated the acquisition of cocaine self-administration behaviour (Ramsey et 
al. 1999) and intra-VTA administration of the MOPr agonist, DAMGO, shifted 
the dose-response curve for cocaine self-administration to the left, suggesting 
an increase in the reinforcing efficacy of the drug, further supporting a key role 
of MOPr in the VTA in the regulation of cocaine rewarding effects (Corrigall 
et al. 1999b). Administration of DAMGO in the pedunculopontine tegmental 
nucleus (PPTg) decreased cocaine self-administration, whereas CTOP 
administration had no effect, showing that activation but not inhibition of MOPr in 
the PPTg can influence cocaine self-administration (Corrigall et al. 1999a). 
Simultaneous intra-Acb and -VTA microinjections of the selective MOPr 
antagonist, p-funaltrexamine, attenuated cocaine self-administration under a 
progressive ratio schedule of reinforcement (Ward et al. 2003), suggesting a 
specific role of the Acb and VTA MOPr in the reinforcing effects of cocaine. 
The MOPr antagonist CTAP injected into the AcbC or rostral VTA, but not the 
caudal VTA, CPu or medial shell of the Acb, attenuated the development of 
cocaine CPP (Soderman and Unterwald 2008). In contrast, CTAP infused into
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the medial shell, but not the core, of the Acb blocked the expression of a 
cocaine-induced CPP (Soderman and Unterwald 2008) suggesting a differential 
involvement of MOPr in the Acb subregions in the development and expression 
of CPP.
Cocaine-induced CPP was also attenuated by administration of naloxone into 
the VP prior to the test session indicating that MOPr in the VP are involved in 
mediating cocaine reinforcement (Skoubis and Maidment 2003). 
Administration of p-funaltrexamine into the VTA or the VP, but not into the 
Acb, reduced rates of responding for speedball to levels similar to the ones 
when they are only responding for cocaine, suggesting MOPr in the Acb and 
VP might facilitate the effects of heroin on cocaine reinforcement (Martin et al. 
2008).
Similar to the response of MOPr knockout mice to opioids, a dose-dependent 
decrease in cocaine self-administration (Mathon et al. 2005) and place preference 
behaviour (Becker et al. 2002; Hall et al. 2004) was demonstrated in mice lacking 
the MOPr, suggesting that MOPr might indirectly regulate the rewarding properties 
of cocaine. However, MOPr knockout mice, depending on dose and experimental 
conditions used, have been also shown to manifest normal cocaine CPP (Contarino 
et al. 2002; Nguyen et al. 2012b). It has been shown that the cocaine-induced CPP 
dose-response curve shifted to the right in the y^-endorphin knockout mice 
(Marquez et al. 2008), proposing a decrease in cocaine sensitivity and a possible 
implication of MOPr//?-endorphin signalling in cocaine reinforcement. 
Furthermore, both MOPr (Chefer et al. 2004; Yoo et al. 2006; Yoo et al. 2003) and
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yff-endoiphin (Marquez et al. 2008) knockout mice showed a reduction in cocaine- 
induced hyperlocomotion, while other studies did not demonstrate this decrease in 
cocaine-induced hyperlocomotion, using the MOPr knockout mice (Becker et al. 
2002; Chefer et al. 2004; Contarino et al. 2002; Hall et al. 2004; Lesscher et al. 
2005) depending on the dose of cocaine used and the genetic background of the 
MOPr knockout mice used. Similarly, sensitisation to locomotor effects of cocaine 
was decreased (Yoo et al. 2006; Yoo et al. 2003), unaltered (Lesscher et al. 2005), 
or increased (Hummel et al. 2004) in MOPr knockout mice, depending on the 
genetic background of the mice (Hummel et al. 2004) and the administration 
regimen used (Allouche et al. 2013; Puig et al. 2012). Moreover, the major allele of 
the OPRMl gene polymorphism, rs2236256, has been associated with a lack of 
cocaine cue-reactivity in African-American, cocaine-dependent male subjects 
further supporting the regulatory role of the MOPr in the cocaine-induced effects 
(Smelson et al. 2012). Altogether, these data suggest that the MOPr plays a key 
role in cocaine-induced effects, including locomotor activity, sensitisation effects 
and reinforcing properties of cocaine (see Table 1.6).
With respect to reinstatement of cocaine-seeking, intra-Acb injection of 
selective MOPr agonists triggered reinstatement of cocaine-seeking, while 
intra-Acb injection of MOPr antagonists attenuated cocaine-primed 
reinstatement in rats (Simmons and Self 2009). Priming-induced reinstatement 
of cocaine-seeking was reversed by CTAP administration within the VP (Tang 
et al. 2005). Conversely, morphine-induced stimulation of the ventral pallidal 
MOPr reinstated cocaine-seeking, an effect that was reversed by CTAP co­
microinjection and enhanced by systemic cocaine administration (Tang et al.
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2005). The cocaine-primed reinstatement was associated with decreased 
extracellular GAB A in the VP which was also reversed CTAP administration, 
suggesting that MOPr in the VP might exert its effects in reversing 
reinstatement by acting on the GABAergic system (Tang et al. 
2005). Interestingly, an increase in MOPr occupancy was detected in the frontal 
and temporal cortices of former cocaine addicts, which was positively 
correlated to relapse potential (Gorelick et al. 2008), further demonstrating the 
key involvement of MOPr in relapse behaviour.
1.8.3 Methamphetamine addiction
Even though the role of MOPr in cocaine addiction has been extensively studied, 
the involvement of MOPr in methamphetamine addiction still remains unclear. It 
has been shown that MAP-induced hyperlocomotion in mice lacking the MOPr was 
decreased or remain unchanged depending on the dose used (Shen et al. 2010), and 
peripheral administration of the MOPr antagonist, naloxonazine, significantly 
reduced the acute MAP-induced increase in locomotor activity (Chien et al. 2012) 
suggesting an essential role of MOPr in the regulation of the MAP-induced 
locomotor effects. Moreover, MOPr knockout mice do not show any behavioural 
sensitisation to MAP indicating the possible involvement of MOPr in driving this 
behaviour (Shen et al. 2010). Repeated central administration of DAMGO 
decreased MAP-induced increase in the linear locomotion and circling behaviour, 
but had no effect following a MAP challenge 3 weeks after the last MAP 
administration signifying that the MOPr at least partly regulate the development of 
behavioural sensitisation to MAP (Toyoshi et al. 1996). In agreement, central 
administration of DAMGO antagonised the increased in behavioural responses
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such as linear locomotion, circling, rearing and grooming induced by the acute 
MAP administration, which were completely reversed by pre-treatment with the 
MOPr antagonist p-funaltrexamine (Ukai et al. 1993), and peripheral 
administration of morphine decreased the MAP-induced self-injurious behaviour in 
mice (Mori et al. 2006), suggesting that stimulation of MOPr plays an inhibitory 
role in some of MAP-induced behavioural responses.
Intra-striatal administration of CTAP attenuated MAP-induced increase in PDYN 
expression as well as the mRNA expression of immediate early genes and reduced 
the MAP-induced stereotypy (Homer et al. 2010), whereas DAMGO 
administration had the exact opposite effect (Homer et al. 2012). These data 
indicate that MOPr activation contributes to MAP-induced gene expression in the 
striatum and stereotypy which may be a homeostatic response to MAP treatment. It 
has been shown that MOPr knockout mice show decreased MAP-induced 
stereotypic behaviour (Park et al. 2011). This was associated with down-regulation 
of the expression of the DA Di receptor and up-regulation of mRNA expression of 
RGS signalling 4 coupled to the DA Di receptor (Park et al. 2011), which may 
indicate a possible interaction between the DA and MOPr system in order to 
regulate the MAP-induced effects. In support of this, administration of the DA 
receptor antagonist haloperidol showed a more potent effect in counteracting the 
MAP-induced stereotypy in mice lacking the MOPr compared to wild-type mice 
(Shen et al. 2010).
MOPr polymorphisms in the OPRMl gene in human MAP addicts have been 
associated with MAP-induced psychosis and dependence suggesting that the
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OPRMl gene variations may be a factor in development and prognosis of MAP- 
induced psychosis (Ide et al. 2004; Ide et al. 2006). Moreover, a role of MOPr in 
MAP abstinence was demonstrated by Chiu et al. (2006), who showed a down- 
regulation of MOPr binding following withdrawal in methamphetamine-sensitised 
mice suggesting possible neuroadaptations of the MOPr in order to counteract the 
effects of MAP administration and withdrawal.
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1.9 Interactions of oxytocin and MOPr system
Early evidence suggested a possible interaction of the oxytocin with the MOPr 
system since the MOPr-preferring antagonist naloxone, was able to increase OT 
neuronal activity (Douglas et al. 1995), by blocking opioid receptors (e.g. Kitano and 
Takemori 1979; Oishi et al. 1983). In addition, opioid peptide neuronal fibres and 
terminals are present in close proximity to OT neurons within the Hyp (Bicknell et 
al. 1988) and MOPr are present in the Hyp, and particularly within the SON and 
PVN nuclei (Atweh and Kuhar 1983), where OT is synthesised (see Section 1.5).
This interaction is further supported by several studies showing that acute morphine 
administration decreases OT release from the Hyp (Clarke et al. 1979) and reduces 
OT release during suckling (Haidar and Sawyer 1978). Similarly, activation of MOPr 
by administration of DAMGO has been shown to inhibit OT release in 
neurohypophysial terminals (Ortiz-Miranda et al. 2003), while naloxone 
administration enhanced oxytocin release in the neurohypophysis (Zhao et al. 1988). 
Altogether, these findings demonstrate that activation of the MOPr system, at least in 
the Hyp, is able to inhibit OT release suggesting that MOPr system can control the 
activity of the OTergic system. Administration of the MOPr agonist, d-Ala2-Gly-ol5- 
enkephalin (DAGO), attenuated the firing of OT-responsive non-pyramidal neurones 
in hippocampal slices, an effect that was reversed by the administration of naloxone 
(Raggenbass et al. 1985) suggesting that MOPr system can regulate the activity of 
OT sensitive neurons. Moreover, administration of the MOPr antagonist P- 
funaltrexamine in the nucleus raphe magnus or periadigular grey was able to 
attenuate the antinociceptive effect of oxytocin in a dose-dependent manner in rats 
(Ge et al. 2002; Wang et al. 2003).
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However, morphine administration had no effect on the electrically stimulated OT 
secretion, but depressed the mammary response to oxytocin (Russell et al. 1993), 
and naloxone-precipitated withdrawal in morphine-tolerant lactating rats produced a 
large, sustained, fluctuating increase in intramammary pressure indicating morphine- 
withdrawal excitation of oxytocin secretion (Russell et al. 1993) suggesting that 
activation or inhibition of the MOPr might control the activity of the OTergic 
system. In pregnant rats central administration of morphine from day 17-18 of 
pregnancy delayed the start of parturition, but did not significantly affect the progress 
of parturition once established, indicating tolerance to the inhibitory actions of 
morphine on oxytocin secretion in parturition, and lack of cross-tolerance to 
endogenous opioids restraining oxytocin in parturition (Russell et al. 1993).
Further evidence supporting possible OT-MOPr interactions was also provided by 
studies using a chronic opioid administration regimen. In particular, chronic 
morphine administration induced a decrease in OT immunoreactivity in the Hip, and 
a reduction in OT mRNA levels within the SON, ME and ARC (Kovacs et al. 1987a; 
Laorden et al. 1998). Moreover, a hypo-OTergic tone in the Hyp with a concomitant 
increase in the OTR binding in the Amy was observed following chronic morphine 
administration and withdrawal (Zanos et al. 2014a). Taken together, these findings 
further support the presence of possible interactions between the MOPr and OTergic 
systems.
Variation in the MOPr gene has been shown to influence attachment behaviour in
infant primates (Barr et al. 2008). Considering the underlying role of the OT system
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in affîliative behaviour (Ross and Young 2009), the OPRMl-related alteration on OT 
levels may indicate the existence of a feedback loop where MOPr control the release 
of OT in order to regulate the mother-infant affiliation, which might imply a 
dysregulation of the OTergic system. Indeed, it has been shown that female monkeys 
possessing the OPRMl gene polymorphism have higher CSF OT levels when 
lactating, while when they are neither lactating nor pregnant they have lower CSF OT 
levels compared to females without the polymorphism (Higham et al. 2011). In 
addition to the possible interaction of these two systems in affiliative behaviours, a 
possible involvement of MOPr and OT system in pregnancy has been proposed. In 
particular, it has been shown that naloxone administration increased OT release in 
conscious rats (day 21), whereas naloxone administration in anaesthetised rats 
potentiated the cholecystokinin-induced firing rate of OT neurons during late 
pregnancy (day 21) (Douglas et al. 1995). This effect was only shown on day 21 of 
pregnancy but not on day 16, or in virgin rats, suggesting that endogenous opioids, by 
acting on the MOPr, might inhibit oxytocin neurons as a protective mechanism to 
avoid premature oxytocin secretion until parturition, when the OT demand is high 
(Douglas et al. 1995).
Altogether these findings provide evidence for the existence of a plausible interaction 
between the MOPr and OT systems. However, the significance of this interaction, as 
well as its possible involvement in the regulation of drug addiction processes still 
remains to be elucidated.
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1.10 Hypothesis and aims
The dysregulation of the OTergic and MOPr systems following chronic drug 
administration and withdrawal and their association with withdrawal-induced 
negative emotional states, which may act as a motivational trigger to re-administer 
the drug and relapse, still remains unclear. Indeed, a number of studies have shown 
alterations in the OTergic and MOPr systems, which have been suggested to be 
associated with the emergence of a negative withdrawal state as well as to be 
associated with relapse to drug use. Therefore, manipulation of these receptor 
systems might be a potential target for preventing relapse.
The research in this thesis tests the hypothesis that the OTergic and the MOPr 
systems are involved in the modulation of several addiction processes following 
chronic drug administration and withdrawal, and that administration of an oxytocin 
analogue will be beneficial in reversing reinstatement of opioid-seeking behaviour in 
mice.
Aim 1; To investigate the ability of activation of the OTergic system on stress- 
and priming-induced reinstatement of morphine-seeking.
Objectives:
• To investigate whether the exogenous administration of the oxytocin 
analogue carbetocin (CBT) can reverse stress- and priming-induced 
reinstatement of morphine-seeking.
• To determine the effects of CBT pre-treatment prior to reinstatement 
of morphine-seeking on the noradrenergic (NAergic) systems in the brain.
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• To elucidate whether treatment with the oxytocin analogue CBT 
induces rewarding or aversive effects.
Aim 2: To investigate the effect of cocaine self-administration, extinction and 
priming- and cue-induced reinstatement of cocaine-seeking behaviour on 
MOPr, OTR and mGIusR systems in mice 
Objectives:
• To determine whether exposure to cues previously associated with 
drug administration and/or a priming injection of cocaine will reinstate 
cocaine-seeking behaviour in mice.
• To investigate the effects of chronic cocaine self-administration, 
extinction and cue- and priming-induced reinstatement of cocaine-seeking 
on MOPr OTR and mGlugR binding using quantitative autoradiography in 
mouse brains.
Aim 3: To investigate the effect of chronic methamphetamine treatment and 
withdrawal on OTR and MOPr binding and the development of emotional 
impairment.
Objectives:
• To determine the effects of chronic MAP administration and
withdrawal on OTR binding in the brain and OT levels in the plasma and 
brain of mice by using quantitative receptor autoradiography and 
radioimmunoassay, respectively.
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• To determine the effects of chronic MAP administration and 
withdrawal on MOPr binding in the brain by using quantitative receptor 
autoradiography.
• To investigate the effects of 7-day MAP withdrawal on emotional-like 
behaviours of mice by using the elevated plus-maze and the forced-swim test.
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Chapter 2
The oxytocin analogue carbetocin prevents 
stress- and priming-induced reinstatement of 
morphine-seeking behaviour
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2.1 Introduction
Opioids are a class of drugs derived from the opium poppy. Opioid drugs, including 
morphine and codeine and the semi-synthetic opiate heroin, exert their actions by 
acting on the three opioid receptor subtypes; MOPr, KOPr and the DOPr (Lord et al. 
1977; Martin et al. 1976a) and by mimicking the actions of the endogenous opioid 
peptides, the enkephalins and the endoiphins. Opioids have several beneficial 
pharmacological effects such as the induction of analgesia, mainly by acting on the 
MOPr in the brain and spinal cord (Wang et al. 2009). They are the most effective 
drugs for the alleviation of pain and therefore they are widely used clinically in pain 
management (see Corbett et al. 2006). However, long-term prescription and use of 
opioids leads to the development of dependence (Fields 2007; also see Section 1.8.1).
Opioid addiction can be defined as a chronic relapsing disorder characterised by loss 
of control over drug taking and the emergence of negative withdrawal symptoms, 
which serve as a motivational trigger to re-administer the drug and to relapse (Le 
Moal and Koob 2007). The major challenge for opioid addicts who are recovering 
from their addiction is the maintenance of a drug-free state. In fact, it has been 
reported that 91% of former opioid addicts relapse back to opioid use while 59% 
relapse within a week of abstinence (Smyth et al. 2010). Although, physical 
symptoms of withdrawal decrease after a short period of time, symptoms associated 
with emotional distress and dysphoria such as irritability, stress and anhedonia may 
persist for months (Martin and Jasinski 1969; Nunes et al. 2004; Peles et al. 2007) 
and serve as a motivational trigger to re-administer the drug and relapse.
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Although several neurotransmitter systems (e.g., glutamate, opioids, CRF) have been 
suggested to be involved (Kalivas 2009; Koob and Kreek 2007; Koob 2008), the 
mechanisms underlying relapse to opioid use remain unclear. Several lines of 
evidence suggest a role of the “social” neuropeptide OT in drug addiction and in the 
effects of several drugs of abuse (Broadbear et al. 2011; McGregor et al. 2008a; 
McGregor and Bowen 2012; Samyai 2011). It has been shown that peripherally 
administered OT dose-dependently attenuated the development of tolerance to 
morphine as well as to the endogenous opioids y5-endorphin and met-enkephalin, 
blocked naloxone-precipitated morphine withdrawal (Kovacs et al. 1985; Kovacs et 
al. 1984) and attenuated the maintenance of heroin self-administration (Kovacs and 
Van Ree 1985) in rodents. Additionally, acute and chronic opioid administration as 
well as acute precipitated withdrawal altered OT peptide content and/or synthesis in 
the forebrain. Hip, Amy and Hyp of rodents (also see section 1.6.1; Kovacs et al. 
1987a; You et al. 2000). Zanos et al. (2014) demonstrated that chronic morphine 
administration and withdrawal induce a hypo-OTergic state in the Hyp and an 
increase in OTR binding in the Amy which was associated with the development of 
negative emotional state during withdrawal. Administration of the OT analogue, 
CBT, was able to reverse the emotional impairment induced by withdrawal from 
morphine highlighting the central role of the OTergic system in the mechanisms 
underlying the development of emotional impairment during withdrawal from 
morphine (Zanos et al. 2014a). With respect to relapse, OT was shown to facilitate 
extinction of methamphetamine-induced CPP and to attenuate stress- (Qi et al. 2009) 
and priming- (Carson et al. 2010a) induced reinstatement of methamphetamine- 
seeking behaviour in rodents. Overall, although the contribution of OT in different
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stages of drug addiction is recognized, its specific role in the reinstatement of opioid- 
seeking remains largely unknown.
A possible mechanism underlying the beneficial effects of OT in drug addiction 
processes might include its effects on the central NAergic system. In particular, it has 
been shown that OT enhances NA release which in turn, at least partly, activates 
hypothalamic OT neurons (Onaka et al. 2003) and NA is able to activate OT 
expression in the PVN and SON (Vacher et al. 2002). Therefore, it can be postulated 
that these systems are inter-linked and interact since OT activates the hypothalamic 
NAergic system and vice versa.
It has been suggested that the NAergic may play an important modulatory role in
regulating the rewarding effects of opioids since it was shown that administration of
the a2-adrenoceptor agonist, clonidine as well as administration of the ai-
adrenoceptor antagonist, prazosin reversed morphine-induced CPP (Zarrindast et al.
2002). Moreover, mice lacking aib-adrenoreceptors showed a decrease in the
morphine-induced hyperlocomotion and completely abolished morphine-induced
CPP (Drouin et al. 2002). Intra-PFC administration of prazosin decreased accumbal
DA-related locomotor hyperactivity induced by morphine (Drouin et al. 2001),
supporting an important role of the NAergic system in the mechanisms underlying
opioid dependence. With respect to withdrawal, Laorden et al. (2000) demonstrated
increased NAergic activity in the PVN following acute opiate withdrawal which was
accompanied by increased NA turnover in this area of the brain suggesting an
implication of the NAergic system in opioid withdrawal. Interestingly, increased
levels of 3-Methoxy-4-hydroxyphenylglycol (MHPG), the main NA metabolite, and
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NA turnover (Martin et al. 2012) as well as increased OT mRNA levels (Laorden et 
al. 1998) was observed following naloxone-precipitated withdrawal in the PVN, the 
principal region responsible for OT synthesis (see Section 1.5). These findings 
further support a possible interaction between the OT and NAergic systems.
Several lines of evidence suggest a role of the NAergic system in the Acb to regulate 
several addiction processes. Specifically, central (Reith et al. 1997) or systemic (Li et 
al. 1996) administration of cocaine as well as systemic administration of 
amphetamine (McKittrick and Abercrombie 2007) enhanced NA concentration in the 
Acb. Gomez-Milanes (2012) also demonstrated that naloxone-induced aversion 
in morphine-dependent mice enhances NA activity in the Acb suggesting a specific 
role of the accumbal NA system in the mediation of at least some of the opioid 
withdrawal effects. In addition, it has been shown that two weeks of withdrawal from 
chronic MDMA administration decreases NA levels in the Acb (Mayerhofer et al. 
2001). These findings highlight the accumbal NAergic system as one of the possible 
systems that are involved in the different stages of drug addiction.
In addition, opioid administration has been shown to induce a dysregulation of the 
. HPA-axis, resulting in increased glucocorticoid release in both humans and animals. 
Specifically, acute (Simon et al. 1975) and chronic (Zanos et al. 2014a) morphine 
administration increase plasma corticosterone levels. The OT system has been also 
demonstrated to act on the HPA-axis. OT knockout mice have been shown to have 
increased corticosterone levels (Amico et al. 2004) and chronic infusion of OT into 
the lateral ventricles of rats decreased the corticosterone response to psychogenic 
stress (Windle et al. 1997). Accordingly, Neumann et al. (2000) showed that OT
Ô1
administration inhibits corticosterone secretion in virgin female rats. Taken together, 
these findings that OT may exert its effects in opioid addictions by regulating the 
activity of the HPA-axis. Interestingly, pre-treatment with an ai-adrenoceptor 
antagonist attenuated the increased corticosterone levels induced by naloxone- 
precipitated withdrawal form morphine administration in rats (Martin et al. 2012) 
suggesting a possible interaction of these two systems in morphine dependence.
Another possible mechanism by which OT might exert its actions is by acting on the 
striatal DAergic system and inducing reward. Ko vacs et al. (1990) showed that both 
central and peripheral administration of OT acutely increased DA utilisation (i.e. 
decreased intracellular DA levels) within the Acb in mice. However, chronic 
subcutaneous administration of OT (0.2 mg/kg for 8 days) decreased DA utilisation 
(i.e. increased intracellular DA levels) within the basal forebrain (nucleus olfactorius 
posterior, Acb, septum) of mice (Kovacs et al. 1986). These discrepancies may 
indicate a neuroadaptive mechanism within the striatum, which could extend to the 
receptor level. Moreover, oxytocin administration in female mice has been shown to 
induce reward as tested with the CPP paradigm (Kent et al. 2013). Taken together, it 
is plausible that the underlying mechanism for the effects of OT in drug addiction 
processes may be by manipulating the DAergic system in the striatum in order to 
induce reward.
In this study, it is hypothesised that the exogenous administration of the oxytocin
analogue CBT will reverse stress- and priming-induced reinstatement of morphine-
seeking, via acting on the HPA-axis and the NAergic system. To assess this
hypothesis, we used the CPP paradigm which is commonly used to assess relapse to
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drug-seeking in rodents (Cordery et al. 2012; Redila and Chavkin 2008), where CBT 
was administered prior to the forced swim stress or the priming injection of 
morphine. The rewarding or aversive potential of CBT was tested using the CPP 
paradigm as well as the effect of the CBT on the peripheral HPA-axis by measuring 
the plasma corticosterone levels and NAergic system by measuring striatal NA and 
MHPG content following reinstatement. In this study CBT was chosen instead of OT 
since this analogue has been shown to be protected from aminopeptidase and 
disulfidase cleavage (Barth et al. 1974), hence it has much longer elimination half- 
life than OT; 85-100 min versus 3-4 min (Engstrom et al. 1998). It has been also 
suggested to be a potential candidate for the treatment of several psychiatric 
disorders (Quay 2005).
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2.2 Methods
2.2.1 Animals
Male C57BL/6J mice (7-week old, 20-25g, Charles River Laboratories, Kingston, 
UK), were housed individually in a temperature-controlled environment with a 12- 
hour light/dark cycle (lights on: 06:00 am). Food and water were available ad- 
libitum. Mice were left to acclimatise in their new environment for seven days prior 
to the experimental start and were handled daily by the experimenter. All 
experimental procedures were conducted in accordance with the U.K. Animal 
Scientific Procedures Act (1986).
2.2.2 Conditioned place preference:
We used a CPP apparatus (Opto-Max Activity Meter v2.16, Columbus Instruments,
OH, USA), as previously described (Figure 2.1; Bailey et al. 2010). The apparatus
consisted of a rectangular Plexiglas box (42 x 20 x 20 cm) divided by a removable
guillotine door into two chambers of equal size (21 x 20 x 20 cm), one comprising a
black floor with four black walls (black compartment), and the other a white floor
with black vertical stripes (2 cm) with four white walls with black vertical stripes
(2 cm; white compartment). The apparatus was covered with a transparent Plexiglas
lid perforated to allow adequate ventilation. A transparent colourless, enclosed
Plexiglas waiting chamber (12 x g x g cm) was affixed to one side of the CPP cage at
the junction of the black and white compartments. Mice were placed in the waiting
chamber and allowed entry via a guillotine door. The cage was equipped with 16
matching pairs of horizontal sensors mounted alongside opposing lengths (42 cm
long). The black and stripped compartments were scanned at a rate of 10 Hz by
seven infrared beams, spaced at 2.54-cm intervals. A null zone was assigned at the
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interface of the black and white zones in the centre of the box and was monitored by 
two beams.
I ^
Figure 2.1: Conditioned place preference apparatus.
The drug is paired with the least preferred compartment o f the apparatus and in the testing days 
the mouse is left to freely explore both compartments to test its preference
The CPP experiments were conducted during the light phase of the light/dark cycle 
(lights on: 07.00 h) and comprised of 7 sequential phases: habituation, pre­
conditioning test, conditioning; post-conditioning test, extinction, post-extinction test 
and reinstatement test. Throughout the experiment, the mice were brought into the 
test room 1 hour before the start of the experiment to habituate with the room. 
During the habituation, pre-conditioning, post-conditioning and reinstatement phase 
animals had free access to explore both compartments of the CPP for 20 min. During 
the conditioning and extinction phases the CPP apparatus was divided into two equal 
chambers (black and white) separated by a removable guillotine door. The 
conditioning and extinction sessions lasted for 45 minutes. In the pre-conditioning 
test, animals that showed unconditioned aversion or preference (spent less than 33% 
or more than 67% of the test time in one compartment) to any compartment were 
excluded. Morphine administration was always paired with the least preferred 
compartment and following post-conditioning test, mice that did not show any 
increase in the time spend in morphine-paired compartment were excluded (see
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Table 2.1). Additionally, an animal was considered to extinguish morphine CPP 
when the time spend in the drug-paired compartment in the Post-Ext test was in a 
range of ±10% from its pre-conditioning time. Animals that did not reach the 
extinction criterion were excluded (see Table 2.1). The ambulatory activity of the 
animals was measured in every session of this paradigm as the number of sequential 
infrared beam breaks, every 5 minutes.
No of animals Stress-induced reinstatement experiment
Priming-induced 
reinstatement experiment
Starting the study 34 26
Excluded following conditioning 3 2
Excluded following extinction 5 5
2.2.3 Stress-induced reinstatement of morphine-seeking behaviour
The CPP reinstatement protocol was modified from Mantsch et al. (2010). Briefly, it 
consisted of a habituation session, pre-conditioning test, 4 conditioning sessions 
(morning saline and 4 hours later 10 mg/kg morphine subcutaneous (s.c.) injections 
daily), a post-conditioning test, 5 extinction sessions (i.e., morphine injection was 
replaced by a saline injection), a post-extinction test and a reinstatement session, 
each carried out on consecutive days. During the reinstatement session, mice were 
pre-treated with either saline (4 ml/kg, i.p.; n=14 mice) or CBT (6.4 mg/kg, i.p.; 
n=12 mice) and after 5 minutes, they were exposed to a 6-min forced-swim session 
(23±rC). The dose of the CBT used was chosen based on previous dose response 
experiments within our laboratory (Zanos et al. 2014a). Following the forced-swim 
stress, mice were towel-dried and placed in the CPP apparatus for 20 minutes. Time 
spent in each compartment was measured during the last 15 minutes of the session. 
In order to ensure that CBT did not induce any antidepressant effects during the 
forced-swim, the immobility time of the saline- and CBT-treated animals was
assessed during the last 4 minutes of the 6-minute session by a trained observer blind 
to the treatment groups. Mice were killed 30 minutes after the reinstatement session 
and brains and trunk blood was collected for quantification of plasma corticosterone 
levels (see Section 2.2.6).
2.2.4 Priming-induced reinstatement of morphine-seeking behaviour
The CPP reinstatement protocol was modified from Ribeiro Do Couto et al. (2003). 
Briefly, it consisted of a habituation session, pre-conditioning test, 4 conditioning 
sessions (morning saline and 4 hours later a 10 mg/kg, s.c, morphine injections 
daily), a post-conditioning test, 4 extinction sessions (i.e., morphine injection was 
replaced by a saline injection), a Post-Ext test and a reinstatement session, each 
carried out on consecutive days. During the reinstatement session, mice were pre­
treated with either saline (4 ml/kg, i.p.; n=10 mice) or CBT (6.4 mg/kg, i.p.; n = ll 
mice) and after 5 minutes, they received a morphine priming injection (2 mg/kg. 
i.p.). Ten minutes after the morphine injection mice were placed in the CPP 
apparatus for 20 minutes. Time spent in each compartment was measured during the 
last 15 minutes of the session. Mice were killed 30 minutes after the reinstatement 
session and brains and trunk blood was collected for quantification of plasma 
corticosterone levels (see Section 2.2.6).
2.2.5 Carbetocin conditioned place preference
To ascertain that CBT does not have any rewarding or aversive effects on its own
when administered chronically, the effects of CBT (6.4 mg/kg, i.p.) were compared
to saline in a CPP paradigm, consisting of one habituation, one pre-conditioning,
four conditioning (with saline injection in the morning and CBT administration 4
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hours later) phases and one post-conditioning phase. Time spent in each 
compartment was assessed during the last 15 minutes of the 20-min post­
conditioning session and compared in the CBT- and saline-treated groups 
(n=6/group).
2.2.6 Noradrenaline measurements
2.2.6.1 Tissue collection
Frozen brains of saline and CBT-treated animals (n=6/group) from the reinstatement 
experiments used in the present study were dissected using a mouse matrix by 
reference to the mouse brain atlas of Frankin and Paxinos (1997). Saline-treated 
animals were used as controls. The Acb and CPu (defined here as striatum) were 
homogenized in 0.1 M perchloric acid, 0.02% ethylenediaminetetraacetic acid 
(EDTA), 0.02% sodium metabisulfite using an ultrasonic cell disrupter (Cole- 
Parmer, Vernon Hills, IE, USA). Samples were then centrifuged (45 min, 4°C, 15300 
X g.) and filtered through a 0.22 pm syringe filter.
2.2.6.2 HPL C measurement
NA and its principal metabolite in the brain MHPG were determined by HPLC with 
electrochemical detection. The mobile phase consisted of a 95% (v/v) mixture of 
water and methanol with sodium acetate (50 mM), citric acid (20 mM), 1-octyl- 
sodium sulfonate (3.75 mM), di-w,butylamine (1 mM) and EDTA (0.135 mM), 
adjusted to pH 4.3. The flow rate was 0.9 mhmin, and chromatographic data were 
analysed with Millenium 2010 Chromatography Manager Equipment (Millipore, 
Bedford, USA). Data were calculated by an external standard calibration. The protein
concentration of the samples was determined by the use of NanoDrop (Thermo 
scientific, UK).
2.2.7 Plasma corticosterone levels
In order to assess whether the effect of CBT to prevent stress- and priming-induced 
morphine CPP was via a regulation of the HPA-axis activity, the animals from both 
these experiments were euthanized 30 minutes after the end of the experimental 
sessions via cervical dislocation and trunk blood was collected in ice-cold EDTA- 
containing tubes. For the collection of plasma, blood was spun for 15 min at 2000 x g  
at 4°C. Plasma corticosterone levels were measured by using a rat/mouse 
corticosterone kit (MP Biomedicals, New York, NY, USA) according to the 
manufacturer’s instructions. All corticosterone levels were determined as a mean of 
duplicate measurement in a single assay.
2.2.8 Statistical analysis:
All values are expressed as mean ± standard error of the mean (SEM). Differences in
stress- and priming-induced reinstatement of morphine-seeking were analysed using
repeated two-way ANOVA with factor ‘CPP phase’ (pre-conditioning, post-
conditioning, post-extinction, reinstatement) and ‘experiment’ (i.e., CBT or saline).
The effect of CBT on the EST, plasma corticosterone levels, ambulatory activity
during reinstatement and on striatal NA, MHPG content and MHPG/NA ratio were
assessed by one-way ANOVA. For analysis of the morphine-, CBT-and saline-
induced locomotor effects repeated measures two-way ANOVA with factors
‘treatment’ and ‘time’ was used. The effect of CBT on CPP was also assessed by
repeated measures two-way ANOVA with factors ‘CPP phase’ and ‘CBT’ (i.e., CBT
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or saline). ANOVAs were followed by a Holm-Sidakpost-hoc test when significance 
was reached (i.e., p<0.05). All relevant F-values are provided in Table 2.1. All 
statistical analyses were performed using SigmaPlot (Systat Software, London, UK).
2.3 Results
2.3.1 Effect of CBT on stress-induced reinstatement
Morphine administration induced a place preference in the CPP paradigm with an 
increase in the time spent in the drug-paired compartment in the post-conditioning 
phase compared to the pre-conditioning phase (p<0.05). The 5-day extinction period 
led to a significant decrease in the time spent in the drug-paired compartment (post­
extinction phase vs post-conditioning phase; p<0.05; Figure 2.2B). A forced-swim 
stress induced reinstatement of the CPP in mice treated with saline, as shown by the 
increased time spent in the drug-paired compartment compared to the post-extinction 
phase (p<0.05; Figure 2.2B). In contrast, mice pre-injected with CBT did not show 
this increase in preference for the morphine-paired compartment during the 
reinstatement phase, compared to the saline pre-treated group (p<0.001; Figure 
2.2B). Animals were not pre-assigned to saline and CBT pre-treatment groups prior 
the start of the experiment due to the exclusion of animals following conditioning 
and extinction phases. Therefore, combined data are represented in the pre­
conditioning, post-conditioning and post-extinction phases as full bars and the 
subdivided data are represented as half bars in the saline and CBT pre-treated groups 
(Figure 2.2B).
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The latency to the first immobility count (Figure 2.3A) as well as the immobility 
time (Figure 2.3A) in the forced-swim test was also scored. CBT pre-treatment did 
not induce any change in the latency to the firs immobility count and immobility 
time compared to the saline pre-treated animals {p>0.05).
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Figure 2.2: Effect of carbetocin (CBT) on stress-induced reinstatement of morphine-seeking 
behaviour and conditioned place preference (CPP).
(A) Experimental protocol with the different phases of the CPP paradigm. Twenty-six mice 
underwent the following protocol: habituation phase; pre-conditioning (Pre-Cond) phase: assessment 
o f spontaneous place preference; conditioning phase: 4 consecutive days with saline injection (10 
ml/kg, S.C., first half o f light period) in the preferred compartment and administration of morphine (10 
mg/kg, s.c. 4 h after the saline injection) in the least-preferred compartment; post-conditioning (Post- 
Cond) session: assessment of conditioning with no injection; extinction phase: 5 consecutive days 
with saline injection (10 ml/kg, s.c. first half o f light period) and then, administration o f saline (10 
ml/kg, s.c. 4 h after the first daily injection) in the drug-paired compartment; post-extinction (Post- 
Ext) test: assessment of extinguished behaviour— no injection; for the reinstatement test, mice were 
then subdivided into two experimental groups to receive either saline (4 ml/kg, i.p.; n=14) or CBT 
(6.4 mg/kg, i.p.; n=12), followed by exposure to a (breed-swim stress 5 min later (23±rC; 6 min).
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Mice were then tested for reinstatement o f morphine-seeking behaviour during a 20-min session. (B) 
Time spent in the morphine-paired compartment for each phase o f the CPP paradigm (analysis o f the 
last 15 min o f the 20-min session). Data are expressed as mean ± SEM (Pre-Cond: n=26; Post-Cond: 
n=26; Post-Ext: n=26; Sal-Forced swim reinstatement n=14; CBT-Forced swim reinstatement: n=12); 
*p<0.05; ***p<0.001. Repeated measures two-way ANOVA followed by Holm-Sidak post-hoc test.
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Figure 2.3: Effect of carbetocin (CBT) on depressive-like behaviour following 5 days extinction 
from the 4-day administration paradigm.
Male C57BL/6J mice were treated with morphine with a 4-day steady dose paradigm ( 4 x 1 0  mg/kg,; 
s.c. per day) and left to extinguish for five days. (A) Immobility time in saline and CBT pre-treated 
animals during the last four minutes o f the six minute forced-swim test and (B) latency to the first 
episode o f immobility were measured. Mice pre-treated with saline or CBT did not show any 
differences in their immobility time and latency to the first immobility episode. Data are expressed as 
mean ± SEM (n=12-14 per group). Unpaired Student’s t-test.
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2.3.2 Effect of CBT on priming-induced reinstatement
Morphine administration induced a place preference in the CPP paradigm with an 
increase in the time spent in the drug-paired compartment in the post-conditioning 
phase compared to the pre-conditioning phase (p<0.01). The 4-day extinction period 
led to a significant decrease in the time spent in the drug-paired compartment (post­
extinction phase vs post-conditioning phase; p<0.01; Figure 2.4B). A priming 
injection of morphine induced reinstatement of the CPP in mice treated with saline, 
as shown by the increased time spent in the drug-paired compartment compared to 
the post-extinction phase (p<0.01; Figure 2.4B). In contrast, mice pre-injected with 
CBT did not show this increase in preference for the morphine-paired compartment 
during the reinstatement phase, compared to the saline pre-treated group (p<0.001; 
Figure 2.4B). Animals were not pre-assigned to saline and CBT pre-treatment groups 
prior the start of the experiment due to the exclusion of animals following 
conditioning and extinction phases. Therefore, combined data are represented in the 
pre-conditioning, post-conditioning and post-extinction phases as full bars and the 
subdivided data are represented as half bars in the saline and CBT pre-treated groups 
(Figure 2.4B).
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Figure 2.4: Effect of carbetocin (CBT) on priming-induced reinstatement of morphine-seeking 
behaviour and conditioned place preference (CPP).
(A) Experimental protocol with the different phases o f the CPP paradigm. Twenty-one mice 
underwent the following protocol: habituation phase; pre-conditioning (Pre-Cond) phase: assessment 
of spontaneous place preference; conditioning phase: 4 consecutive days with saline injection (10 
ml/kg, S.C., first half of light period) in the preferred compartment and administration of morphine (10 
mg/kg, s.c. 4 h after the saline injection) in the least-preferred compartment; post-conditioning (Post- 
Cond) session: assessment of conditioning with no injection; extinction phase: 4 consecutive days 
with saline injection (10 ml/kg, s.c. first half o f light period) and then, administration o f saline (10 
mhkg, s.c. 4 h after the first daily injection) in the drug-paired compartment; post-extinction (Post- 
Ext) test: assessment of extinguished behaviour— no injection; for the reinstatement test, mice were 
then subdivided into two experimental groups to receive either saline (4 ml/kg, i.p.; n=10) or CBT 
(6.4 mg/kg, i.p.; n=ll ) ,  followed by a priming morphine injection (2mg/kg; s.c) 10 minutes later. 
Mice were then tested for reinstatement o f morphine-seeking behaviour during a 20-min session. (B) 
Time spent in the morphine-paired compartment for each phase of the CPP paradigm (analysis o f the 
last 15 min of the 20-min session). Data are expressed as mean ± SEM (n=10- l l  mice per group); 
**p<0.01\ ***p<0.001. Repeated measures two-way ANOVA followed by Holm-Sidak post-hoc test.
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2.3.3 Effect of morphine on ambulatory activity during conditioning
Morphine treatment increased ambulatory activity during the 4-day morphine 
administration in both the stress- (p<0.001; Figure 2.5A) and priming- (p<0.001; 
Figure 2.5B) induced reinstatement experiments. Following the first day of morphine 
administration, behavioural sensitisation was observed as indicated with the 
significant increase in the ambulatory activity in days 2, 3 and 4 compared to day 1, 
in both the stress- and priming-induced reinstatement experiments (p<0.001; Figure 
2.5A,B). The decrease in ambulatory activity over time during saline treatment is due 
to their habituation with the environment (Figure 2.5A,B).
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Figure 2.5: Effect of morphine on ambulatory activity during the conditioning sessions.
Male C57BL/6J mice were treated with saline (morning) or morphine (afternoon) with a steady 
dose paradigm (lOmg/kg, s.c. per day). Stimulated ambulatory activity of (A) stress- and (B) 
priming-induced reinstatement experiment were measured daily in 5-minute bins for 45 minutes 
during the conditioning sessions. The average activity of the 5-minnute bins o f the 45 minutes 
was calculated. Morphine administration increased ambulatory activity compared to saline. Data
are expressed as mean ± SEM (n=-21-26 per group). *** p<0.001 vs Saline; ^p<0.01, 
**^p<0.001vs Morphine Day 1. Repeated measures two-way ANOVA followed by Holm-Sidak 
post-hoc test.
96
2.3.4 Effect of CBT pre-treatment on ambulatory activity during 
reinstatement testing
CBT did not change the ambulatory activity of the animals following the forced- 
swim stress (Figure 2.6A) and the priming injection (Figure 2.6A) of morphine 
during the reinstatement testing compared to the saline pre-injected animals
(p>0.05).
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Figure 2.6: : Effect of CBT on ambulatory activity during the reinstatement testing.
Male C57BL/6J mice were pre-treated with saline (4ml/kg, i.p.) or CBT (6.4mg/kg, i.p.) and 
subjected to either a forced-swim stress or received a priming injection o f  morphine. The 
ambulatory activity was measured during (A) stress- and (B) priming-induced reinstatement of 
morphine-seeking in 5 min bins for 20 minutes during the reinstatement testing. The average 
activity o f  the 5-minute bins o f  the last 15 minutes was calculated. CBT and saline pre-treated 
animals did not show any differences in their ambulatory activity. Data are expressed as mean ±  
SEM (n=-10-14 per group). Unpaired Student’s t-test.
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2.3.5 Effect of CBT on conditioned place preference
A possible mechanism by which CBT modulates the stress- and priming-indueed 
reinstatement of morphine CPP is by indueing reward. Thus, the rewarding or 
aversive properties of CBT (6.4 mg/kg; i.p.) were assessed using the CPP paradigm. 
The 4-day CBT administration did not induce any conditioned plaee preference or 
aversion (p>0.05; Figure 2.7B.) compared to the saline control group.
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Figure 2.7: Carbetocin (CBT) does not induce conditioned place preference or aversion.
A) Experimental protocol with the different phases o f the CPP paradigm. Twelve mice 
underwent the following protocol: habituation phase; preconditioning (Pre-Cond) phase: 
assessment o f spontaneous place preference; conditioning phase: 4 consecutive days with saline 
injection (4 rnl/kg, i.p., first half o f light period) in the preferred compartment and 
administration o f CBT or saline (6.4 mg/kg, i.p. 4 h after the saline injection) in the least- 
preferred compartment; post-conditioning (Post-Cond) session: assessment o f conditioning with 
no injection; (B) Time spent in the CBT- or saline-paired compartment (analysis o f the last 15 
minutes o f the 20-minute session) during the pre-conditioning (Pre-Cond) and post-conditioning 
(Post-Cond) phases o f the CPP paradigm. Data are expressed as mean±SEM (n=6 mice/group). 
Repeated measures two-way ANOVA.
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2.3.6 Effect of CBT on ambulatory activity
CBT administration did not induce any alterations to the ambulatory activity 
compare to the saline controls during the 4 days of administration (p>0.05; Figure 
2.8). Both the saline and CBT treated animals decreased their ambulatory activity 
over time due to their habituation with the environment (Figure 2.8).
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Figure 2.8: Effect of a 4-day carbetocin (CBT) administration on ambulatory activity
Male C57BL/6J mice were treated with either saline (4ml/kg, i.p.) or CBT for a period o f  4 days 
(6.4 mg/kg, i.p. per day) in a CPP paradigm. The ambulatory activity was measured for 45 
minutes after the injection during in 5 minute bins. The average activity o f  the 5-minute bins o f  
the 45 minutes was calculated. CBT and saline treated animals did not show any differences in 
their ambulatory activity. Data are expressed as mean ±  SEM (n=-6/group). Repeated measures 
two-way ANOVA.
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2.3.7 Effect of CBT on corticosterone levels
No changes in plasma coricosterone levels were observed in the CBT-treated group 
compared with the saline-control group following stress- and priming-induced 
reinstatement of morphine-seeking (p>0.05; Figure 2.9/
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Figure 2.8: Effect of saline and carbetocin (CBT) pre-treatment 
following stress- and priming-induced reinstatement of morphine- 
seeking.
Male C57BL/6J mice were treated with morphine (4 days, 10 mg/kg, 
s.c. per day) in a CPP paradigm. Following extinction animals were 
subjected to a forced-swim stress or received a priming injection of 
morphine to induce reinstatement. Plasma corticosterone levels were 
measured in saline and CBT pre-injected animals in both priming- and 
stress-induced reinstatement o f  morphine-seeking. Data are expressed 
as mean ±  SEM (n=10-14 per group). Unpaired Student’s t-test.
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2.3.8 Effect of CBT and saline pre-treatment on the NAergic system following 
stress-induced reinstatement of morphine-seeking
Both stress- and priming-induced reinstatement of morphine-seeking increased the 
striatal levels of NA levels (stress: p<0.05; Figure 2.10A, priming: p<0.05; Figure 
2.11 A) and MHPG levels (stress: p<0.05; Figure 2.1 OB, priming: p<0.05; Figure
2.1 IB) in the saline and CBT pre-treated morphine reinstatement animals compared 
to saline control animals. CBT pre-treatment prior to the stress-induced reinstatement 
did not induce any alterations in the NA (Figure 2.10A) and MHPG (Figure 2.1GB) 
content in the striatum as well as in the MHPG/NA ratio (p>0.05; Figure 2.IOC). 
CBT pre-treatment prior to the priming-induced reinstatement did not induce any 
alterations in the NA (Figure 2.11 A) and MHPG (Figure 2.1 IB) content in the 
striatum. However, CBT pre-treatment prior to priming-induced reinstatement 
decreased the MHPG/NA ratio compared to both control animals and to the saline 
pre-treated animals undergoing reinstatement (p<0.01; Figure 2.11C).
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Figure 2.9: Effect of saline and carbetocin pre-injection prior to the stress-induced 
reinstatement on noradrenaline (NA) and 3-Methoxy-4-hydroxyphenylglycol (MHPG) striatal 
content.
Male C57BL/6J mice were treated with morphine (4 days, 10 mg/kg, s.c. per day) in a CPP paradigm. 
Following extinction animals subjected to a forced-swim stress in order to induce reinstatement. 
Striatal (A) NA, (B) MHPG levels as well as (C) MHPG/NA ratio were measured in animals pre- 
injected with saline and CBT prior to stress-induced reinstatement of morphine-seeking. CBT pre­
treated animals compared to the saline pre-treated animals did not show any differences in striatal NA, 
MHPG and NA turnover. Data are expressed as mean ± SEM (n=6 /group). *p<0.05 vs Saline. One­
way ANOVA followed by Holm-Sidak post-hoc test.
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Figure 2.10: : Effect of saline and carbetocin pre-injection prior to the priming-induced 
reinstatement on noradrenaline (NA) and 3-Methoxy-4-hydroxyphenylglycol (MHPG) striatal 
content.
Male C57BL/6J mice were treated with morphine (4 days, 10 mg/kg, s.c. per day) in a CPP paradigm. 
Following extinction animals received a priming injection of morphine to induce reinstatement. 
Striatal (A) NA, (B) MHPG levels as well as (C) MHPG/NA ratio were measured in animals pre- 
injected with saline and CBT prior to the priming-induced reinstatement o f morphine-seeking. CBT 
pre-treated animals compared to the saline pre-treated animals did not show any differences in striatal 
NA, MHPG following reinstatement. However, CBT pre-treatment induced a decreased in the NA  
turnover compared with the saline pre-treatment following priming-induced reinstatement o f  
morphine-seeking. Data are expressed as mean ± SEM (n=6 /group). *p<0.05 vs Saline, **p<0.01 vs 
Mor-CBT. One-way ANOVA followed by Holm-Sidak post-hoc test.
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Table 2.2: Relevant Effects for Biochemical and Behavioural Data- Chapter 2.
Treatment effect Experimental phase Interaction effect
Overall effects for Figure 2.2,2.4 and 2.7
'onditioned Place Preference Factor 'experiment'
Stress-induced reinstatem ent (n=12-14) F[i,24] = 6.36; p<0.05
Priming-induced reinstatem ent (n= 10-ll) F[i,i9]=2.38; p= 0.14
CBT-induced CPP F[i,io] = 0.05; p=0.83
fverail effects for Figure 2.5
,mbulatory activity
Stress-induced reinstatem ent (n=12-14)
Priming-induced reinstatem ent (n= 10-ll) F[i,20]=960.32
Factor 'treatm ent'
F[i,27]=1142.81 p <0.001
p<0.001
)veraii effects for Figure 2.8
imbulatory activity
CBT-induced CPP (n=6)
)veraii effects for Figure 2.10 and 2.11
triatal NA, MHPG and MHPG/NA levels (n=6) 
Stress-Induced reinstatem ent
Factor 'treatm ent'
F[i,101=0.322 p=0.583
Factor 'treatm ent'
NA Fi2.i5f5.926 p<0.05
MHPG Fi2.i5f 11.74 p<0.001
MHPG/NA Fi2.i5fl.941 p=0.178
Priming-Induced reinstatem ent
NA Fi2.i5f5.680 p<0.05
MHPG Fi2.i5]=12.08 p<0.001
MHPG/NA Fi2.i5fl0.48 p<0.01
Factor 'CPP Phase'
F[3,72] =
10.67; p<0.001
F,3,571=11.32 p<0.001
F[i, 101=1.27 p=0.29
Factor 'Time (days)'
Fi3.8ifO.630 p=0.598
F[3,6oi=3.391 p <0.05
Factor 'Time (days)'
F[3,301=22.63 p=<0.001
Factor 'experim ent'x 'CPP phase'
F[3.72i = 4.18; p<0.01
F[3,571=4.43 p<0.01
F[i,io] =
0.0001; p=1.00
Factor 'trea tm en t'x  'Time(days)'
F[3,811=26.123 p<0.001
F[3,601=27.127 p<0.001
Factor 'trea tm en t'x  'Time(days)' 
F[3,301=0.242 p=0.867
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2.4 Discussion
The present study demonstrated that the OT analogue, CBT was able to prevent 
both stress- and priming-induced reinstatement of morphine CPP in mice. 
Moreover, it was shown that CBT does not have any abuse liability since did not 
produce any rewarding effects in the CPP paradigm. CBT pre-treatment did not 
induce any alterations in the corticosterone levels in either priming- or stress- 
induced reinstatement of morphine-seeking compared to saline pre-treated animals. 
While no differences were observed between saline and CBT pre-treatment in the 
striatal NA and MHPG levels as well as in MHPG/NA ratio following stress-induce 
reinstatement, CBT administration significantly decreased MHPG/NA ratio in the 
striatum during priming-induced reinstatement, compared to saline pre-treated 
animals.
This is the first study to report the beneficial effect of CBT in preventing stress- 
and priming-induced reinstatement of morphine-seeking following extinction. CBT 
administration did not induce any changes in ambulatory activity compare to the 
saline pre-injected animals suggesting that the behavioural effects observed are not 
due to a possible effect of CBT on locomotion. Moreover, with respect to the 
stress-induced reinstatement experiment, the animals did not show any differences 
in their swimming behaviour, suggesting that the reinstatement of morphine- 
seeking behaviour observed in the present study is evidently due to the stress effect 
of the FST and not due to depressive-related symptoms induced by morphine 
extinction. Indeed, it was previously shown that the emotional deficits are 
associated with a longer (i.e., 7-day) escalating-dose, morphine administration
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regimen and 7-day or 4-week withdrawal period (Goeldner et al. 2011; Zanos et al. 
2014a).
A mechanism that might underlie the reinstatement-protective effects of CBT is by 
acting on the mesolimbic DArgic pathway and inducing reward. In fact, a recent 
paper by Kent et al. (2013) showed that oxytocin administration induced CPP and 
therefore reward in female mice. However, in the current study, four days CBT 
administration at the dose of 6.4mg/kg (i.p.) did not induce any rewarding or 
aversive effects as shown by the lack of difference in the time spent in the CBT- 
paired compartment between the pre-conditioning and post-conditioning test using 
the CPP paradigm. These discrepancies might be due to the different gender of 
mice used, i.e., females males. Females naturally have higher OT levels 
compared to males and it has been already demonstrated that intranasal OT induced 
different neural and behavioural effects in healthy female compared to male 
volunteers (Rilling et al. 2014). Moreover, in the study by Kent et al. (2013) the 
dose of OT used was higher than the respective dose of OT used in humans and 
with the respective dose of CBT used in the current study.
Although, a possible mechanism underlying the effects of CBT may involve 
modulation of the HPA-axis activity (Windle et al. 2004), in the current study CBT 
pre-treatment did not induce any alterations in plasma corticosterone levels 
following both stress- and priming-induced reinstatement of morphine-seeking, 
suggesting that CBT had no effect on the peripheral arm of the HPA axis. 
However, our data do not exclude the possibility that CBT exert its effects by 
acting on the extra-hypothalamic CRF system. Indeed, several lines of evidence
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indicate that CRF system is activated following exposure to stress and some of the 
physiological and behavioural responses observed during stress can be mimicked 
via an exogenous administration of CRF receptor agonists (see Dunn and Swiergiel
2008).
The current study demonstrated that stress-induced reinstatement of morphine- 
seeking caused an increase in the striatal NA and MHPG levels which might 
account for the hyperactivity of the NAergic system. It has been previously shown 
that stress-induced reinstatement of opioid-seeking is mediated by the activation of 
the NAergic system (see Lu et al. 2003) and intra-BNST injection of the ai- 
adrenoreceptor agonist, clonidine reversed footshock-induced reinstatement of 
morphine-seeking (Wang et al. 2001). Nonetheless, CBT pre-treatment did not 
induce any alterations in the NA and MHPG content in the striatum and 
MHPG/NA ratio, suggesting that the striatal NA system does not account for the 
effects of CBT in stress-induced reinstatement of morphine-seeking.
Although the role of the NAergic system in stress-induced reinstatement of 
morphine-seeking has been extensively studied, the literature around the role of the 
NAergic system in priming-induce reinstatement of morphine-seeking is limited. 
This the first study to report increase in the striatal NA and MHPG levels, as well 
as in the NA turnover following morphine-primed reinstatement suggesting a 
possible role of the striatal NAergic system in mediating reinstatement induced by 
a morphine priming injection. In line with this, Ventura et al. (2005) demonstrated 
that selective depletion of medial prefrontal cortical NAergic afférents abolished 
morphine-induced increase in DA release in the Acb and attenuated both morphine-
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induced CPP and morphine-primed reinstatement. Interestingly, a CBT-induced 
decrease of striatal NA turnover following priming-induced reinstatement of 
morphine-seeking was observed in the present study, indicating a possible NA- 
dependent mechanism underlying the effect of CBT to prevent morphine-primed 
reinstatement. It has been previously demonstrated that peripheral injection of OT 
facilitates the disappearance of NA in the mesencephalon (Kovacs and Telegdy 
1983). Therefore, the decrease in the NA turnover observed in the current study 
might be due to an indirect effect of CBT in preventing the morphine-induced 
increase in NA release. However, the mechanisms underlying the exact role of OT 
on the NAergic system opioid-primed reinstatement remains to be elucidated.
Another possible mechanism underlying the CBT to prevent reinstatement of 
morphine-seeking is by acting on the DArgic system in the striatum. Indeed it has 
been shown that OT administration facilitates DA turnover in the striatum of 
treatment-naive animals (Kovacs and Telegdy 1983) as well as in MAP-treated (Qi 
et al. 2008) and cocaine-treated (Kovacs et al. 1990) animals. Thus, CBT might 
exert its effects in reversing stress-induced reinstatement by regulating the activity 
of the DAergic system and decreasing DA levels in the Acb. It is plausible that 
CBT administration might also act on the DAergic system and indirectly affecting 
the striatal NAergic system or vice versa. Considering that depletion of NA 
neurons in the mPFC decrease the morphine-induced enhancement in DA release in 
the Acb (Ventura et al. 2005) along with the effects of morphine and OT on the 
striatal DArgic system (see Section 1.8.1 and 1.6), it can be hypothesised that CBT 
exert its effects in reversing stress- and priming- induced reinstatement of 
morphine-seeking by either acting directly on the NAergic system in the mPFC to
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alter DA levels in the Acb or acting on the striatal DAergic system to indirectly 
regulate the activity of the NAergic system in order to reverse morphine-induced 
reinstatement.
Moreover, Qi et al. (2009) demonstrated that central administration of OT was able 
to reverse stress-induced reinstatement of MAP-seeking by decreasing the stress- 
induced increase in glutamate levels in the mPFC. Interestingly, OT administration 
had no effect on MAP-induced increase in glutamate levels suggesting a specific 
effect of OT in regulating the stress-induced hyperactivity of the glutamatergic 
system (Qi et al. 2009). These findings may suggest that CBT in the current study 
might have acted on the glutamatergic system, in order to reverse stress-induce 
reinstatement of morphine-seeking. Indeed, CBT has been shown to decrease the 
striatal glutamate content following stress- but not priming-induced reinstatement 
of morphine-seeking (unpublished data from our laboratory). Although a possible 
action of CBT on the glutamatergic system in the prevention of priming-induced 
reinstatement of morphine-seeking cannot be excluded, considering the existing 
literature this effect is highly unlikely.
Taken together, this is the first study to report that the non-rewarding and non- 
aversive OT analogue CBT prevents both stress- and priming-induced 
reinstatement of morphine-seeking. A possible mechanism for the beneficial effects 
of CBT in the priming-induced reinstatement of morphine-seeking might be its 
actions on the striatal NAergic system. In contrast, we have shown that CBT had no 
effect on the NAergic system in the striatum following stress-induced reinstatement 
suggesting a differential mode of action of CBT depending on the type of
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reinstatement. Moreover, the peripheral HPA-axis was not affected by CBT 
administration following by stress- and priming-induced reinstatement of 
morphine-seeking. Overall, this study supports the OT system as a potential target 
for the treatment of opioid addiction and prevention of relapse to opioid use.
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Chapter 3
Differential regulation of MOPr, OTR and 
mGlusR, systems by priming- and cue- 
induced reinstatement of cocaine-seeking
behaviour in mice
1 1 1
3.1 Introduction
Cocaine is purified fi*om the leaves of the Erythroxylum coca plant originally 
grown in South America, Mexico, Indonesia, and the West Indies (see(see 
Goldstein et al. 2009). Cocaine is one of the most prevalent psychostimulants in the 
EU, and its use and abuse causes severe health and socioeconomic problems 
(EMCDDA 2014). Cocaine can be administered via several routes, including 
intravenous injection, intranasal administration of cocaine hydrochloride and 
smoking of cocaine base also known as “crack” cocaine (Hatsukami and Fischman 
1996). Cocaine is categorised as a Class A psychostimulant drug and acts on 
monoamine transporters in the brain to block the re-uptake of DA, NA and 5-HT, 
thus increasing their synaptic concentrations (see Nestler 2005b). The pre-synaptic 
blockade of the DA transporter in the DAergic neurons projecting from the VTA to 
the Acb causes increased DA levels in the synaptic cleft, which by binding to the 
DA receptors in the Acb cause euphoric effects (see Nestler 2005b).
Cocaine addiction is a chronic relapsing brain disorder characterised by compulsion 
to seek and take the drug, loss of control in limiting intake, and emergence of a 
negative emotional state following abstinence (Le Moal and Koob 2007). The key 
problem for the treatment of drug addiction is the repeated cycles of relapse to drug 
use after periods of abstinence (O'Brien 2005). In humans, relapse to cocaine 
administration can be triggered by exposure to the drug itself, by cues 
previously associated with drug administration, and by stress (Bossert et al. 
2013). Several lines of evidence supports that different brain regions and 
neurotransmitter systems are implicated in each type of reinstatement. For 
example, in cocaine-primed reinstatement the glutamatergic and DAergic systems
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in the PFC, Acb and VP were highlighted as the major systems involved in this type 
of reinstatement, whereas the glutamatergic system in the BLA and the DAergic 
system in the VTA have been shown to have an essential role in driving cue- 
induced reinstatement of cocaine-seeking (see Shaham et al. 2003). Lastly, it is 
believed that stress-induced reinstatement of cocaine-seeking is driven by the 
activation of the central stress systems including the CRF system in the CeA and 
the BNST (see Shaham et al. 2003). To date, there is no effective pharmacotherapy 
for the treatment of cocaine addiction and prevention of relapse, which is the 
hallmark for the treatment of drug addiction (see Section 1.4). Therefore, the 
delineation of the neuronal mechanisms underpinning relapse to drug use is critical 
in order to develop targeted effective pharmacotherapy for its prevention.
Several lines of evidence suggest a role of the MOPr system in reinstatement of 
cocaine-seeking behaviour. Specifically, injection of y^-endorphins or injection 
of DAMGO, a MOPr selective agonist, in the Acb triggered reinstatement of 
cocaine-seeking, whereas intra-Acb injection of MOPr antagonists reduced 
cocaine self-administration (Ward et al. 2006) and cocaine-primed 
reinstatement in rodents (Simmons and Self 2009; Tang et al. 2005). Moreover 
pre-treatment with the mu opioid preferring antagonist, naltrexone attenuated 
cue- (Burattini et al. 2008) and priming-induced (Gerrits et al. 2005) 
reinstatement of cocaine-seeking in rats. Interestingly, increase in MOPr 
binding in frontal and temporal cortices of former cocaine addicts was shown 
to be correlated to relapse potential of cocaine use (Gorelick et al. 2008). 
Moreover, increased MOPr binding in the anterior cingulate, medial frontal, 
middle frontal, middle temporal, and sublobar insular gyri was also correlated
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with shorter duration of cocaine abstinence during treatment (Ghitza et al. 
2010). Altogether, these findings support the involvement of MOPr in driving 
reinstatement to cocaine-seeking behaviour.
A role of the neurohypophysial peptide OT and its receptor (OTR) has been 
proposed in the modulation of addictive properties of psychostimulants and 
reinstatement behaviour (Broadbear et al. 2011; McGregor and Bowen 2012; 
Samyai 2011). With respect to cocaine, an inhibitory effect of OT administration 
has been demonstrated on cocaine-induced hyperactivity, locomotor sensitisation, 
stereotypic behaviours, the development of cocaine tolerance and cocaine self­
administration (Samyai 1998). Additionally, acute cocaine administration increased 
OT peptide levels within the Hyp and Hip (Samyai et al. 1992c), while chronic 
administration of cocaine decreased both plasma levels and OT immunoreactivity 
within the Hyp and Hip (Samyai et al. 1992a), and increased OTR binding in the 
Amy of rat dams (Johns et al. 2004). In agreement with the pre-clinical data. Light 
et al. (2004) showed that mothers who used cocaine during pregnancy had lower 
plasma OT levels. Moreover, systemic administration of OT has been shown to 
attenuate methamphetamine self-administration and hyperactivity as well as 
priming- (Carson et al. 2010a) and stress- (Qi et al. 2009) induced reinstatement of 
methamphetamine-seeking behaviour in rodents. This suggests the involvement of 
the OTergic system in the modulation of reinstatement to psyschostimulant dmgs 
of abuse (see Section 1.8.2 and 1.8.3).
Moreover, recent evidence suggests a possible interaction between the MOPr and 
OTR systems with the metabotropic glutamate receptor 5 (mGlusR) system.
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specifically, allosteric modulation of mGlusR has been shown to affect agonist- 
induced MOPr signalling and regulation which lead to the hypothesis that an 
interaction/heterodimerization of MOPr and mGluSR occurs (Koob 2009b; 
Schroder et al. 2009). This hypothesis was further supported by co- 
immunoprecipitation studies providing evidence for an interaction between MOPr 
and mGlusR which is facilitated by the treatment with the negative mGlusR 
allosteric modulator, 2-methyl-6-(phenylethynyl)-pyridine (MPEP; Schroder et al.
2009). Additionally, it has been shown that glutamate and oxytocin are synthetized 
in similar structures and areas in the brain. The first direct evidence of interaction 
of these systems came from Pampillo et al. (2001) where they showed that 
hypothalamic oxytocin release was regulated by the activation mGluRs in adult 
male rats. Furthermore, it has been demonstrated that mGluR activation increases 
oxytocin release in rat hypothalamo-neurophypophysial explants (Morsette et al. 
2001). Taken together, these data suggest a fimctional interaction between the 
MOPr- mGlusR and OTR- mGlusR systems.
In addition to the possible interaction between these systems, there is substantial 
evidence demonstrating that glutamatergic projections from the mPFC to the 
accumbens play a critical role in both priming-induced and cue-induced 
reinstatement (Kalivas 2009). In particular, both in vivo and in vitro studies have 
highlighted the mGlusR as an important mediator of accumbal glutamate 
transmission and reinstatement (Kalivas 2009). The involvement of the mGlugR in 
cocaine addiction has been confirmed by studies using a mouse model of global 
genetic deletion of mGlus receptor, which prevented the acquisition of cocaine self­
administration (Chiamulera et al. 2001). In addition, systemic (Backstrom and
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Hyytia 2006; Kumaresan et al. 2009; Martin-Fardon et al. 2009) and intra-AcbC 
(Wang et al. 2013b) administration of mGlusR negative allosteric modulators 
decreased priming- and cue-induced reinstatement of cocaine-seeking. 
Cocaine-primed reinstatement was also attenuated by intra-AcbSh injection of 
mGlusR negative allosteric modulators (Kumaresan et al. 2009). Together, 
these findings implicate accumbal and amygdalar mGlusR in the mechanism 
underpinning reinstatement and suggest that pharmacological manipulation of 
mGlus receptor may be a potential therapeutic target for the treatment of cocaine 
addiction and prevention of relapse.
As MOP, OT and mGlug receptors have all been implicated in psychostimulant 
self-administration and reinstatement behaviour, we hypothesise that cocaine self­
administration, extinction, cue- and priming-induced reinstatement of cocaine- 
seeking will induce brain region specific alterations of these receptor systems 
which may be involved in the development of drug craving during withdrawal 
and/or in the induction of reinstatement behaviour. To test this hypothesis, full 
autoradiographic mapping of mGlus, MOP, and OT receptors was carried out in 
the brains of mice following acquisition of cocaine self-administration, extinction 
and cue- and priming-induced reinstatement of cocaine-seeking and their 
respective saline controls. Moreover the effect of the two different types of 
reinstatement was assessed in order to identify any differential regulation of 
receptor binding levels.
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3.2 Methods
3.2.1 Animals
Male CD-I outbred mice (Charles River, France), 7 weeks old and weighing 20- 
25 g upon arrival at the laboratory, were individually housed under a 12-h light-
dark cycle (lights on at 8:00am), at constant temperature (21±1°C) and humidity
(55 ±10%). Food and water were provided ad libitumMicQ were left to acclimatise
in their new environment for seven days prior to the experimental start and were 
handled daily by the experimenter . Animal care and experimental procedures were 
in accordance with institutional and international standards (the European 
Communities Council Directive 86/609/EEC, 24 November 1986) and approved by 
the local Ethics Committee (CEEA-PRBB).
3.2.2 Operant cocaine self-administration
The cocaine self-administration and priming- and cue-induced reinstatement of 
cocaine-seeking were performed by Prof. Rafael Maldonado lab in the University 
of Pompeu Fabra, Spain. The cocaine self-administration and reinstatement 
procedures were performed as previously described (Soria et al. 2008). Briefly, 
mice were implanted with intravenous silastic catheters and, after a recovery period 
of three days, they were trained to self-administer cocaine hydrochloride, 1 
mg/kg/infusion (Ministerio de Sanidad y Consume, Spain), at the fixed ratio 1 of 
reinforcement. The training consisted of 2-h daily self-administration sessions and 
was conducted in operant chambers (MED Associates, Georgia, VT, USA) 
equipped with nose-poke holes. When the animal poked the ‘active’ hole a cocaine 
infusion was obtained simultaneously with a light cue. Poking of the ‘inactive’ hole
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had no effect. The training was carried out during 12 consecutive days. Following 
the 12-day acquisition period, those that achieved the acquisition criteria of self­
administration as described by Soria et al. (2008) were subjected to an extinction 
period which consisted of two 2-h daily sessions in the operant cages, during which 
nose poking was not reinforced by cocaine administration (see Table 3.1). The 
extinction training was carried out for 6 days per week until the mice reached the 
extinction criteria as described in Soria et al. (2008).
Table 3.1: Summary of the number of animals excluded from the cocaine
Animals at the Animals completed Animals excluded Animals failed
start of study the study due to death to acquire cocaine self-administration
121 40 3 80
Following the extinction period, animals were tested for priming- (n=9) and cue- 
induced reinstatement (n=16) of nose-poke behaviour elicited either by a priming 
injection of cocaine (10 mg/kg, i.p.) given immediately prior the placement of mice 
in the operant chamber or by presentation of the conditioned light cue previously 
associated with cocaine administration. During the 2-hour reinstatement sessions, 
nose-pokes in the ‘active’ hole did not result in infusion of cocaine at any time 
point. An animal was considered to be a responder in the reinstatement test when 
the number of nose pokes on the ‘active’ hole was at least double the corresponding 
nose-pokes during the last extinction session and when the number of responses on 
the ‘active’ hole was equal or greater than ten.
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3.2.3 Quantitative receptor autoradiography
Cleaning and subbing o f microscope slides: Microscope slides were left to soak 
overnight in Decon, a water-based detergent. Slides were then rinsed in hot running 
water for 15 minutes followed by a rinse in cold distilled water for a ftirther 15 
minutes. The slides were then soaked in a 10% hydrochloric acid (HCl) -90% 
ethanol solution for 20 minutes followed by another 15 minute rinse in distilled 
water. Slides were coated by a 2-minute immersion in 1% gelatine/chrom-alum 
solution and left to dry before use.
Tissue preparation: Seven animal groups were used for autoradiographic analysis 
of receptor binding: a) mice subjected to cocaine self-administration; b) Mice 
subjected to extinction training following cocaine self-administration; mice 
subjected to extinction training following cocaine self-administration, which then 
underwent testing for reinstatement triggered by c) cocaine priming injection (10 
mg/kg, i.p.) or d) by a light cue associated with cocaine administration; e) mice 
receiving saline infusions instead of cocaine in the Skinner box (saline self­
administration; f) mice receiving saline infusions undergoing saline priming- 
induced reinstatement or g) cue-induced reinstatement. All the animals from the 
aforementioned experiments were euthanized by decapitation 24 hours after the last 
2h-session in the operant chamber. Brains were removed and frozen in -25°C 
isopentane solution for 30 seconds and stored at -80°C until use. Prior to 
sectioning, brains were removed from -80°C and placed into a -21 C cryostat 
apparatus (Zeiss Microm 505E, Hertfordshire, U.K.) and coronally aligned by 
fixing the cerebellum onto a mounting stage using a plastic embedding liquid 
(O.C.T. compound, BDH chemicals, Dorset, U.K.). 20 pm frozen coronal sections 
were cut (300 pm apart) in a cryostat (Zeiss Microm 505E, Hertfordshire, U.K.)
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throughout the whole brain and thaw-mounted onto gelatin subbed ice-cold 
microscope slides and processed for autoradiography as described previously 
(Kitchen et al. 1997).
For MOPr autoradiography slides were pre-incubated for 30 minutes in 50 mM 
Tris-HCl buffer, containing 0.9% NaCl HCl (pH 7.4, room temperature) to remove 
endogenous ligands. For the determination of total binding, slides were incubated 
for 60 minutes in 4 nM [^H]-tyrosyl-3,5-3H(N) (DAMGO) (PerkinElmer, 1905.5 
GBq/mmol) in Tris-HCl (pH 7.4, room temperature). Adjacent sections were 
incubated in [^HJDAMGO (4nM) in the presence of 1 pM naloxone (Sigma- 
Aldrich, Poole, UK), to determine NSB. Receptor binding was terminated by three 
5-minute rinses in ice-cold Tris-HCl buffer (ph 7.4) followed by a final rinse in ice- 
cold distilled water before being rapidly dried in cool air for 2 hours.
For OTR autoradiography sections were pre-incubated for 2 x 10 minutes in 
50 mM Tris-HCl buffer (pH 7.4, room temperature) to remove endogenous 
oxytocin. For the determination of total binding, slides were incubated in 50 pM 
-ornithine vasotocin (OVTA) (PerkinElmer, 81.4 TBq/mmol) in an incubation 
buffer medium (50 mM Tris-HCl, 10 mM MgC12, 1 mM EDTA, 0.1% w/v bovine 
serum albumin, 0.05% w/v bacitracin; Sigma-Aldrich, Poole, UK, pH 7.4 at room 
temperature) for 60 minutes. For the determination of NSB, adjacent sections were 
incubated with [^^^I]-OVTA (50 pM) in the presence of 50 pM unlabelled (Thr4, 
Gly7)-oxytocin (Bachem, Germany). Incubation was terminated with three 5- 
minute rinses in ice-cold rinse buffer (50 mM Tris-HCl, 10 mM MgC12, pH 7.4) 
followed by a 30 minute wash in the ice-cold rinse buffer. The slides were washed
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for 2 seconds in ice-cold distilled water before being rapidly dried in cool air for 2 
hours.
For mGlusR quantitative autoradiography, slides were pre-incubated in 50 mM 
Tris-HCl buffer, containing 120mM NaCl, 5mM KCl, 2mM CaCli and ImM 
MgCli (pH 7.4, room temperature; 20 min) in order to remove endogenous 
glutamate. To determine total binding, slides were incubated for 60 minutes in 10 
nM [^H]-2-methyl-6-([3,5-3H] phenylethynl) pyridine (MPEP) (American 
Radiolabeled Chemical, 2.22 TBq/mmol) in Tris-HCl (pH 7.4, 4°C). For the 
determination of non-specific binding (NSB) adjacent sections were incubated in 
[^H]MPEP (10 nM) in the presence of lOpM fenobam (Tocris Bioscience, Bristol, 
UK). Receptor binding was terminated by two rapid rinses in ice-cold Tris-HCl 
buffer ( 2 x 1  min, ph 7.4) and a final rinse in ice-cold distilled water before being 
rapidly dried in cool air for 2 hours.
Radioligand bound sections were desiccated in anhydrous calcium sulphate 
(Drierite- BDH Chemicals, Dorset, UK) for 1 week and then apposed to Kodak 
BioMax MR-1 films (Sigma-Aldrich, Gillingham, UK), along with appropriate 
microscale standards, to allow quantification. Different apposition times were used 
depending on the autoradiographic binding (mGlugR binding - 3 weeks; MOPr 
binding - OTR binding - 3 days). Slides with brains sections from all the treatment 
groups were laid down against the same film, developed (using 50% Kodak D19 
developer, 3 min) and analysed in parallel in a complete paired protocol as 
described by (Kitchen et al. 1997). All structures were identified by reference to the
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mouse brain atlas of Franklin & Paxinos (2001), and analysed using an image 
analyzer (MCID; Image Research, Linton, UK).
3.2.4 Statistical analysis:
All the values were expressed as mean ± SEM. For analysis of acquisition of 
cocaine self-administration behaviour repeated measures two-way ANOVA with 
factors ‘hole’ (i.e., active and inactive) and ‘time (day)’ was performed. For the 
analysis of priming- and cue-induced reinstatement of cocaine-seeking behaviour, 
two-way ANOVA was performed with factors ‘hole’ (i.e., active and inactive) and 
‘experimental phase’ (ie, last day of self-administration, first day of extinction, last 
day of extinction and priming- or cue-induced reinstatement). For analysis of 
treatment and experimental phase on mOlu^R, MOPr and OTR autoradiographic 
binding, two-way ANOVA with factors ‘treatment’ (i.e., saline and cocaine) and 
‘experimental phase’ (i.e., self-administration, priming- and cue-induced 
reinstatement) were performed in each brain region analysed. The effect of 
‘experimental phase’ (i.e., self-administration, extinction, priming- and cue- 
induced reinstatement) on the cocaine-treated groups on receptor autoradiographic 
binding was analysed by one-way ANOVA in each brain region. ANOVAs were 
followed by a Holm-Sidak post hoc test when significant interaction effect was 
reached (i.e., p<0.05). All relevant F-values are provided in Table 3.1. All 
statistical analyses were performed using SigmaPlot (Systat Software, London, 
UK).
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3.3 Results
3.3.1 Acquisition, extinction, priming- and cue- induced reinstatement of 
cocaine self-administration behaviour
The results for acquisition of self-administration were pooled for all experimental 
groups which involved acquisition of self-administration (n=36). The percentage 
of mice that reached the acquisition criteria after the 12-day training period was 
42%. During the training period, mice readily learned to discriminate between the 
active and inactive hole. A significant ‘time’ x ‘hole’ interaction indicated that 
animals increased the number of responses on the active hole along the time. The 
response to the active hole compared to the inactive hole reached statistical 
significance on day 4 and persisted until the last day of the training period (Figure
3.1 A).
Mice which were not killed at the end of the acquisition phase of self­
administration underwent 2 h daily extinction sessions during which nose poking 
was not reinforced by the administration of the drug. The mice that reached the 
acquisition and extinction criteria were then separated into two groups, cue- and 
priming-induced reinstatement groups. In both groups a significant ‘experimental 
phase’ effect, as well as a significant ‘experimental phase’ x ‘hole’ interaction were 
observed, indicating that mice responded differentially to active and inactive hole 
in each phase. Holm- Sidak post-hoc test revealed that cocaine self-administration 
induced an increase in the number of responses on the active hole compared to the 
inactive hole (p<0.001). This increase persisted during the first day of the 
extinction period in both groups (p<0.05; Figure 3.1B,C). Responses to both holes
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were not significantly different on the last day of the extinction period (p>0.05) 
demonstrating that cocaine-seeking behaviour was successfully extinguished. 
During the reinstatement testing both presentation of the cocaine-associated cue 
and a priming injection (10 mg/kg) were able to induce reinstatement of cocaine- 
seeking behaviour since responses to the active hole were significantly higher 
compared to the inactive hole (p<0.001, Figure 3.1B,C). Moreover, the responses 
of the animals to the active hole were increased in both cue and priming 
reinstatement phases compared to the last day of the extinction phase (Figure 
3.1B,C). The priming injection of cocaine induced more robust reinstatement 
compared to cue-induced reinstatement as indicated by the higher responses to the 
active hole in cocaine-primed reinstatement compared to cue-induced reinstatement 
of cocaine-seeking (p<0.07).
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3.3.2 Effect of cocaine self-administration, extinction, priming- and cue- 
induced reinstatement of cocaine seeking on MOPr binding in mouse 
brain
Quantitative analysis of |i receptor binding showed a significant ‘treatment’ and 
‘experimental phase’ effect in the AcbSh, AcbC and CPu (Figure 3.2A, B). 
Decreased MOPr binding was observed in the AcbSh in mice subjected to cocaine 
self -administration compared to saline controls, irrespective of the experimental 
phase (Figure 3.2A, B). Moreover, in the AebC and CPu a significant ‘treatment’ 
X ‘experimental phase’ interaction was identified. Holm-sidak post-hoc test 
revealed a significant decrease in p receptor binding in the AcbC ip<0.01) and CPu 
(p<0.01, p<0.05) in mice subjected to cocaine self-administration and cue-induced 
reinstatement of cocaine-seeking compared to their respective saline controls 
(Figure 3.2A, B).
Analysis of the effect of ‘experimental phase’ (i.e., self-administration, extinction, 
priming- and cue-induced reinstatement) within the cocaine groups on p receptor 
autoradiographic binding (Figure 3.2C) revealed a significant effect in the AcbC 
(p<0.05), CPu (p<0.05), VDB (p<0.05) and BLA (p<0.05). Cocaine-primed 
reinstatement induced a significant up-regulation of p receptor binding in the AcbC 
(p<0.05 vs cue-reinstatement), CPu (p<0.05 vs self-administration and cue- 
reinstatement) and VDB (p<0.05 vs self-administration) (Figure 2C). In the BLA, 
reduced MOPr levels were observed following extinction of cocaine self­
administration behaviour compare to the animals self-administering cocaine 
(p<0.05). However, priming- but not cue- induced reinstatement of cocaine-seeking 
restored p receptor binding to the levels of cocaine-self administration (p<0.05 vs
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cocaine extinction). Moreover, one-way ANOVA within the saline groups in each 
individual brain region did not reveal any significant differences between the 
different experimental phases.
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3.3.3 Effect of cocaine self-administration, extinction, priming- and cue- 
induced reinstatement of cocaine-seeking on OTR binding in mouse 
brain
Quantitative analysis of OTR binding showed a significant ‘treatment’ effect in the 
central nucleus of Amy (Figure 3.3A, B). No significant differences were found in 
the other brain regions analysed.
One-way ANOVA of OTR binding in brains of mice undergoing cocaine self­
administration, extinction and priming- and cue-induced reinstatement showed no 
significant experimental phase effect in any of the regions analysed. No significant 
experimental phase effect was detected between the saline treated groups in any of 
the regions analysed (Figure 3.3C)
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3.3.4 Effect of cocaine self-administration, extinction, priming- and cue- 
induced reinstatement of cocaine-seeking on mGluRS binding in mouse 
brain
Quantitative analysis of mGluRS binding showed a significant treatment effect in 
the BLA and LS (Figure 3.4A, B). Higher levels of mGlugR binding were detected 
in the LS of the groups of mice subjected to cocaine self-administration and 
reinstatement compared to saline controls, irrespective of experimental phase 
(Figure 3.4A, B). On the other hand, lower levels of mGlugR binding were 
observed in the BLA of animals trained to self-administer cocaine compared to the 
saline controls, irrespective of experimental phase (Figure 3.3B). A significant 
effect of the factor ‘experimental protocol’ but not of ‘treatment’ was observed in 
the AcbC (Figure 3.4A,B).
Analysis of cocaine self-administration and reinstatement of cocaine-seeking to test 
the effect of experimental phase (i.e., self-administration, extinction, priming- and 
cue-induced reinstatement) on mGlugR autoradiographic binding revealed a 
significant up-regulation of mGlusR binding in priming-induced reinstatement of 
cocaine-seeking compared to cocaine self-administration, extinction and cue- 
induced reinstatement of cocaine-seeking in the AcbC (p<0.05) (Figure 3.4A, C). 
Moreover, one-way ANOVA within the saline groups in each individual brain 
region did not reveal any significant differences between the different experimental 
phases.
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Table 3.2: Relevant Effects for Biochemical and Behavioural Data- Chapter 3.
Treatment effect Experimental phase Interaction effect
Overall e ffects fo r  Figure 3.1
Cocaine effects on nose pokes Factor 'hole' Factor 'tim e (days)' Factor 'hole 'x  'time'
Self-administration (n=36) F [ i ,719] =  97.881; p<0.001 F [i i ,719] = 6.665 p<0.001 F [ i i ,719] = 16.174 p<0.001
Reinstatem ent o f  cocaine-seeking Factor 'hole' Factor 'experim ental phase' Factor 'hole'x 'experim entalphase'
Cue-induced reinstatem ent (n=16) F[i,97] = 35.732; p<0.001 F(3,97] -  7.204; p<0.001 F[3,97] = 11.537; p<0.001
Priming-induced reinstatem ent (n=9) F[i,6ii = 120.177; p<0.001 F[3,61] =49.186; p<0.001 F[3,6i] = 29.945; p<0.001
Overall e ffects fo r  Figure 3.2
MOPr autoradiography(n=5-6) Factor 'treatm ent' Factor 'experim entalphase' Factor 'trea tm en t'x  'experim entalphase'
MtCx F [i ,321 =0.633; p=0.433 F[2,32) = 1.901; p=0.169 F[2,32] = 0.291; p=0.750
CgCx F[i,3o] =  1.213; p=0.282 F[2,30] = 0.684; p=0.514 F[2,3oj = 1.894; p=0.172
CPU F [i ,301 = 21.921; p<0.001 F[2,30] = 2.230; p=0.130 F[2,3o] = 3.771; p<0.05
AcbC F[i,3ii = 31.560; p<0.001 F[2,31] = 6.756; p<0.01 F[2,3i] = 3.702; p<0.05
AcbSh F[i ,3i] = 22.272; p<0.001 F[2,31] = 3.462; p<0.05 F[2,3i i  = 1.471; p=0.248
MS F [i ,30] =  3.479; p=0.074 F[2,30) = 0.703; p=0.505 F(2,30] = 0.843; p^O.443
VDB F [ i ,30] = 3.714; p=0.066 F[2,30] = 1.250; p=0.305 F[2,3oi = 2.449; p=0.108
LS F[i,3o) = 0.226 p=0.639 F[2,30] = 0.0048; p=0.348 F[2,30] = 1.105; p=0.348
VP F [i ,30] =  2 . 0 2 2 ; p=0.168 F[2,30] = 0.108; p=0.899 F[2,3o] = 0.251; p=0.780
Hip F [i ,30] = 0.500; p=0.487 F[2,30] = 1.117; p=0.344 F[2,30] = 1.601; p=0.223
Th F[i,3o] -  0.300; p=0.589 F[2,30] = 3.840; p<0.05 F[2,30] = 2.368; p=0.116
Hyp F[i ,3oi = 0.0656; p=0.800 F[2,30] = 0.369 p=0.695 F|2,30] = 2.230; p=0.130
BLA F [i ,30] = 0.312; p=0.582 F[2,30) = 4.200; p<0.05 F i2,30] = 0.657; p=0.528
MOPr autoradiography (n=5-6) Factor 'experimental phase '
MtCx F[3,23] =0.837; p=0.489
CgCx F[3,21] = 1.226; p=0.329
CPU F[3,20] = 4.409; p<0.05
AcbC F(3,22] = 4.579; p<0.05
AcbSh F[3,22] = 2.005; p=0.146
MS F[3,21] = 1.065; p=0.389
VDB F(3,20] = 4.351; p<0.05
LS F[3,2i] = 0.308 p=0.819
VP F(3,21] = 0.009 p=0.999
Hip F(3,21] = 0.310 p=0.487
Th F[3,2i] =2.612 p=0.083
Hyp F[3,21] = 1.870 p=0.171
BLA F[3,2ij = 4.875 p<0.05
Overall e ffects fo r  Figure 3.3
oradiography(n=5-6) Factor 'treatm ent' Factor 'experimental phase ' Factor 'trea tm en t'x  'experim entalphase'
AOM F[i,33] = 4.001; p=0.055 F[2,33] = 2.580; p=0.094 F[2,33] = 0.234 p=0.793
AOV F[i,35] = 0.0199; p=0.889 F[2,35] = 1.147; p=0.331 F[2,35] = 0.323 p=0.727
AOL Fu,341 = 0.495; p=0.477 F[2,34] = 0.180; p=0.836 F[2,34] = 0.278 p=0.759
CgCx F[i,341 = 0.0701; p=0.793 F[2,34] = 0.141; p=0.869 F[2,34] = 1.288 p=0.291
Pir F[i,35] = 0.0148; p=0.904 F[2,35] = 0.239; p=0.789 F[2,35] = 0.0624; p=0.940
Acb F[i ,351 = 0.385; p=0.540 F[2,35] = 1.206; p=0.313 F[2,35] -  0.840 p=0.442
CPU F[i ,351 = 0.0260; p=0.873 F[2,35] = 1.853; p=0.174 F[2,35] = 1.283 p=0.292
MS F[i,35] = 1.396; p=0.247 F[2,35] = 0.756; p=0.478 F[2,35I = 0.548 p=0.584
VDB F[i,35] = 0.138; p=0.713 F[2,35] = 0.118; p=0.889 F[2,35I = 0.573 p=0.570
LS F[i,34] = 1.307; p=0.262 F[2,34] = 0.249; p=0.782 F[2,34I = 0.253 p=0.778
Hip F[i,34] = 1.648; p=0.209 F[2,34] = 2.544; p=0.096 F[2,34] = 0.897 p=0.416
Th F[i,35] = 0.0024; p=0.961 F[2,35) = 0.880; p=0.425 F[2,35I = 2.607 p=0.090
CeA F(i,35) = 7.007; p<0.05 F(2,35) = 0.0125; p=0.225 F[2,35) = 0.190 p=0.828
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OTR autoradiography(n=6) Factor 'experimental phase'
AOM F[3,23] = 1.471 p=0.253
AOV F[3,23] = 0.722 p=0.551
AOL F[3,23] = 0.199 p=0.896
CgCx F[3,23] = 1.111 p=0.371
Pir F[3,23] = 0.220 p=0.881
Acb F[3.23] = 0.991 p=0.417
CPU F[3,23] = 1.154 p=0.352
MS Fi3,231 = 0.523 p=0.672
VDB F [3,23] = 0.342 p=0.795
LS F[3,23] = 0.541 p=0.660
Hip F[3,23] = 0.172 p=0.914
Th F[3,23] = 1.471 p=0.425
CeA F[3,231 = 1.154 p=0.352
Overall e ffects fo r  Figure 3.4
mGluRB autoradiography (n=5-6)
MtCx
PrL
CgCx
CPU
AcbC
AcbSh
MS
VDB
LS
Hip
Th
Hyp
BLA
Factor 'treatm ent' Factor '
MtCx F[i,35] -  2.483; p=0.126 F[2,35] = 0.125; p=0.883 F[2,35] = 0.526 p=0.596
PrL F[i ,35] = 2.203; p=0.140 F[2,35] = 0.173; p=0.842 F[2,35] = 2.493 p=0.100
CgCx F[i,35] = 0.0103; p=0.920 F[2,35] = 0.223; p=0.802 F[2,35] = 0.514 p=0.603
CPU F(i,35] = 2.0.75; p=0.160 F[2,35] = 1.382; p=0.267 F[2,3S] = 1.410 p=0.260
AcbC F[i,35] = 3.420; p=0.074 F[2,35] = 8.539; p<0.01 F[2,35] = 2.877 p=0.0.72
AcbSh F[i ,35] = 0.923; p=0.344 F[2,35] = 1.691; p=0.201 F[2,35] = 0.403 p=0.672
MS F[i ,34] -  0.0246; p=0.877 F(2,34] = 0.822; p=0.450 F[2,34] = 2.723 p=0.082
VDB F[i,35] = 0.494 p=0.488 F[2,35] = 0.456; p=0.638 F[2,35] = 3.016 p=0.064
LS F[i,35] = 12.915; p<0.01 F[2,35] = 0.775; p=0.470 F[2,35] = 0.489 p=0.618
Hip F[i,34] = 0.784; p=0.383 F[2,34] = 0.494; p=0.615 F[2,34] = 1.132 p=0.336
Th F[i,34] = 4.134; p=0.051 F[2,34] = 0.180; p=0.836 F[2,34] = 0.0001; p=1.000
Hyp F[i ,34] = 3.241; p=0.082 F[2,34] = 0.290; p=0.750 F[2,34] -  0.747 p=0.483
BLA F[i,33] = 16.375; p<0.001 F(2,33] = 0.472; p=0.629 F[2,33] = 2.837 p=0.076
F[3,23] = 1.380 
F[3,23] = 1.203 
F[3,23] = 0.489 
F[3,23] = 1.894 
F[3,23) = 5.911 
F[3,23) = 1.184 
F[3,23] = 1.875 
F[3,23] = 0.956 
F[3,23] = 0.830 
F[3,22] = 1.265 
F[3,22] = 1.202
F(3,221 = 0.567 
F[3,2 i i  = 2.934
p=0.278
p=0.334
p=0.694
p=0.163
p<0.01
p=0.341
p=0.166
p=0.433
p=0.493
p=0.315
p=0.336
p=0.643
p=0.061
138
3.4 Discussion
This study provides direct evidence of reinstatement-triggered receptor alterations 
in the brain that are likely to contribute to the neurobiological mechanisms 
underpinning relapse to cocaine-seeking. In addition, we observed distinct 
regulation of mGlusR and MOPr by cue- and priming-induced reinstatement, 
highlighting the differential regulation of these receptor systems mainly in AcbC 
and BLA following the different triggers of cocaine reinstatement.
The behavioural data obtained from the cocaine self-administration and 
reinstatement protocol are in complete agreement with Soria et al (2008), who used 
a similar reinstatement paradigm, confirming the reliability and validity of this 
operant self-administration protocol in mice. Priming injection of cocaine was 
found to be much more potent stimulus in reinstating cocaine-seeking behaviour 
compared to drug-associated cue, as reflected by the significantly higher number of 
active nose pokes during the priming reinstatement test. A possible effect of 
injection-induced stress can be ruled out based on previous observations by Soria et 
al (2008) who showed that an acute saline-primed injection was not able to trigger 
reinstatement of cocaine-seeking behaviour, using a similar cocaine self- 
administration and extinction protocol.
Autoradiographic brain analysis demonstrated a significant decrease of MOPr 
binding in the AebC and CPu following cocaine self-administration and cue- but 
not priming-induced reinstatement compared to saline control groups, suggesting a 
differential regulation of MOPr following different triggers of cocaine 
reinstatement. These findings are supported by previous studies using non-
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contingent administration of cocaine (Hurd and Herkenham 1993; Sharpe et al. 
2000; Soderman and Unterwald 2009). However, other studies have also reported 
an increase or no difference in MOPr activation, mRNA and binding following 
chronic cocaine exposure in the striatum (see Yoo et al. 2012). The reason for these 
discrepancies may lie with the differential effect of contingent vs non-contingent 
administration of cocaine, which has been shown to differ in terms of their 
molecular and behavioural effects (Markou et al. 1999; Metaxas et al. 2010). 
Interestingly, decreased levels of MOPr binding following cue- but not priming- 
induced reinstatement of cocaine-seeking in AebC and CPu, as well as decreased 
levels of MOPr binding in cocaine self-administration compared to priming- 
induced reinstatement in CPu and VDB were observed. Given the positive 
correlation between MOPr levels with relapse potential of cocaine use in 
former cocaine addicts (Gorelick et al. 2008), it is possible that the difference 
in MOPr levels observed in mice subjected to cue- and priming-induced 
reinstatement of cocaine-seeking may at least partly underlie the differences in 
the magnitude of reinstatement responses induced by the light cue and the 
priming injection of cocaine observed in our study. Of particular interest was the 
finding in the BLA, where decreased levels of MOPr binding were observed 
following cocaine extinction compared to cocaine self-administration. In this 
region, priming- but not cue-induced reinstatement of cocaine-seeking restored 
MOPr binding levels back to levels observed in the cocaine-self administration 
group prior to extinction. Although BLA has been implicated in the development of 
craving during withdrawal and in priming- as well as cue-induced reinstatement of 
cocaine-seeking (see Shaham et al. 2003), this is the first study to suggest a role of 
the MOPr system underlying these addictive behaviours in this brain region.
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The present study demonstrates a cocaine-induced increase of OTR binding in the 
CeA compared to saline controls, which is in line with previous findings fi"om 
Johns et al. (2004), who found increased OTR density in the Amy of lactating rat 
dams following gestational treatment with cocaine. Since chronic cocaine 
administration has been shown to decrease hypothalamic OT content as well as 
plasma OT levels (Samyai et al. 1992c), it is likely that the increased OTR binding 
observed in the CeA represents a compensatory neuroadaptation to a persistent 
hypo-OTergic state induced by chronic cocaine self-administration.
Furthermore, a significant increase of mGlugR binding in the LS together with a 
significant decrease in the BLA of mice subjected to cocaine self-administration 
compared to saline controls was observed. The observed region-specific alterations 
in the mGlugR system may indicate a possible mechanism underlying the transition 
from the impulsive use of the drug to the compulsive use. In support of this, Hao et 
al. (2010) reported a down-regulation of mGlu$R in the BLA of rats with long 
access to cocaine, which was shown to be positively correlated with the transition 
from cocaine use to dependence. Importantly, the current study demonstrated an 
up-regulation of mGlu^R binding following priming- but not cue- induced 
reinstatement of cocaine-seeking in the AcbC, suggestive of an mGlusR-mediated 
mechanism in the induction of cocaine-primed reinstatement. Although, the 
functional significance of this up-regulation cannot be firmly ascribed, the 
evidence that prevention of coeaine-indueed reinstatement following an intra- 
AebC injection of an mGlusR negative allosteric modulator in rats (Schmidt et 
al. 2014; Wang et al. 2013b), points to the probability that priming-induced
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increase of mGlusRs might, at least partly, underlie the marked reinstatement of 
cocaine-seeking following a priming injection. The lack of up-regulation of 
mGlusR binding following cue-induced reinstatement of cocaine-seeking 
behaviour does not preclude the involvement of mGlusR in this type of 
reinstatement, but merely that up-regulation of mGlugR binding is not the 
underlying mechanism. In fact, injection of mGlugR negative allosteric 
modulators in the AcbC of rats decreased cue-induced reinstatement of 
cocaine-seeking (Wang et al 2013), which has also been mimicked in striatum- 
specific mGlusR knockout mice (Novak et al. 2010).
Overall, the results of this study demonstrate significant region-specific 
neuroadaptations of the mGlugR, MOPr and OTR systems following cocaine self­
administration and/or cue- or priming-induced reinstatement of cocaine-seeking. 
More importantly, differential regulation of mGlugR and MOPr by priming- and 
cue-induced reinstatement of cocaine-seeking was observed, consistent with 
findings from Ziolkowska et al. (2011), who observed differences in the levels of 
regional brain activation, as measured by induction of immediate early genes, 
following priming- compared to cue-induced reinstatement of cocaine-seeking 
behaviour. Overall, the novel findings of the present study provide further insight 
into specific neurobiological mechanisms underlying relapse to drug-seeking and 
highlight specific differences in neuroehemieal adaptations depending on the 
challenge that triggers relapse (priming vs cue). These data support the importance 
of the development of novel targeted pharmacotherapy for the prevention of relapse 
to cocaine-seeking following abstinence.
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Chapter 4
Differential regulation of OTR, MOPr and 
CRF systems by methamphetamine 
administration and withdrawal: 
association with the methamphetamine 
withdrawal-induced emotional 
impairment
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4.1 Introduction
Methamphetamine (MAP), or methylamphetamine, is the A-methylated analogue 
of the psychostimulant amphetamine, which share common pharmacological 
properties (Melega et al. 1995). MAP is a potent psychostimulant drug with a high 
prevalence of abuse worldwide (Panenka et al. 2013). The relatively easy 
clandestine manufacture of MAP from low cost over-the-counter ingredients sueh 
as pseudoephedrine, a common ingredient in eold medications, and the consequent 
low street cost have led to epidemic MAP use in Japan (see Wada 2011) and near­
epidemic proportions in the United States (Gonzales et al. 2010). Acutely, MAP 
stimulates DA, NA and 5-hydroxytryptamine (5-HT) release via amine 
redistribution from synaptic vesicles to the cytoplasm and by reversing the action 
of monoamine transporters (Krasnova and Cadet 2009; see Sulzer et al. 2005). 
Actions of MAP on striatal DAergie nerve terminals are hypothesised to account 
for its acute rewarding effects (Vollm et al. 2004).
Chronic use of MAP leads to neurotoxic effects by either damaging the striatal 
DAergie neurons (Wagner et al. 1980), or by the formation of reactive oxygen 
species (Cubells et al. 1994; La Voie and Hastings 1999; ODell et al. 1991; 
Yamamoto and Zhu 1998), or via glutamate exeitotoxicity as a consequence of 
MAP-induced glutamate release in the striatum (Abekawa et al. 1994; Nash and 
Yamamoto 1992; Stephans and Yamamoto 1994). Repeated administration of MAP 
has also been shown to induce emotional impairments including social avoidance 
and isolation, aggressiveness, aggression, depression and anxiety and can also 
induce psychotic behaviour in humans (Grant et al. 2012; MeKetin et al. 2011). 
Even after long-term abstinence from MAP, former addicts suffer from cognitive
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and emotional withdrawal-related symptoms, whieh may act as a motivational 
trigger to re-administer the drug and relapse (Zoriek et al. 2010). Currently, 
pharmacotherapy for addiction to psychostimulant drugs, including MAP, is 
limited (Cieearone 2011).
Although several mechanisms have been suggested, the molecular mechanisms 
underpinning the addictive properties of chronic MAP use and its behavioural and 
emotional consequences remain unclear. During the last decade, the OT system has 
been hypothesised to be involved in MAP addiction processes (see McGregor and 
Bowen 2012). In particular, it has been suggested that regulation of the OT system 
by ‘party drugs’, including MAP, might by be responsible for some of the 
behavioural effects observed during drug administration, such as pro-social and 
pro-sexual effects, as well as the emotional impairment occurring during 
withdrawal (see McGregor et al. 2008b). Moreover, exposure to MAP decreases 
pup-directed behaviours, impaired nest building and overly aggressive maternal 
defence, which have been associated with a dysregulation of the OT system in rats 
(Slamberova et al. 2005a; Slamberova et al. 2005b). With respect to addictive 
related behaviours, it has been shown that centrally administered OT reduces both 
MAP-induced hyperlocomotion and DA release in the Acb in mice (Qi et al. 2008), 
demonstrating a key role for OT in the modulation of behavioural effects of MAP, 
possibly via a DAergic-dependent mechanism. Indeed, OTR are eo-localised and 
functionally interact with DA Di receptors in the Acb (Romero-Femandez et al. 
2012) further supporting a bi-directional regulation between the two systems. 
Dopamine D2 receptors have been found to be expressed in cell bodies and 
dendrites of OT neurons within the MPOA, SON and PVN of male rats
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(Baskerville et al. 2009). This finding suggests that DA may bind to and regulate 
OT cells via a D2 reeeptor-mediated mechanism. Moreover, central (Qi et al. 2009) 
and peripheral administration of OT attenuated the MAP-indueed reinforcing 
effects and reversed stress- (Qi et al. 2009) and priming-induced (Carson et al. 
2010a) reinstatement of MAP-seeking in rodents, providing further evidence for 
OT’s “antireward/anticraving” and relapse prevention potential for MAP addiction.
Nonetheless, the mechanisms by which the OTergic system modulates these MAP 
addiction processes remain unclear. A plausible mechanism by whieh the OT and 
MOPr system exerts its effects on MAP addiction is by interacting with the CRF 
system in the brain as well as the HPA-axis. It has been shown that genetic deletion 
of CRF receptor-2 (CRF-R2) dampens the locomotor response to MAP in mice 
(Giardino et al. 2012). CRF-R2 are localised on OTergic neurons and axon 
terminals, and activation of these receptors has been postulated to positively 
regulate OT release; likewise, the activation of OTR might also regulate the 
excitability of CRF neurons in the PVN (Dabrowska et al. 2011). Since OT 
administration has also been shown to decrease MAP-induced hyperlocomotion (Qi 
et al. 2008), it is possible that an interaction between the OT and CRF systems may 
regulate MAP addiction processes. This hypothesis is further supported by the fact 
that CRF cell bodies are highly expressed in the PVN (Matthews et al. 1991), 
where OT is also synthesised (see Section 1.5) and OT administration inhibits CRF 
release in virgin female rats (Neumann et al., 2000). Importantly, increased 
amygdalar CRF levels have been reported following 10 days of withdrawal from 
MAP self-administration and this effect was associated with the emergence of 
anxiety-like behaviour in rats (Nawata et al. 2012). Moreover, activation of the OT
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system via the administration of its analogue earbetoein was shown to prevent 
anxiety-like behaviours associated with morphine withdrawal in rodents (Zanos et 
al. 2014a). Taken together, these findings might indicate a beneficial role of the 
activation of the OT system in preventing drug-withdrawal induced emotional 
deficits via inhibiting of the CRF system in the Amy.
The MOPr system has been also shown to be involved in MAP addiction processes. 
In particular, it has been shown that mice lacking the MOPr exhibit decreased 
MAP-induced hyperloeomotion and stereotypy and do not manifest behavioural 
sensitisation to MAP (Shen et al. 2010). Moreover, administration of morphine, a 
MOPr agonist, increased MAP-induced reinforcing and stereotypic behaviour, 
which was at least partly attributed to the synergistic effect of morphine and MAP 
in causing an increase in striatal DA release (Lan et al. 2009), suggesting a possible 
regulation of MAP-induced rewarding effects by the MOPr system. With respect to 
withdrawal, Chiu et al. (2006) demonstrated a down-regulation of MOPr binding 
in brain membranes following an 8-day withdrawal period fi*om chronic MAP 
administration, which was followed by a rebound increase after 21 days of 
withdrawal in methamphetamine-sensitised mice. The potency of DAMGO for 
MOPr as well as the sensitivity of MOPr to DAMGO was found to be enhanced 
during abstinence from MAP, as measured by [^^S]-GTPyS binding studies in brain 
membranes (Chiu et al. 2006), further suggesting an involvement of the MOPr 
system during MAP abstinence. In contrast, MOPr gene expression and protein 
levels was significantly reduced in the frontal cortex of mice following long-term 
withdrawal from repeated MAP administration (Yamamoto et al. 2011). These
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discrepancies highlight regional specificity in the regulation of MOPr during MAP 
withdrawal.
Furthermore, MAP administration has been shown to induce a dysregulation of the 
HPA-axis, resulting in increased glucocorticoid release in both humans and 
animals. Specifically, it was reported that adolescent MAP users have higher 
cortisol levels following exposure to stress compared to control individuals (King 
et al. 2010). Similarly, acute, as well as repeated administration of MAP induces an 
increase in plasma corticosterone levels in rodents (Grace et al. 2010; Herring et al. 
2008; Schaefer et al. 2006). The OT and MOPr systems have been also shown to 
act on the HPA-axis. Specifically, it has been shown that OT administration 
inhibits corticosterone secretion in virgin female rats (Neumann et al., 2000) and 8- 
day intranasal administration of OT has been shown to decrease ACTH levels in 
monkeys, which was shown to correlate with a protective role of the activation of 
the OT system against the effects of social isolation-induced stress in animals 
(Parker et al. 2005; Smith and Wang 2012). Regarding the MOPr system, 
administration of MOPr-preferring antagonists sueh as naloxone, nalmefene and 
naltrexone in healthy volunteers has been shown to disinhibit the HPA-axis leading 
to the release of ACTH and cortisol (McCaul et al. 2000; Schluger et al. 1998; 
Wand et al. 1998). Taken together, another possible mechanism for the actions of 
OT and MOPr system in MAP-induced related effects is by regulating the activity 
of the HPA-axis.
In the present study, it was hypothesised that chronic administration of MAP and 
withdrawal will cause a persistent dysregulation of the central OTergic and MOPr
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systems which will result in the development of emotional impairement following a 
7-day withdrawal period. Moreover, dysregulation of the HPA-axis and CRF stress 
systems were also hypothesised to be implicated in the behavioural effects induced 
by chronie MAP administration and withdrawal. Therefore, in order to assess 
whether a 7-day withdrawal period from MAP administration induces mood 
disturbances, we assessed behavioural responses of MAP withdrawn animals in 
tests predicting anxiety- and depressive-like behaviours.
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4.2 Methods
4.2.1 Animals
Male C57BL/6J mice (7-week old, 20-25g, Charles River Laboratories, Kingston, 
UK), were housed individually in a temperature-controlled environment with a 12- 
hour light/dark cyele (lights on: 06:00 am). Food and water were available ad- 
libitum. Mice were left to acclimatise in their new environment for seven days prior 
to the experimental start and were handled daily by the experimenter. All 
experimental procedures were conducted in accordance with the U.K. Animal 
Scientific Procedures Act (1986).
4.2.2 Chronie steady-dose methamphetamine administration paradigm
Mice were randomly divided into four groups; saline-, MAP-treated, saline- 
withdrawn and MAP-withdrawn animals. Chronie MAP-treated animals were 
injected i.p. for 10 days with MAP (2 mg/kg) (Sigma-Aldrich, Poole, UK), once 
per day (09:00), in accordance with small modifications of studies carried out by 
(Broom and Yamamoto 2005). The chronie saline-treated group were administered 
with saline (10 ml/kg, i.p.) for 10 days, once per day (09:00). The saline-withdrawn 
and MAP-withdrawn animals were treated with the same administration paradigm 
and left to spontaneously withdraw for 7 days.
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4.2.3 Behavioural experiments
4 .2 .3 .1  L o c o m o to r  a c t iv i ty
Locomotor activity of each mouse was measured daily (8:00 am, 2 hours after the 
start of the light cycle) in loeomotor chambers (40cm x 20cm x 20cm; Linton 
Instrumentation, Norfolk, U.K.). Each chamber had two lines of 16 photocells 
located at right angles to each other, projecting horizontal infrared beams 2.5. cm 
apart and 6 cm above the cage floor to measure horizontal and vertical activity 
(rears), respectively. Mice were treated with either chronie saline or steady-dose 
MAP administration paradigm for 10 days and then left to spontaneously withdraw 
for 7 days in their home cage. During the administration period, mice were 
habituated in locomotor chambers for 60 minutes prior to saline/MAP injections in 
order to assess basal activity, then received an i.p. injection of saline or MAP and 
returned immediately to the chamber where horizontal and vertical activity 
(rearing) was measured for 90 minutes. Behavioural activity (pre- and post- 
injeetion) of each animal was monitored daily for the 10-day duration of the 
treatment and 7 days after the last treatment injection (withdrawal). Horizontal and 
vertical activities were recorded as the number of sequential infrared beam breaks, 
every 5 mins. The average activity of the hourly 5 min bins were calculated daily.
4.2.3.2 Emotional impairment testing
Separate cohorts of C57BL/6J mice were treated with an identical chronic saline 
and MAP administration paradigm (see Section 4.2.2) followed by 7-8 days 
withdrawal period and then tested for anxiety- (7 days withdrawal) and depression­
like behaviours (8 days withdrawal) using the EPM and EST respectively. These 
two tests were performed 24 h apart in the same animals. The order of testing was
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determined by the degree of anxiety inducing properties of eaeh test with the least 
stressful eondueted first and the most potentially distressing test last (Clemens et al. 
2007). Both the EPM and EST were performed at 9:00 am.
Elevated plus-maze: The elevated plus-maze was used to measure anxiety-like 
behaviour. The apparatus (Linton Instruments, UK) consisted of four equal-sized 
lanes (30em long x 5cm wide) converging at a centre square (5em x 5cm) to form 
the shape of a plus and elevated 40em off the floor. Of the four arms, two were 
enclosed by a 15cm high solid wall on the long sides of the arms (closed arms) and 
the other two had no sides (open arms). Eaeh mouse was allowed to habituate in the 
test room for 1 hour prior to test session. To assess anxiety-like behaviours, the 
“experimental” mouse was positioned with its head and forelimbs in the centre 
square of the apparatus and was allowed to explore the whole apparatus for 5 
minutes. The time spent in each arm was measured for each mouse by an 
automated tracking system (EthoVision v.3.0, Noldus Information Technology, 
Wageningen, Netherlands) and validated by an observer blind to the treatment 
groups. Anxiety-like behaviour was determined by calculating the amount of time 
spent and number of entries each mouse made in the open and closed arms and 
reported as the total time and the percentage number of entries respectively. The 
test was carried out in dim light conditions (10 lux).
Forced-swim test: The EST measures depressive-like behaviours as previously 
described (Porsolt et al. 1977). Briefly, mice were placed individually into clear 
glass cylinders (25cm height x 17cm diameter) filled with 2.5 litres of water at 
room temperature (24±1°C) for 6 minutes. Animals were removed from the water, 
dried by the experimenter with a paper towel, placed into the recovery chambers
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for 10 minutes (30°C) and placed baek in their home cages. The test session was 
recorded using a videocamera (Sony Handycam CX-250, Sony, Japan). Immobility 
time, defined as passive floating with no additional activity other than that 
necessary to keep the mice head above water, was scored by two treatment- 
eondition blinded observers during the 6-minute test session. Latency to the first 
encounter to immobility was also measured. Faecal boli of the animals were 
counted at the end of the FST. The test was carried out in normal lighting 
conditions (300 lux).
4.2.4 Biochemical and Neurochemical analysis
Separate cohorts of C57BL/6J mice were treated with an identical chronic saline 
and MAP administration paradigm as described above, and were left to 
spontaneously withdraw in their home cage for 7 days following their last treatment 
injection. Mice were killed by decapitation 1 hour post-final injection for the 
chronic saline/MAP administration groups or 7 days post-final injection for the 
withdrawal groups.
4.2.5 OTR and MOPr autoradiography
Tissue preparation, quantitative autoradiographic binding of the OTR and MOPr as 
well as subsequent autoradiographic procedures were carried out as detailed in 
Section 3.2.3.
4.2.6 DA D% receptor autoradiography
Autoradiography was performed as detailed by Lena et a l (2004). Slides were 
defrosted thoroughly for 30 minutes then pre-incubated for 20 minutes at room
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temperature in a 50 mM Tris-HCl assay buffer containing 120 mM NaCl, 5 mM 
KCl, 2 mM CaCl] and ImM MgCb (pH 7.4). The DA D% receptor agonist 
[^HJraelopride (Perkin Elmer Ltd, Belgium) was used to label DA D2 receptors at a 
4 nM eoncentration, 3-4 times Kd of ligand as previously described in the literature 
(Kohler et al. 1985). The incubation buffer was made up of the radioligand in the 
assay buffer as stated above for both total and non-specific binding. 10 pM of DA 
D2 antagonist sulpiride (Tocris Bioseiences, Bristol, UK) was added to the assay 
buffer containing 4 nM [^HJraclopride to determine non-specific binding.
1 ml of incubation buffer for total and non-speeifie binding was pipetted over the 
appropriate slides, ensuring all sections were completely covered, for 60 minutes at 
room temperature. The slides were then washed 6 times for 1 minute in ice-eold 
rinse buffer (50 mM Tris-HCl, pH 7.4) followed by a 1 minute rinse in ice-cold 
distilled water. The slides were dried under a eold stream of air for 2 hours and 
stored in an airtight box with anhydrous calcium sulphate for 7 days at room 
temperature for further drying.
4.2.7 Oxytocin peptide levels in the brain and plasma
The brains were removed following decapitation and Hyp, Amy and striatum (Acb 
+ CPu) were dissected by reference to the mouse brain atlas of Frankin and Paxinos 
(1997) and immediately preserved in dry ice and stored in -80°C until use. Peptides 
were extracted from the brain regions in accordance to previously described 
protocol by Christensson-Nylander et al., (1985) with minor modifications. Briefly, 
tissues were mixed with IM acetic acid, heated to 95°C for 10 min, homogenised 
and stored in -80°C overnight. The following day, the samples were thawed on ice 
and centrifuged at 9000 x g  for 20 min (4 °C) and the supernatant was collected and
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lyophilized. In all the extracted samples, contents were measured in specific 
radioimmunoassays as previously described (Landgraf 1981). OT levels were 
determined in duplicate in a single assay.
For plasma oxytocin levels, trunk blood from the mice was collected in tubes 
containing EDTA and aprotinin (500 KlU/ml of blood). The samples were 
centrifuged at 1600 x g  for 15 min (4°C) and supernatant stored in -80°C. Solid 
phase extraction of samples was performed using 200mg C l8 Sep-Pak Columns 
(Phoenix Pharmaceuticals Inc., Karlsruhe, Germany). The extraction of the peptide 
in plasma was followed according to the method described in Landgraf (1991). The 
eluent from the extraction process was collected and lyophilised. The oxytocin 
peptide levels were measured by radioimmunassay using iodinated tracer 
(approximately 2000 cpm) in accordance with Landgraf (1981). OT levels were 
determined in duplicate in a single assay.
4.2.8 Plasma corticosterone levels
Trunk blood from the mice was collected in EDTA-containing tubes and spun for 
15 min at 2000 x g at 4°C. Plasma was collected and corticosterone levels were 
measured by using a rat/mouse corticosterone [^ ^^ I] kit (MP Biomedicals, New 
York, NY, USA) according to the manufacturer’s instructions. All coricosterone 
levels were determined in duplicate in a single assay.
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4.2.9 Single- labelling immunohistochemistry for CRF neurons and c-Fos 
neuronal activity marker
Brain tissues were sectioned as described previously in Section 3.2.3. Analysis of 
total c-Fos and CRF was made on free-floating sections (20pm). Following the 
blocking of the samples with H2O2 and with 0.3% normal goat or rabbit serum 
(Vector Laboratories, USA), tissue sections were incubated overnight at room 
temperature with a goat/rabbit anti-CRF/anti-c-Fos antibody respectively (Santa 
Cruz Biotechnology). This was followed by application of a biotinylated anti- 
rabbit/anti-goat IgG (Vector Laboratories). Antigens were visualised using an 
avidin-biotin immunoperoxidase protocol according to manufacturer’s instructions 
(Vectastasin ABC Elite kit. Vector Laboratories). 3 ,3-diaminobenzidine (DAB) 
nickel-intensifrcation (Sigma, USA) was used as a chromogen for c-FOS (black 
colour) and DAB for CRF (brown colour). Sections were mounted onto gelatin 
coated slides, dehydrated through graded alcohols, cleared in xylene and cover- 
slipped with dibutyl phthalate xylene.
4.2.10 Double-labelling immunohistochemistry of CRF positive neurons
For the double-labelling brain sections were initially processed for c-Fos as 
described in Section 4.2.9. Then sections were rinsed with PBS and were processed 
for CRF as described in Section 4.2.9.
4.2.11 Quantification of c-Fos and CRF immunoreactivity and CRF-positive 
neurons
CRF and c-Fos immunostaining as well as CRF-positive neurons in the Amy were 
quantified bilaterally for each mouse, for all treatment groups by an observer blind
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to the treatment groups. The density of CRF-, c-Fos- and CRF^-like 
immunoreactivity was determined using a computer assisted image analysis system 
(Qwin; Leiea, Spain). A square field (195 pm side) was superimposed upon the 
captured image (xlO magnification) to use as a reference area.
4.2.12 Statistical analysis:
All values are expressed as mean ± SEM. Differences in locomotor activities were 
analysed using repeated measures two-way ANOVA with factor ‘Treatment’ 
(saline/MAP) and ‘Time (days)’ (repeated factor). Faecal boli production in the 
FST was analysed with non-parametric Mann-Whitney U-test. For the analysis of 
the effect of MAP withdrawal on anxiety and depressive-like behaviour, an 
unpaired t-test was used. For analysis of the OT levels and OTR binding two-way 
ANOVA was performed in each individual brain region or plasma for factors 
‘treatment (saline/MAP)’ and ‘experimental phase’ (chronic/withdrawal). 
Corticosterone levels and c-Fos, CRF and c-Fos/CRF were analysed using two-way 
ANOVA for factors ‘treatment (saline/MAP)’ and ‘experimental phase’ 
(chronic/withdrawal). ANOVAs were followed by a Holm-Sidak post hoc test 
when significance was reached {\.Q.,p<0.05). All relevant F-values are provided in 
Table 3.1. All statistical analyses were performed using SigmaPlot (Systat 
Software, London, UK).
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4.3 Results
4.3.1 Effect of chronic MAP administration on locomotor activity in mice
MAP treatment increased the horizontal aetivity of mice during the 10-day 
administration paradigm compared with saline-treated mice (p<0.001; Figure
4.1 A). Following 5 days of MAP administration, there was a significant increase in 
MAP-stimulated horizontal activity from Days 5-10 compared with Day 1 
(p<0.001), indicating the acquisition of behavioural sensitisation to the locomotor- 
stimulating effect of MAP.
MAP-treated animals had increased vertical activity compared to saline controls 
from Day 2 which was persistent up to Day 10 (p<0.001; Figure 4.IB)
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Figure 4.1: Effect of chronic MAP administration on horizontal and vertical locomotor 
activity during the 10-day administration paradigm.
Male C57BL/6J mice were treated with either saline or MAP with a 10- day steady-dose 
administration paradigm (2 mg/kg, i.p. per day). Stimulated (A) horizontal and (B) vertical activity 
(representing rearing) were measured daily in 5 min bins for 90 minutes hour post- MAP or saline 
injection during the 10-day steady-dose MAP and saline administration paradigm. The average 
activity of the hourly 5-min bins was calculated daily. Chronic MAP administration increased 
horizontal and vertical activity compared to saline. Sensitisation to the locomotor hyperactivity has 
been developed during chronic administration o f MAP. Data are expressed as mean ± SEM (n=13 
per group). ***p<0.001 vs Saline; ^p<0.001  V5 MAP Day 1 (repeated measures two-way ANOVA 
followed by Holm-Sidak post-hoc test).
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4.3.2 Effect of MAP pre-treatment on basal locomotor activity following 
chronic and 7-day abstinence
Basal horizontal activity was increased by MAP treatment at Day 2, 3 and 4 
(p<0.01, p<0.001) but was not significantly different compared to the saline 
controls at Day 1 and between Days 5-10 (p>0.05). Following the 7-day 
withdrawal period animals that were receiving MAP during the chronic phase 
showed an increase in their horizontal activity compared to their respective saline 
controls (p<0.05; Figure 4.2A).
Basal vertical activity was increased by MAP treatment between Days 2-6 (p<0.05, 
p<0.01, p<0.001) and Days 8-9 but was not significantly different at Day 1, 7 and 
10 ip>0.05) when compared to saline controls. Following the 7-day withdrawal 
period animals receiving MAP during the chronic phase showed an increase in their 
vertical activity compared to their respective saline controls {p<0.05\ Figure 4.2B)
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Figure 4.2: Effect of chronic MAP pre-treatment and withdrawal on basal horizontal and 
vertical locomotor activity.
Male C57BL/6J mice were treated with either saline or MAP with a 10-day steady-dose 
administration paradigm (2 mg/kg, i.p. per day). Basal (A) horizontal and (B) vertical activity 
(representing rearing) were measured daily in 5 min bins for 60 minutes hour pre- MAP or saline 
injection during the 10-day steady-dose MAP and saline administration paradigm. The average 
activity of the hourly 5-minute bins was calculated daily. Chronic MAP administration increased 
horizontal and vertical activity compared to saline. Sensitisation to the locomotor hyperactivity has 
been developed during chronic administration of morphine. Data are expressed as mean ± SEM 
(n=13 per group). *p<0.05, **p<0.01, ***p<0.001 V5 Sa\ine;^p<0.001 V5 MAP Day 1 (repeated 
measures two-way ANOVA followed by Holm-Sidak post-hoc test).
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4.3.3 Effect of 7-day withdrawal from chronic MAP administration on 
depressive-like behaviour in mice
Depressive-like behaviour in saline and MAP-withdrawn mice was assessed with 
the use of the FST following 7-day withdrawal. MAP-withdrawn animals did not 
have any differences in their immobility time or latency to the first immobility 
count compared to saline-withdrawn animals (p>0.05; Figure 4.3A,B)- Number of 
faecal boli production of each mouse was also measured during the forced-swim 
session. MAP-withdrawn mice produced significantly more faecal boli compared to 
saline-withdrawn mice (p<0.05; Figure 4.3C).
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Figure 4.3: Effect o f a 8-day withdrawal period from  M AP adm inistration on depressive- 
like behaviour
Male C57BL/6J mice were treated either with saline or MAP with a 10-day steady-dose 
administration paradigm (2 mg/kg, i.p. per day) and left to spontaneously withdraw for a period 
o f  8 days. (A) latency to the first episode o f  immobility, (B) Immobility time and (C) number 
o f  faecal boli production were measured in saline and MAP-withdrawn animals during the 6- 
min duration o f  the forced-swim test. M ice chronically withdrawn from MAP did not show any 
depressive-like behaviour but increased their defecation during the FST. Data are expressed as 
mean ±  SEM (n=6 per group). *p<0.05, (Mann-Whitney non-parametric t-tesf).
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4.3.4 Effect of 7-day withdrawal from chronic MAP administration on 
anxiety-like behaviour in mice
Anxiety-related behaviour in saline and MAP-withdrawn mice was assessed with 
the use of the EPM following the 7-day withdrawal period. Time spent on the open 
arms was not significantly different in MAP-withdrawn compared to saline- 
withdrawn animals {p>0.05\ Figure 4.4A). However, MAP-withdrawn mice 
showed a small but significantly less percentage of entries into the open arms 
compared to saline-withdrawn controls (p<0.05; Figure 4.4B).
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Figure 4.3: Effect of a 7-day withdrawal period from MAP administration on depressive-like 
behaviour.
Male C57BL/6J mice were treated either with saline or MAP with a 10-day steady-dose 
administration paradigm (2 mg/kg, i.p. per day) and left to spontaneously withdraw for a period o f 7 
days. (A) Time in open-arm and (B) open-arm entries (%) were measured in saline and MAP- 
withdrawn animals during the 5 min duration of the elevated plus-maze test. Mice chronically 
withdrawn from MAP demonstrated increased anxiety-like behaviour. Data are expressed as mean ± 
SEM (n=6 per group). *p<0.05 (unpaired t-test).
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4.3.5 Effect of the 10-day MAP administration followed by 7-day withdrawal 
on OTR binding in mice
Quantitative analysis of OTR binding showed a significant ‘treatment’ effect in the 
LS and in the Hip (Figure 4.5A,B). An ‘experimental phase’ effect was also 
observed in LS. Moreover, a significant ‘treatment’ x ‘experimental phase’ 
interaction was identified in the LS and Amy. Holm-Sidak post-hoc test revealed a 
significant increase in OTR binding in the Amy following the 10-day MAP 
administration (p<0.05), which was normalised following the 7-day withdrawal 
period (p<0.05) and a significant increase in OTR binding in the LS following the 
7-day withdrawal fi*om chronic MAP administration (Figure 4.5A,B; p<0.001).
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Figure 4.4: Effect of chronic MAP administration and withdrawal on [1251]-OVTA binding to OTRs
Male C57BL/6J mice were treated either with saline or MAP with a 10-day steady-dose administration paradigm (2 
mg/kg, i.p. per day) and left to spontaneously withdraw for a period of 7 days. (A) Computer-enhanced 
representative autoradiograms of adjacent coronal brain sections from chronic saline-, MAP-treated, saline- 
withdrawn and MAP-withdrawn mice at the level o f the caudate putamen (Bregma 0.86mm, first row) and the 
thalamus (Bregma -2.06mm, second row). OTRs were labelled with ['^^I]-OVTA (50pM). The colour bar illustrates 
a pseudo-colour interpretation of black and white film images in fmol/mg tissue equivalent. Representative images 
for the non-specific binding (50pM ['^^I]-OVTA in the presence of 50pM unlabelled oxytocin) are shown for all the 
treatment groups. (B) Quantitative oxytocin receptor autoradiographic binding and in brain regions of mice treated 
with a chronie 10-day steady-dose MAP administration paradigm and in mice-withdrawn for 7 days from this 
paradigm. Data are expressed as mean ± SEM (n=6) specific [^^^I]-OVTA binding (fmoEmg tissue equivalent). 
Two-way ANOVA followed by Holm-Sidak post-hoc test. Abbreviations; AcbC, nucleus accumbens core; AcbSh, 
nucleus accumbens shell; Amy, amygdala; AOL, anterior olfactory nucleus-lateral; AOM, anterior olfactory 
nucleus-medial; AOV, anterior olfactory nucleus-ventral; CgCx, cingulate cortex; CPu, caudate-putamen; Hip, 
hippocampus; Hyp, hypothalamus; LS, lateral septum; MS, medial septum; Pir, piriform cortex; PV Th, 
paraventricular nucleus o f thalamus; Th, thalamus; VDB, vertical limb of the diagonal band of Broca.
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4.3.6 Effect of the 10-day MAP administration and the 7-day withdrawal on 
OT levels in the brain and plasma in mice
Chronic MAP administration and withdrawal did not induce any alterations in the 
OT content compared to their respective controls in the striatum (p<0.05; Figure 
4.6A), Hyp (p<0.05; Figure 3.6B), Amy (p<0.05; Figure 4.6C) and plasma 
(p<0.05; Figure 4.6D).
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Figure 4.5: Effect of chronic MAP administration and withdrawal on brain and 
plasma oxytocin peptide levels.
Male C57BL/6J mice were treated either with saline or MAP with a 10-day steady-dose 
administration paradigm (2 mg/kg, i.p. per day) and left to spontaneously withdraw for a 
period o f 7 days. OT peptide levels (pg/mg of tissue or pg/ml of plasma) were measured in 
the (A) striatum, (B) Hyp, (C) Amy and (D) Plasma. Data are expressed as mean ± SEM 
(n=6-7). Two-way ANOVA followed by Holm-Sidak post-hoc test.
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4.3.7 Effect of the 10-day MAP administration followed by the 7-day 
withdrawal on MOPr binding in mice
Quantitative analysis of MOPr binding showed a significant ‘treatment’ effect in 
the AcbC, AcbSh and CPu, No significant ‘experimental phase’ effect or 
‘treatment’ x ‘experimental phase’ interaction was observed (Figure 4.7A,B).
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Figure 4.6: Effect of chronic MAP administration and withdrawal on [^H]DAMGO binding to 
MOPr.
Male C57BL/6J mice were treated either with saline or MAP with a 10-day steady-dose 
administration paradigm (2 mg/kg, i.p. per day) and left to spontaneously withdraw for a period o f 7 
days. (A) Computer-enhanced representative autoradiograms of adjacent coronal brain sections from 
chronic saline-, MAP-treated, saline-withdrawn and MAP -withdrawn mice at the level o f the 
caudate putamen (Bregma 0.86mm). MOPrs were labelled with [^HjDAMGO (4nM). The colour bar 
illustrates a pseudo-colour interpretation o f black and white film images in fmol/mg tissue 
equivalent. Representative images for the non-specific binding (4nM [^HjDAMGO in the presence 
of lOpM Naloxone) are shown for all the treatment groups. (B) Quantitative MOPr autoradiographic 
binding in brain regions of mice treated with a chronic 10-day steady-dose MAP administration 
paradigm and in mice-withdrawn for 7 days from this paradigm. Data are expressed as mean ± 
SEM (n=6) specific [^HjDAMGO binding (fmol/mg tissue equivalent). Two-way ANOVA followed 
by Holm-Sidak post-hoc test. Abbreviations: AcbC, nucleus accumbens core; AcbSh, nucleus 
accumbens shell; Amy, amygdala; CgCx, cingulate cortex; CPu, caudate-putamen; Hip, 
hippocampus; Hyp, hypothalamus; LS, lateral septum; M l,M2, Motor cortex; MS, medial septum; 
Pir, piriform cortex; Th, thalamus; VDB, vertical limb of the diagonal band of Broca.
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4.3.8 Effect of the 10-day MAP administration followed by the 7-day 
withdrawal on D2 binding in mice
Two-way ANOVA did not reveal any significant differences in the DA D2 binding 
following MAP administration and withdrawal (Figure 4.8A,B).
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Figure 4.7: Effect of chronic MAP administration and withdrawal on (3H]-Raclopride on D2 
receptors.
Male C57BL/6J mice were treated either with saline or MAP with a 10-day steady-dose 
administration paradigm (2 mg/kg, i.p. per day) and left to spontaneously withdraw for a period of 7 
days. (A) Computer-enhanced representative autoradiograms o f adjacent coronal brain sections 
from chronic saline-, MAP-treated, saline-withdrawn and MAP - withdrawn mice at the level o f the 
caudate putamen (Bregma 0.86mm). D2 receptors were labelled with [^H]-Raclopride (4nM). The 
colour bar illustrates a pseudo-colour interpretation o f black and white film images in fmol/mg 
tissue equivalent. Representative images for the non-specific binding (4nM [^H]-Raclopride in the 
presence o f lOpM Sulpride are shown for all the treatment groups. (B) Quantitative D2 receptor 
autoradiographic binding and in brain regions of mice treated with a chronic a 10-day steady-dose 
MAP administration paradigm and in mice-withdrawn for 7 days from this paradigm. Data are 
expressed as mean ± SEM (n=6) specific [^H]-Raclipride binding (fmol/mg tissue equivalent). Two- 
way ANOVA followed by Holm-Sidak post-hoc test. Abbreviations: AcbC, nucleus accumbens 
core; AcbSh, nucleus accumbens shell; CPu, caudate-putamen.
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4.3.9 Effect of the 10-day MAP administration followed by the 7-day 
withdrawal on CRF levels in the Amy in mice
Immunohistochemical analysis of CRF^ neurons and CRFVc-Fos neurons in the 
Amy showed a ‘treatment’ and ‘experimental phase’ effect following MAP 
administration and withdrawal. A significant ‘treatment’ x ‘experimental phase’ 
interaction was revealed in amygdalar CRF^ neurons. Chronic MAP treatment and 
withdrawal induced an increase in amygdalar CRF^neurons (p<0.05; Figure 4.9B) 
and CRFVc-Fos neurons (p<0.001; Figure 4.9A,D) in MAP-treated animals 
compared to saline-treated animals, which was persistent during withdrawal 
(p<0.001; Figure 4.9). No significant difference was observed in the number of c- 
Fos neurons between the MAP- and saline-treated, as well as between the MAP 
withdrawn and saline withdrawn animals (p>0.05; Figure 4.9C).
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Figure 4.8: Effect of chronic MAP administration and withdrawal on c-Fos, CRF and CRF-positive neurons in the amygdal
Male C57BL/6J mice were treated either with saline or MAP with a 10-day steady-dose administration paradigm (2 mg/kg, i.p. p 
day) and left to spontaneously withdraw for a period of 7 days. (A) Representative immunohistochemical images o f CRF-positi 
neurons from the amygdala from chronic saline-, MAP-treated, saline-withdrawn and MAP - withdrawn mice. Quantitati 
immunohistochemical analysis o f (B) c-Fos, (C) CRF and (D) CRF-positive neurons in the amygdala o f mice treated with a cliror 
10-day steady-dose MAP administration paradigm and in mice-withdrawn for 7 days from this paradigm. Data are expressed 
mean ± SEM (n=6 per group). *p<0.05, ***p<0.001 vi' Saline. Two-way ANOVA followed by Holm-Sidak post-hoc test.
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4.3.10 Effect of the 10-day MAP administration and the 7-day withdrawal on 
plasma corticosterone levels in mice
Two-way ANOVA showed a significant ‘treatment’, ‘experimental phase’ and 
interaction ‘treatment’ x ‘experimental phase’ effect. Chronic MAP treatment 
increased plasma corticosterone levels {p<0.05), but levels were comparable to the 
control group following a 7-day MAP withdrawal period (Saline withdrawal vs 
MAP w i t h d r a w a l , O J ;  Figure 3.10).
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Figure 4.9: Effect of chronic MAP administration and withdrawal on plasma corticosterone 
levels.
Male C57BL/6J mice were treated either with saline or MAP with a 10-day steady-dose 
administration paradigm (2 mg/kg, i.p. per day) and left to spontaneously withdraw for a period o f 7 
days. Plasma corticosterone levels were measured in chronic saline-treated, MAP-treated, saline- 
withdrawn and MAP-withdrawn mice. Data are expressed as mean ± SEM (n=6 per group). 
*p<0.05 vs Saline/MAP withdrawal. Two-way ANOVA followed by Holm-Sidak post-hoc test.
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Table 4.1: Relevant Effects for Biochemical and Behavioural Data- Chapter 4.
Treatment effect Experimental phase Interaction effect
Overall e ffects fo r  Figure 3.1
MAP effects on locomotor activity Factor 'treatm ent' Factor 'time (days)' Factor 'trea tm en t'x
stim ulated horizontal activity (n=13) F[i ,271=210.70; p<0.001 F(9,2431=1.152 p=0.327
'time'
F[9, 2431 “  3.027 p<0.001
Stimulated vertical activity (n=13) F[i,271=6.754; p<0.05 F[9,2431=15.320 p<0.001 F[9, 2431 -  7.057 p<0.001
Basal horizontal activity (n=13) F[i, 241= 14.62 p<0.001 F[i0.2401= 26.29 p<0.001 F[io, 2401=26.29 p<0.01
Basal vertical activity (n=13) F[i, 241=18.44; p<0.001 F[io, 2401= 8.366; p<0.001 F[io, 2401 = 1.588 p=0.111
Overall e ffects fo r  Figure 3.5
OTR autoradiography (n=5-6) Factor 'treatm ent' Factor 'experim ental phase' Factor 'trea tm en t'x
AOM F[i,2oi-1 .2 1 1 p=0.284 Fu,2oi=1.115 p=0.304
'experimental phase'
Fu,201=0.027 p=0.871
AOV F[i,2oi=1.952 p=0.178 F[i,201=2.222 p=0.152 Fu,201=6.442 p<0.05
AOL F[i,201=2.002 p=0.172 F[i,201=5.273 p<0.05 F[i,2oi=0.720 p=0.406
CgCx F[i,i9i=0.S12 p=0.483 F[i,i91=0.186 p=0.671 F[i ,i91=0.899 p=0.355
Pir F[i,201=1.642 p=0.215 F[i,201=2.387 p=0.138 F[i,2oi=0.647 p=0.431
AcbC F[i,191=0.243 p=0.628 F[i,191=0.001 p=0.97S F(i ,i 91=0.068 p=0.796
AcbSh F[i,i 9i=0.073 p=0.790 Fii,i91=0.540 p=0.472 F[i,i9]=0.665 p=0.42S
CPu Fu,191=0.460 p=0.506 F[i,191=0.031 p=0.862 F[i,i91=1.002 p=0.329
MS F[i,191=0.579 p=0.456 F[i,191=0.0007 p=0.980 F[i ,i91=1.501 p=0.235
VDB F[i,i81=1.167 p=0.294 Fii,i81=0.493 p=0.492 F[i ,i81=3.354 p=0.084
LS F[i,201=8.608 p=0.383 F[i,201=7.352 p<0.05 F[i,201=7.001 p<0.05
Hip F[i,i91=5.029 p<0.05 F[i,i91=1.123 p=0.303 F[i ,i91=1.461 p=0.242
Th F[i,191=2.729 p=0.115 F[i,19,=2.972 p=0.101 F[i,i91=0.260 p=0.616
Hyp F[i,191=0.00002 p=0.99S F(i,191=0.171 p=0.S84 F[i ,i91=1.189 p=0.155
Amy F[i,i91=0.126 p=0.762 F[i,191=0.898 p=0.355 F[i,i91=8.944 p<0.01
Overall e ffec ts fo r  Figure 3 .6
OT levels 
(n=6-7)
Striatum
Hyp
Amy
Plasma
Overall e ffects fo r  Figure 3 .7
MOPr autoradiography (n=5-6)
Factor 'treatm ent' Factor 'experimental phase '
F[i,23]-0.301  
F[i,23]=0.005 
F[i,23]=0.776 
F[i,231=1-137
p=0.531
p=0.944
p=0.387
p=0.297
Factor 'treatm ent'
F[i,231=0.645 
F[i,231=3.209 
F[i,23i=0.020 
Fii,231=0.082
p=0.420
p=0.086
p=0.888
p=0.777
Factor 'experimental phase'
Factor 'treatm ent' x  
'experimental phase' 
F[i.23i=0.406 p=0.531
F[i,231=1.901 p=0.181
Fii,231=2.923 p=0.101
F[i,23i=2.872 p=0.104
Factor 'treatm ent' x  
'experimental phase '
MtCx
AcbC F[i,2oi=16.956 p<0.001 F[i,2oi-0 .0 1 5
p=0.489
p=0.904 F[i ,2oi-1 .0 1 5 p=0.326
AcbSh F[i ,2oi=15.554 p<0.001 Fu,2oi=0.0005 p=0.982 F[i ,2oi=0.616 p=0.442
CPU F[i,2oi=6.053 p<0.05 F[i ,2oi=0.043 p=0.839 F[i ,2oi=0.070 p=0.793
CgCx F[i,i9i=1.951 p=0.179 F[i,i91=0.165 p=0.689 F[i ,i91=1.426 p=0.247
LS F[i ,i91=0.344 p=0.S64 F[i,i91=1.287 p=0.271 F[i,i9i=0.0006 p=0.981
MS F[i ,i91=2.457 p=0.134 Fu,i91=1.794 p=0.196 F[i,i91=0.011 p=0.919
VDB F[i,i91=1.758 p=0.201 F[i ,i91=2.749 p=0.114 F[i ,i91=0.819 p=0.377
Pir Fu,i91=1.040 p=0.321 F[i,i91=3.172 p=0.091 F[i,i91=0.174 p=0.681
Th F[i,i91=0.409 p=0.530 F[i,i91=0.253 p=0.621 F[i,i 91=0.101 p=0.754
Hyp F[i,i9i=0.043 p=0.837 F[i,i91=0.305 p=0.587 F[i ,i91=0.0001 p=0.991
Hip F[i ,i91=0.170 p=0.685 F[i,191=0.173 p=0.682 F[i,i91=0.073 p=0.790
Amy F[i,i91=0.061 p=0.808 F[i,i9i=0.085 p=0.774 F[i ,i91=2.780 p=0.112
Overall e ffects fo r  Figure 3.8
Û2 autoradiography (n=5-6) Factor 'treatm ent' Factor 'experimental phase' Factor 'treatm ent' x
CPU F[i,191=0.565 p=0.461 Fu,i91=0.970 p=0.337
'experimental phase ' 
F[i,i9i=0.016 p=0 .9 0 0
AcbC F[i,i91=1.108 p=0.306 F[i,191=1.008 p=0.328 Fu,i 91=0.016 p=0.901
AcbSh F[i,i91=0.714 p=0.409 F[i,i91=0.260 p=0.616 F[i,i91=0.045 p=0.834
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Overall effects for Figure 3.9
Am ygdalar CRF levels (n=6)
c-Fos
CRF
CRF/c-
Fos
Overall effects for Figure 3.10
Plasma corticosterone levels (n=5-6)
Factor 'treatm ent'
F[i,201=2.389 p=0.138
F(i,2oi=40.273 p <0.001
F[i,2oi=23.154 p <0.001
Factor 'treatm ent'
F[i,191=4.961 p<0.05
Factor 'experimental phase' 
F[i,201=0.001 p=0.972
F[i,201=12.010 p<0.01
F[i,201= 6 .787  p<0.05
Factor 'experim entalphase' 
F[i,191=11.026 p<0.01
Factor 'trea tm en t'x  
'experimental phase'
F[i,201= 0 .465  p=0.503
F[i,201= 7 .798  p<0.05
F[i,2oi=2.062 p =0.167
Factor 'trea tm en t'x  
'experimental phase'
F[i,191=6.996 p<0.05
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4.4 Discussion
This study demonstrated that chronie MAP administration and withdrawal 
dysregulate the OTR and MOPr system, as well as the Amygdalar CRF system and 
induces alterations in the HPA-axis activity which might be associated with the 
development of anxiety-related behaviours during MAP withdrawal.
The present study demonstrated that a 10-day MAP administration induced a 
significant increase in OTR binding in the Amy and Hip and caused an increase in 
the MOPr binding in the AcbC, AcbSh and CPu. These receptor changes were 
accompanied by an increase in plasma corticosterone and amygdalar CRF levels. 
Following a 7-day withdrawal period, a significant up-regulation of OTR binding 
was observed in the LS, as well as a persistent increase in the OTR binding in the 
Hip, whereas OTR binding in the Amy returned to baseline levels. The increased 
MOPr binding in the AcbC, AcbSh and CPu was also persistent during withdrawal. 
While plasma corticosterone levels returned to levels comparable to controls 
following 7 days of MAP withdrawal, the increase in amygdalar CRF levels 
persisted. Although in the current study a 7-day MAP withdrawal period did not 
induce any depressive-like behaviours in mice, it induced anxiety-like symptoms 
including decreased open-arm entries in the EPM and increased defecation during 
the FST session, which has been proposed to be associated with measures of 
anxiety (Waif and Frye 2007) and emotionality (Craft et al. 2010) respectively. 
These findings are in line with previous studies showing anxiety-like effects of 10 
days withdrawal from MAP self-administration (Nawata et al. 2012) as well as 5 
days withdrawal from a frxed-dose injection regimen of MAP (Kitanaka et al. 
2010) in rodents. It has been recently demonstrated that extended access
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to methamphetamine produces a depressive-like state during early withdrawal (i.e, 
2 days), but not during protracted withdrawal (i.e., 15 days) in rats (Jang et al.
2013). Therefore, the lack o f depressive-like symptoms in the present study where 
a 7-day withdrawal period was used is perhaps not surprising.
Neuroadaptations in the OT system have been previously demonstrated following 
chronic administration o f other drugs o f abuse, including cocaine (Samyai et al. 
1992c) and morphine (Laorden et al. 1997; Laorden et al. 1998; Zanos et al. 2014a) 
and have been associated with the presence o f anxiety-related behaviours in mice 
(Zanos et al. 2014a). With respect to the MAP-induced up-regulation specifically in 
the Hip, it has been demonstrated that chronic cocaine administration decreases OT 
levels in the Hip (Samyai et al. 1992e), while microinjection of OT in the dorsal 
Hip reversed stress-induced reinstatement of MAP-seeking (Beesley et al. 2014). 
Hence, the persistent MAP-induced increase in OTR binding in the Hip observed in 
the present study might be a compensatory mechanism to counteract the decreased 
hippocampal OT levels induced by chronic MAP administration. In fact, elevated 
levels of OT induce desensitisation of OTR (Evans et al. 1997), therefore it is 
possible that decreased levels of OT might result in an increase in OTR.
It has been previously shown that chronic MAP administration increases OTR 
binding in the Amy (Zanos et al. 2014b). While in the present study we have 
observed MAP-induced increase in amygdalar OTR binding, this effect did not 
persist following 7 days of withdrawal. This result is in contrast with previous 
studies showing that withdrawal from morphine induced profound up-regulation of 
the OTR in the Amy (Zanos et al. 2014a). These discrepancies might be due to the
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differential regulation of OTRs by different drugs o f abuse and hence the 
consequently differential behavioural phenotype o f these animals following 
morphine and MAP withdrawal. For instance, in the study of Zanos et al. (2014a) 
up-regulation of the OTRs in the Amy were accompanied with the emergence of 
anxiety- as well as depressive-like behaviour, whereas in the current study, MAP 
withdrawal was not associated with depressive-related symptoms. However, an 
increase in the OTR binding in the LS o f MAP withdrawn mice was observed, an 
effect previously associated with emotional impairment induced by morphine 
withdrawal (Zanos et al. 2014a). Importantly, the septum is a brain region known to 
be responsible for the anxiolytic effects of OT (Curley et al. 2012; Lukas et al. 
2012), suggesting the dysregulation of the OTR system in the LS as a possible 
mechanism underlying the observed anxiety-related symptoms. In addition, as there 
is considerable evidence demonstrating abnormalities of both Hip (Kuczenski et al. 
1995) and LS (Cornish et al. 2012) following chronic drug use, it is possible that 
the compensatory region-specific up-regulation of OTRs might represent a 
homeostatic mechanism to oppose the anxiety-related symptoms induced by 
chronie MAP withdrawal.
In addition to the possible involvement of the dysregulation of the OTR system in 
driving the anxiety-like behaviour induced by MAP withdrawal, alterations in the 
central MOPr might also account for these behavioural responses. For instance, 
Filliol et al. (2000) demonstrated that MOPr knockout mice have decreased 
anxiety-like behaviour. Interestingly, MOPr antagonists have been shown to 
induce anxiogenie-like effects (Tejedor-Real et al. 1995; Tsuda et al. 1996; Zhang 
et al. 1996), while MOPr agonists, including morphine, were found to have
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anxiolytic effects (Asakawa et al. 1998; Koks et al. 1999; Millan and Duka 1981; 
Zarrindast et al. 2005). Overall these findings suggest a key role of the MOPr 
system in the regulation of anxiety behaviours in rodents. In the present study, a 
persistent increase in MOPr binding was observed in the striatal regions o f the 
brain (AcbC, AcbSh and CPu) following chronic MAP administration, which 
persisted after 7 days of withdrawal. The accumbal MOPr has been implicated in 
the regulation o f anxiety-like behaviours since intra-accumbal administration of 
morphine has been shown to induce anxiolytic effects, which were reversed by 
intra-aceumbal administration o f naloxone (Zarrindast et al. 2008). Therefore, the 
increased MOPr binding in the Acb reported in the current study might be a 
compensatory mechanism to counteract the development of anxiety-like behaviour 
associated with MAP withdrawal.
Indeed, a similar increase in the striatal brain regions was observed following 
chronie cocaine administration and withdrawal (see Yoo et al. 2012) which is in 
agreement with data from cocaine addicts showing increased MOPr binding in the 
CPu (Gorelick et al. 2005; Gorelick et al. 2008; Zubieta et al. 1996). Therefore, the 
up-regulation of MOPr binding in the Aeb and CPu observed in this study might be 
due to the decreased release of endogenous opioid following chronic MAP 
administration and withdrawal. Indeed, repeated drug use has been associated with 
decreased release of endogenous opioids, an effect that may contribute to 
withdrawal-related symptoms, including anhedonia and anxiety (see Goldstein and 
Volkow 2011).
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Anxiety-related behaviours have been extensively linked with changes in both the 
HP A axis activity (see Faravelli et ah 2012), as well as hyperactivation of the CRF 
system in the brain (see Binder and Nemeroff 2010). Here, an increase in the 
plasma corticosterone levels was observed following chronie MAP treatment, 
which was normalised after withdrawal, suggesting that the MAP-withdrawal 
induced anxiety-like symptoms were probably not mediated by a dysregulation of 
the peripheral arm of the HPA-axis. In contrast, a persistent increase in Amygdalar 
CRF^ neurons was demonstrated following the 10-day MAP administration, and 
this effect was even enhanced during withdrawal. Interestingly, it has been 
previously suggested that up-regulation of the CRF systems in the Amy promote 
drug abstinence related behaviours, including anxiety (see Zorrilla et al. 2014), 
suggesting a possible involvement of the increased Amygdalar CRF levels in the 
development of anxiety-like behaviours in MAP-withdrawn animals.
In the present study in addition to the MAP-induced increased in horizontal and 
vertical locomotor activities of mice, which are in line with previous findings 
showing increase locomotor activity following steady-dose MAP administration 
(Fujii et al. 2007) and steady dose of other psehyhostimulant drugs like cocaine 
(e.g. Bailey et al. 2008; Bailey et al. 2007; Koff et al. 1994; Metaxas et al. 2012; 
Schlussman et al. 2003; Tolliver and Camey 1994), it has been shown that the 
horizontal activity of MAP-treated animals was significantly higher ftom Day 5 
onwards compared to Day 1, indicating the acquisition of locomotor sensitisation. 
Development of behavioural sensitisation is a charaeteristie of psychostimulant 
drugs of abuse which is thought to model the increased drug craving in 
psychostimulant abusers (Robinson and Berridge 1993).
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Moreover, this is the first study to show increased basal horizontal and vertical 
locomotor activities following previous exposure to MAP by using a steady-dose 
administration paradigm, an effect which persisted following 7 days of spontaneous 
withdrawal. This finding shows a persistent MAP-induced contextual sensitisation 
(i.e. the animals show behavioural sensitisation in an environment paired with the 
drug injection). The environment associated with drug administration has been 
shown to modulate both the development as well as the expression of behavioural 
sensitisation (Badiani and Robinson 2004). Locomotor sensitisation in the drug- 
paired environment has been linked with drug craving (Robinson and Berridge 
2008), which might contribute to relapse following abstinence. Indeed, a low dose 
“challenge” with a previously paired drug during long-term abstinence from the 
administration paradigm induces the expression of behavioural sensitisation (see 
Pierce and Kalivas 1997). Thus, the increases in both basal horizontal and vertical 
activity, especially following the 7-day abstinence period might indicate the 
sensitised behavioural response to MAP that persist during withdrawal which 
models the increased drug craving in MAP abusers.
Both the OTR and MOPr have been implicated in the behavioural sensitisation 
induced by psychostimulants (see Section 1.6.2, 1.6.3, 1.8.2 and 1.8.3). Reduced 
behavioural sensitisation to MAP was demonstrated in mice lacking the MOPr 
(Shen et al. 2010) and MOPr binding was found to be decreased in the CPu and 
unaltered in the Acb of MAP-sensitised mice (Tien et al. 2007). However, in this 
study an increase in the MOPr binding was observed in the CPu as well as in the 
Acb following the 10-day MAP administration which was persisted after the 7-day
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withdrawal period, indicating that the locomotor sensitisation observed was not 
driven by the MOPr system.
OT administration has been shown to facilitate cocaine-induced behavioural 
locomotor sensitisation in rodents, possibly via interacting with the DAergic 
system within the striatum (Samyai et al. 1992b) since OT administration decreases 
DA utilisation in the striatum and Acb (Samyai et al. 1990). Although the present 
study showed alterations of OTR binding in the Amy, LS and Hip, but not the 
striatum following chronic MAP administration and withdrawal, it is important to 
highlight the possibility of OTR dysregulation taking place in the Amy, LS and Hip 
to influence DAergic neurotransmission in the Acb and thus modulating the 
observed basal hyperlocomotion and motivation to dmg-taking. In fact, a clear 
connection between the Acb and the Amy has been proposed to control limbic 
function and motivation. For instance, it has been suggested that the CeA affects 
basal DAergic tone in the VTA, thereby regulating DAergic tone in the Acb and 
modulating the incentive value of environmental stimuli (Phillips et al. 2003). 
Moreover, bilateral lesions of DAergic terminals in the Amy produced enhanced 
DA activity in the Acb and enhanced locomotor response to d-amphetamine 
(Simon et al. 1988). It has been also shown that DAergic neurons innervating the 
septum exert a facilitatory action on the DA release in the Acb (Louilot et al. 1989) 
and chemical stimulation o f the ventral Hip increases DA in the Acb by activating 
DAergic neurons of the VTA (Legault et al. 2000).
181
Moreover, MAP abusers has been found to have significantly lower level of the 
DA D2 receptor availability in the caudate and putamen, an effect which might be 
associated with craving and compulsive drug intake in drug-addicted subjects 
(Volkow et al. 2001). Since OTR is co-localised and facilitates allosteric functional 
interactions with D2 receptors in the striatum (Romero-Femandez et al. 2013), it is 
possible that OTR system is involved in the regulation of the basal hyperlocomotor 
activity observed during MAP withdrawal. Therefore, considering the functional 
interaction of OTR and DA D2 receptors in the striatum, along with the behavioural 
sensitisation and dysregulation of the OTR system observed in this study, the 
possibility of dysregulation o f the D2 receptor system was tested. However, no 
significant changes were found in D2 receptor binding following chronic MAP 
administration and withdrawal in the striatal regions analysed, suggesting that D 2 
receptor system was not involved in the behavioural effects observed, or 
neuroadaptations of this system occurred further down the downstream pathways 
and not at the receptor level. This finding is in agreement with previous findings 
showing no differences on D2 binding in the striatum using a similar MAP regimen 
with the current study (Tien et al. 2007).
Overall, the results of this study demonstrate dysregulation of the OTR, MOPr and 
central CRF system which may be associated with the development o f the negative 
emotional state during MAP withdrawal. The novel findings of the present study 
provide further insight into the specific neurobiological mechanisms underlying 
MAP withdrawal and provide information for potential targets for the alleviation of 
the emotional impairment observed during withdrawal and preventions of relapse.
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C h a p te r  5
G e n e ra l  d isc u ss io n
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5.1 General discussion
This thesis investigated the effect of chronic psychostimulant administration, 
withdrawal and reinstatement on OT and MOPr system and the efficiency of OT- 
based compounds in modulating relapse to opioid-seeking. Previous research has 
raised questions as to whether the OTergic and MOPr systems are involved in 
chronic drug administration, withdrawal and reinstatement to drug use, and whether 
these systems are implicated in the emergence o f emotional impairment following 
withdrawal from drug administration. The studies presented in this thesis provide 
clear evidence for profound alterations in the OTR system in the Amy, and MOPr 
system in the striatum of the brain induced by cocaine and MAP administration, 
withdrawal, as well as reinstatement. Moreover, acute administration o f an OT 
analogue reversed both stress- and priming-induced reinstatement o f opioid- 
seeking. These findings bring us closer in understanding the mechanisms 
underlying the involvement of OTR and MOPr system at different stages of the 
addiction. Currently there is no effective pharmacotheraphy for the treatment of 
drug addiction and prevention of relapse. Therefore these findings can assist in the 
development o f new and more effective targeted pharamacotherapies for the 
treatment of drug addiction.
5.1.1 Oxytocin analogues: Novel pharmacotherapy to assist with relapse 
prevention
The present pre-clinical work demonstrated that oxytocin-based compounds may 
be an effective therapeutic intervention for the prevention of relapse to opioid use. 
The present work not only adds to the existing evidence for an important role of the 
OTergic system in opioid addiction, but also points towards the need for
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randomised double-blind placebo controlled trials with opioid addicts undergoing 
detoxification to investigate the effects of OT administration in monitoring 
abstinence and preventing relapse. With respect with other drugs of abuse small 
pilot studies demonstrated that intranasal OT administration decreased craving and 
stress in marijuana-dependent individuals (McRae-Clark et al. 2013) and blocks 
alcohol withdrawal symptoms in humans (Pedersen et al. 2013).
Although the present study clearly showed that acute administration of an oxytocin 
analogue prevents stress- and priming-induced reinstatement of opioid-seeking, one 
concern for studies looking at effects of exogenously administered OT is that OT 
has a very short plasma (1-2 min) and central (30 min) half-life (see Ludwig and 
Leng 2006). However, intranasal administration o f OT has been shown to induce 
more prolonged release for at least 80 min (Burri et al. 2008) and has extended 
biological (endocrine and sexual) activity, even after a single dose in humans 
(Uvanas-Moberg et al. 2005).
The main issue with OT administration is that being a peptide and water soluble, it 
has limited ability to cross the blood brain barrier (BBB); -0.1%  of systemic OT 
enters the brain (Jones and Robinson 1982). Nevertheless, there is some evidence 
suggesting that OT might cross the BBB. It has been shown that peripheral 
injections of OT can mirror some effects seen after central administration of the 
peptide. For example, in Mongolian gerbils, affiliation between monogamous 
females and their partners was significantly increased upon subcutaneous injections 
o f OT (Razzoli et al. 2003). Moreover, peripheral administration of OT in rats 
increased c-Fos expression in a number of OTR-dense brain regions including the
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SON, PVN, CeA, lateral parabrachial nucleus, and the locus coeruleus (Hicks et al. 
2012). A double-labelling approach showed that peripherally administered OT 
increased c-Fos activation within OT-containing neurons of the PVN and SON, 
further supporting previous observations that systemic OT is capable of stimulating 
its own release from central sites (Moos et al. 1984). It might be possible that OT 
can cross the BBB via the circumventricular region which allows a less restricted 
transport of molecules into the brain (see Ermisch et al. 1985). Another possible 
mechanism by which systemically administered OT may affect the CNS is via the 
formation of active fragments that may have the capability to cross the BBB. In fact, 
fragments of OT have been found to cross the BBB and regulate several memory 
processes (Burbach et al. 1983). Once in the brain, OT may bind to OTRs on OT- 
containing neurons in the PVN and SON; thus, even small quantities may stimulate 
the release of significant quantities o f endogenous OT to trigger a feed-forward 
response (Rossoni et al. 2008). Although intranasally administered oxytocin has 
been shown to cross the BBB and to exert central effects (Bom et al. 2002; Chang et 
al. 2012; Pedersen et al. 2013), the development of smaller non-peptide OT agonists 
or a pro-dmg OT ligand with high specificity for central OTRs is undoubtedly 
desirable.
One important question that has yet to be addressed is whether long-term 
administration of oxytocin, or oxytocin-based compounds, can cause any side 
effects. In fact, high doses of intravenous OT have been associated with severe 
cardiovascular side-effects including hypotension and myocardial ischemia in 
humans (Dyer et al. 2011). Concerns also include the safety of oxytocin 
administration in females at different reproductive phases due to the peripheral
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effects of OT (i.e. milk ejection, labour induction)(Insel et al. 1997). Chronic OT 
administration has the potential to cause electrolyte imbalances due to its structural 
similarity to arginine vasopressin and its effects in the kidneys (Rasmussen et al. 
2004). Moreover, repeated administration of high OT dose in mice has been shown 
to induce anxiety-like behaviours with a concomitant reduction of OTR binding 
within the septum, the basolateral and medial Amy, as well as the median raphe 
nucleus, which are brain regions important in the regulation of anxiety (Peters et al.
2014). However, in the same study repeated administration of low dose of OT has 
been shown to be protective against anxiety-like behaviours (Peters et al. 2014). 
Sub-chronic (i.e., 5-day) administration o f CBT, which was used in the present 
study, did not induce any changes in the OTR binding in the brain (unpublished 
data from our laboratory) suggesting that this OT analogue might induce different 
neuroadaptations compared to OT. Nevertheless, these findings highlight the need 
for further investigation in order to determine the long-term effects of chronic 
treatment with OT or OT-based compounds.
5.1.2 Dysregulation of the OTR system: Possible neurobiological mechanism 
underlying negative emotional symptoms of drug abstinence and 
reinstatement of drug-seeking.
The data presented in this thesis show a profound brain-region specific alterations 
of the OTergie system following chronic administration, withdrawal and/or 
reinstatement from psychostimulant drugs of abuse. Specifically, the data presented 
here highlight the common up-regulation of the OTergic system in the Amy 
following cocaine self-administration and chronic non-contingent MAP treatment. 
Although the consequences of this dysregulation need further investigation, based
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on the findings of the present work, it is highly likely to be involved in the 
modulation of drug-associated negative emotional state and the induction of relapse 
to drug use.
Considering the anxiolytic effects of OT administration in humans when 
administered with an intranasal spray (Baumgartner et al. 2008; Di Simplicio et al. 
2009; Kirsch et al. 2005), or in animal models when administered centrally or 
peripherally (Dabrowska et al. 2011; Windle et al. 2004), this up-regulation of the 
OTR system in the Amy may constitute a neurobiological mechanism underpinning 
the negative emotional state induced by chronic drug administration. This 
hypothesis is further supported by the presence of a similar pattern o f OTR up- 
regulation in the Amy to that observed in other mental disorders characterised by 
emotional impairments, including schizophrenia (see (Kring and Moran 2008). For 
example, chronic administration of the NMDA receptor antagonist phencyclidine 
that induces similar behaviours to schizophrenia (Qiao et al. 2001; Sams-Dodd 
1999), decreased OT mRNA expression in the Hyp and increased OTR binding in 
the CeA (Lee et al. 2005). More recently, Zanos et al. (2014) have demonstrated an 
association between increased OTR binding in the Amy and the emergence of 
mood disturbances, including anxiety, depression and sociability deficits, further 
supporting a correlation of this dysregulation of the OTR system with a negative 
emotional state.
Interestingly, similar up-regulation o f the OTR binding within the Amy was also 
observed following administration of other addictive substances, such as nicotine 
and alcohol (unpublished data from our laboratory). Therefore, the development of
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a site-specific knockout mouse model lacking the OTR gene specifically in the 
Amy and its behavioural phenotypic characterisation under basal, acute/chronic 
administration, withdrawal and reinstatement of drug-seeking behaviours would be 
of particular importance in order to identify the mechanisms underlying drug 
addiction processes. With regards to translational studies, directions for future 
research would be to measure amygdalar activation after an intranasal OT 
administration during protracted drug withdrawal and during drug-seeking periods, 
by means of a double-blind placebo-controlled fMRI scanning trial in humans. In 
fact, OT administration has been shown to attenuate Amy activation to fear in 
humans (Kirsch et al. 2005), which further implicates the amygdalar OTergic 
system in the modulation of emotional impairment.
The current study also raises the question of whether people with OTR gene 
polymorphisms have a differential propensity to develop emotional deficits and 
relapse during long-term withdrawal from drug-taking. It has been demonstrated 
that alcohol addicts with the OTR polymorphism rs4564970 show higher levels of 
aggressive behaviour (Johansson et al. 2012) suggesting an interactive effect of 
OTR polymorphisms and alcohol-induced aggressive behaviour. However, this was 
the only study which investigated the involvement of OTR polymorphisms in 
relevance with drug addiction, highlighting the need for further investigation in 
order to determine whether there is a possible association of OTR gene 
polymorphisms with the different phases of drug addiction as well as the emotional 
impairment induced by drug administration and withdrawal. Moreover, there is 
recent evidence that the OTR polymorphism rs53576A is associated with higher 
anxiety-related behaviours and individuals with this polymorphism exhibit smaller
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Amy volumes (Wang et al. 2013a). Therefore, considering the possible 
involvement of OTR gene polymorphisms in propensity to develop emotional 
deficits and relapse, along with the association o f OTR polymorphisms with 
anxiety-related behaviours and Amy volume, OTR polymorphisms in the Amy may 
predict the treatment outcome during abstinence and the potential of relapse to drug
use.
5.1.3 Dysregulation of the MOPr system: Possible neurobiological
mechanism underlying negative emotional symptoms of drug 
abstinence and reinstatement of drug seeking.
The data presented in this thesis demonstrated evidence of withdrawal- and 
reinstatement-triggered brain region-specific MOPr system alterations. These 
alterations are plausible to be associated with the emergence of the negative 
emotional state occurring during long-term abstinence from drugs o f abuse and 
relapse. Specifically, the data presented here highlight the differential dysregulation 
of the MOPr in the striatum (Acb and CPu) following administration and 
withdrawal, as well as reinstatement to psychostimulant use. Indeed, it has been 
suggested that activation of the striatal MOPr system might contribute to the 
positive reinforcement/hedonic effect o f psychostimulant drugs and to the 
development of craving during withdrawal and consequent by relapse to 
psychostimulant-seeking (see Yoo et al. 2012), at least partly by interacting with 
the DA system in the striatum and regulating DA release (Ambrose et al. 2004; 
Azaryan et al. 1996; Park et al. 2011).
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Although dysregulation of the MOPr system in the Acb has been shown to be 
implicated in the regulation o f anxiety-like and reward-related behaviours (see Le 
Merrer et al. 2009; Lutz and Kieffer 2013), the use o f MOPr modulators in the 
treatment for drug withdrawal-associated emotional impairment is accompanied 
with important limitations including the abuse liability o f such compounds and/or 
the development of tolerance upon repeated use. However, alterations in the MOPr 
system can be used as an indicator for the development o f craving (Gorelick et al. 
2005; Heinz et al. 2005) and prediction of relapse to drug use (Ghitza et al. 2010). 
Interestingly, the data presented in this thesis demonstrate that MOPr, specifically 
in the striatum, are differentially regulated by different triggers of reinstatement 
(cue vs priming) as well as by different drugs (cocaine vs MAP). Cue- but not 
priming-induced reinstatement of cocaine-seeking decreased MOPr binding in the 
AcbC and CPu suggesting a different regulation o f the striatal MOPr by these two 
stimulus. Even though it has been previously demonstrated that antagonism of 
MOPr in the Acb prevents cocaine-primed reinstatement (Simmons and Self 2009), 
there is limited published work for the involvement o f MOPr, in cue-induced 
reinstatement of cocaine-seeking. This is the first study to provide direct evidence 
for the down-regulation of striatal MOPr following cue-induced reinstatement of 
cocaine-seeking which might be a possible underlying mechanism triggering 
reinstatement. While the priming injection o f cocaine did not induce any change in 
the MOPr binding, considering the existing literature (see Section 3.3.2), the 
possibility of the dysregulation of the MOPr system to be occurring further down 
the signalling pathway cannot be precluded. Therefore, these results indicate that 
the striatal MOPr system might be differentially regulated depending on the 
addiction stage.
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In contrast with the cocaine data where a decrease in MOPr binding was observed 
following cocaine self-administration and extinction in the striatum, chronic MAP 
administration and withdrawal induce an increase in MOPr binding in the striatum. 
These findings demonstrate the differential regulation o f the same system by two 
different drugs o f abuse, cocaine and MAP, which might highlight some of the 
different behavioural effects induced by cocaine and MAP. It has been suggested 
that the MOPr may manifest a biphasic temporal pattern with up-regulation during 
early phases of cocaine withdrawal but a down-regulation at later times (Sharpe et 
al. 2000). Therefore, the differential effect o f MAP and cocaine withdrawal on 
MOPr binding might be the result o f diverse withdrawal periods. Nevertheless, the 
dysregulation of the MOPr system in the striatum might be associated with the 
motivation and craving to seek and take drug during withdrawal. Indeed, accumbal 
MOPr have been associated with the development of craving to psychostimulants 
as well as with the motivation to administer the drug (see Tien and Ho 2011; Yoo 
et al. 2012). Therefore, the development of conditional knockout rodent models 
lacking or overexpressing the MOPr gene specifically in the striatum will be of 
particular interest since it will shed light in the mechanisms underpinning the 
different types o f reinstatement as well as the mode of action o f different drug of 
abuse.
In addition to the pre-clinical research, translational studies are essential in order to 
determine the specific role o f MOPr in drug addiction. While there are several 
imaging studies investigating the involvement of MOPr in cocaine addicts (Ghitza 
et al. 2010; Gorelick et al. 2005; Zubieta et al. 1996), there is no published research
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investigating the possible alterations of MOPr system in MAP addicts. Therefore, 
directions for future clinical research would be to assess MOPr alterations in MAP 
addicts and correlate those with relapse potential in this population. Moreover, it 
will be of particular interest to test whether people with MOPr gene polymorphisms 
have a differential propensity to develop emotional deficits and/or relapse potential 
during long-term abstinence from drug-taking. In fact, the single-nucleotide 
polymorphism of MOPr, A118G, has been associated with opioid and alcohol 
addiction (Deb et al. 2010; Nagaya et al. 2012), as well as with MAP-induced 
psychosis (Ide et al. 2006). Therefore, investigating the alterations of the MOPr 
system, perhaps focusing in the striatal regions of the brain, in drug addicts tested 
with MOPr polymorphisms may predict the treatment outcome during abstinence 
and the potential of relapse to drug-taking.
5.1.4 OTR-MOPr interactions: autoradiographic evidence
A plausible underlying condition for the beneficial effects of CBT on reversing 
reinstatement of opioid-seeking is the presence o f possible interactions between the 
MOPr OTR systems in the brain. Indeed, manipulation o f the MOPr system by 
chronic administration of morphine or by withdrawal from this paradigm induced 
long-term alterations in the OTR binding in the brain o f mice (Zanos et al. 2014a). 
In order to further explore this possible interaction, we performed OTR binding 
(method as detailed in Section 3.2.3) in brains o f male WT and MOPr KO mice 
(kindly offered by Prof. Brigitte Kieffer, IGBMC Institute, France). Importantly, 
significantly higher levels o f OTR binding were observed in the brains o f MOPr 
knockout WT mice. Interestingly, the up-regulation was found to be localised in 
the Amy of MOPr knockout mice (0.377±0.03 0.564±0.01; p<0.01), which is
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supportive of a MOPr-OTR interaction in a region of high MOPr expression 
(r=0.79, p<0.01; Kitchen et al. 1997), and a region responsible for the anxiolytic 
effects o f OT (Kirsch et al. 2005). The significance of this receptor interaction in 
the modulation o f addictive disorders and comorbid emotional deficits remains to 
be determined.
5.1.5 Concluding remarks:
Collectively, the results described in this thesis show that the central OTergic and 
MOPr system is involved in different phases of drug addiction and that the 
exogenous administration of an OT analogue is beneficial in preventing 
reinstatement of opioid-seeking. These results support an important role of the 
dysregulation of these systems as an underlying mechanisms contributing to the 
development of negative emotional state following withdrawal and relapse to drug- 
taking. They also highlight the use o f OT ligands as a novel pharmacotherapy for 
relapse prevention.
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